KR102427777B1 - 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법 - Google Patents
디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법 Download PDFInfo
- Publication number
- KR102427777B1 KR102427777B1 KR1020217036438A KR20217036438A KR102427777B1 KR 102427777 B1 KR102427777 B1 KR 102427777B1 KR 1020217036438 A KR1020217036438 A KR 1020217036438A KR 20217036438 A KR20217036438 A KR 20217036438A KR 102427777 B1 KR102427777 B1 KR 102427777B1
- Authority
- KR
- South Korea
- Prior art keywords
- phenyl
- pyrimidin
- tki
- methyl
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 206
- 230000036210 malignancy Effects 0.000 title claims abstract description 144
- 238000000034 method Methods 0.000 title claims abstract description 74
- AAFJXZWCNVJTMK-GUCUJZIJSA-N (1s,2r)-1-[(2s)-oxiran-2-yl]-2-[(2r)-oxiran-2-yl]ethane-1,2-diol Chemical compound C([C@@H]1[C@H](O)[C@H](O)[C@H]2OC2)O1 AAFJXZWCNVJTMK-GUCUJZIJSA-N 0.000 title claims abstract description 71
- 230000035772 mutation Effects 0.000 title claims abstract description 58
- 229950000758 dianhydrogalactitol Drugs 0.000 title claims abstract description 53
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title claims description 200
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title claims description 200
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 title claims description 166
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 title abstract description 37
- 229950010913 mitolactol Drugs 0.000 title abstract description 34
- MMAXAFOTGLVFQZ-UHFFFAOYSA-N [2-acetyloxy-1,2-bis(oxiran-2-yl)ethyl] acetate Chemical compound C1OC1C(OC(=O)C)C(OC(C)=O)C1CO1 MMAXAFOTGLVFQZ-UHFFFAOYSA-N 0.000 title abstract description 29
- 230000008482 dysregulation Effects 0.000 title abstract description 18
- 206010071602 Genetic polymorphism Diseases 0.000 title description 6
- 238000011282 treatment Methods 0.000 claims abstract description 118
- 238000012217 deletion Methods 0.000 claims abstract description 90
- 230000037430 deletion Effects 0.000 claims abstract description 89
- 102100024407 Jouberin Human genes 0.000 claims abstract description 87
- 230000014509 gene expression Effects 0.000 claims abstract description 74
- -1 dianhydrogalactitol Chemical class 0.000 claims abstract description 55
- 210000004602 germ cell Anatomy 0.000 claims abstract description 38
- 239000000203 mixture Substances 0.000 claims abstract description 31
- 210000004027 cell Anatomy 0.000 claims description 173
- 108090000623 proteins and genes Proteins 0.000 claims description 97
- 201000011510 cancer Diseases 0.000 claims description 69
- 102000004169 proteins and genes Human genes 0.000 claims description 63
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 61
- 108010040168 Bcl-2-Like Protein 11 Proteins 0.000 claims description 54
- 102000001765 Bcl-2-Like Protein 11 Human genes 0.000 claims description 53
- 230000001225 therapeutic effect Effects 0.000 claims description 53
- 101710163923 Jouberin Proteins 0.000 claims description 47
- 108010029485 Protein Isoforms Proteins 0.000 claims description 24
- 102000001708 Protein Isoforms Human genes 0.000 claims description 24
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 16
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 16
- 108091000080 Phosphotransferase Proteins 0.000 claims description 15
- 102000020233 phosphotransferase Human genes 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 claims description 9
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 claims description 6
- 230000006882 induction of apoptosis Effects 0.000 claims description 6
- 101150092671 BIM gene Proteins 0.000 claims description 5
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 claims description 5
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 3
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 claims 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 claims 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 claims 1
- YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 claims 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 claims 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 1
- 235000011180 diphosphates Nutrition 0.000 claims 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical compound OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 claims 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims 1
- 125000005341 metaphosphate group Chemical group 0.000 claims 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 claims 1
- 229940095102 methyl benzoate Drugs 0.000 claims 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 claims 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 claims 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 claims 1
- 229940049953 phenylacetate Drugs 0.000 claims 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims 1
- 229950009215 phenylbutanoic acid Drugs 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 claims 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 claims 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- 229940071104 xylenesulfonate Drugs 0.000 claims 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical class OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 abstract description 136
- 230000000694 effects Effects 0.000 abstract description 82
- 101000833492 Homo sapiens Jouberin Proteins 0.000 abstract description 43
- 239000000126 substance Substances 0.000 abstract description 41
- 230000006907 apoptotic process Effects 0.000 abstract description 32
- 101150038313 AHI1 gene Proteins 0.000 abstract description 26
- 239000003803 thymidine kinase inhibitor Substances 0.000 abstract description 7
- 229940123056 Thymidine kinase inhibitor Drugs 0.000 abstract description 3
- 210000004881 tumor cell Anatomy 0.000 abstract description 3
- 239000003112 inhibitor Substances 0.000 description 113
- 150000007857 hydrazones Chemical class 0.000 description 88
- 125000000217 alkyl group Chemical group 0.000 description 71
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 70
- 239000003814 drug Substances 0.000 description 57
- 235000018102 proteins Nutrition 0.000 description 54
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 51
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 51
- 230000006872 improvement Effects 0.000 description 44
- GOUHYARYYWKXHS-UHFFFAOYSA-N 4-formylbenzoic acid Chemical compound OC(=O)C1=CC=C(C=O)C=C1 GOUHYARYYWKXHS-UHFFFAOYSA-N 0.000 description 42
- 150000001875 compounds Chemical class 0.000 description 42
- 125000001424 substituent group Chemical group 0.000 description 42
- 102000054765 polymorphisms of proteins Human genes 0.000 description 41
- 125000003118 aryl group Chemical group 0.000 description 40
- JVTZFYYHCGSXJV-UHFFFAOYSA-N isovanillin Chemical compound COC1=CC=C(C=O)C=C1O JVTZFYYHCGSXJV-UHFFFAOYSA-N 0.000 description 36
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 34
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 32
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 32
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 32
- 229960002411 imatinib Drugs 0.000 description 32
- 102000001301 EGF receptor Human genes 0.000 description 31
- 108060006698 EGF receptor Proteins 0.000 description 31
- 230000003034 chemosensitisation Effects 0.000 description 30
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 28
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 28
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 27
- 239000006114 chemosensitizer Substances 0.000 description 27
- 201000010099 disease Diseases 0.000 description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 229940079593 drug Drugs 0.000 description 27
- 230000001965 increasing effect Effects 0.000 description 27
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 27
- 230000005764 inhibitory process Effects 0.000 description 25
- 229940043355 kinase inhibitor Drugs 0.000 description 25
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 25
- 230000004044 response Effects 0.000 description 25
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 23
- 229940124597 therapeutic agent Drugs 0.000 description 23
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 description 22
- 230000027455 binding Effects 0.000 description 22
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 22
- 229940002612 prodrug Drugs 0.000 description 22
- 239000000651 prodrug Substances 0.000 description 22
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 22
- 238000002560 therapeutic procedure Methods 0.000 description 22
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 22
- 102000000646 Interleukin-3 Human genes 0.000 description 20
- 108010002386 Interleukin-3 Proteins 0.000 description 20
- 125000001072 heteroaryl group Chemical group 0.000 description 20
- 125000005842 heteroatom Chemical group 0.000 description 20
- 229960003685 imatinib mesylate Drugs 0.000 description 20
- 208000032839 leukemia Diseases 0.000 description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 18
- 230000026731 phosphorylation Effects 0.000 description 18
- 238000006366 phosphorylation reaction Methods 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 18
- 102000000395 SH3 domains Human genes 0.000 description 17
- 108050008861 SH3 domains Proteins 0.000 description 17
- 125000003342 alkenyl group Chemical group 0.000 description 17
- CNUDBTRUORMMPA-UHFFFAOYSA-N formylthiophene Chemical compound O=CC1=CC=CS1 CNUDBTRUORMMPA-UHFFFAOYSA-N 0.000 description 17
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 17
- 125000005843 halogen group Chemical group 0.000 description 16
- 150000003217 pyrazoles Chemical class 0.000 description 16
- 229910052717 sulfur Inorganic materials 0.000 description 16
- 125000000304 alkynyl group Chemical group 0.000 description 15
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 15
- 230000019491 signal transduction Effects 0.000 description 15
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 description 14
- 125000002252 acyl group Chemical group 0.000 description 14
- 150000002148 esters Chemical class 0.000 description 14
- 230000007246 mechanism Effects 0.000 description 14
- 230000002018 overexpression Effects 0.000 description 14
- 229910052760 oxygen Inorganic materials 0.000 description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 14
- 229910052799 carbon Inorganic materials 0.000 description 13
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical class OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 13
- 125000000623 heterocyclic group Chemical group 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 238000003780 insertion Methods 0.000 description 13
- 230000037431 insertion Effects 0.000 description 13
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 13
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- 108060006633 protein kinase Proteins 0.000 description 13
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 102000001253 Protein Kinase Human genes 0.000 description 12
- 230000004913 activation Effects 0.000 description 12
- 229940100198 alkylating agent Drugs 0.000 description 12
- 239000002168 alkylating agent Substances 0.000 description 12
- 125000003710 aryl alkyl group Chemical group 0.000 description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 12
- 108010087686 src-Family Kinases Proteins 0.000 description 12
- 102000009076 src-Family Kinases Human genes 0.000 description 12
- 108700020796 Oncogene Proteins 0.000 description 11
- 230000000875 corresponding effect Effects 0.000 description 11
- 125000000753 cycloalkyl group Chemical group 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- 125000004404 heteroalkyl group Chemical group 0.000 description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 11
- 230000001566 pro-viral effect Effects 0.000 description 11
- 210000000130 stem cell Anatomy 0.000 description 11
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 10
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 125000005647 linker group Chemical group 0.000 description 10
- 229950004847 navitoclax Drugs 0.000 description 10
- 239000000816 peptidomimetic Substances 0.000 description 10
- 230000000861 pro-apoptotic effect Effects 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- 102100027308 Apoptosis regulator BAX Human genes 0.000 description 9
- 102000051485 Bcl-2 family Human genes 0.000 description 9
- 108700038897 Bcl-2 family Proteins 0.000 description 9
- 102100032305 Bcl-2 homologous antagonist/killer Human genes 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 9
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 9
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 9
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 9
- 102100035548 Protein Bop Human genes 0.000 description 9
- 108050008794 Protein Bop Proteins 0.000 description 9
- 229940122924 Src inhibitor Drugs 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 9
- 238000002512 chemotherapy Methods 0.000 description 9
- 125000004122 cyclic group Chemical group 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 238000007726 management method Methods 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 230000001686 pro-survival effect Effects 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000013268 sustained release Methods 0.000 description 9
- 239000012730 sustained-release form Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 9
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 8
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 108700024394 Exon Proteins 0.000 description 8
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 8
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 8
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 8
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 8
- PQAPVTKIEGUPRN-UHFFFAOYSA-N N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide Chemical compound CC(C)C1=CC=CC=C1CC1=CC(C(=O)NC=2C=CC(=CC=2)S(=O)(=O)C=2C(=CC=CC=2)C(C)(C)C)=C(O)C(O)=C1O PQAPVTKIEGUPRN-UHFFFAOYSA-N 0.000 description 8
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 8
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 108700000711 bcl-X Proteins 0.000 description 8
- 102000055104 bcl-X Human genes 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 8
- 229960002448 dasatinib Drugs 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000009368 gene silencing by RNA Effects 0.000 description 8
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- DWEHITNKTMMZBR-RUZDIDTESA-N n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-4-(4,4-dimethylpiperidin-1-yl)benzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCC(C)(C)CC1)[N+]([O-])=O)SC1=CC=CC=C1 DWEHITNKTMMZBR-RUZDIDTESA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 230000011664 signaling Effects 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 7
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 7
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 7
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 229960001948 caffeine Drugs 0.000 description 7
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 230000001332 colony forming effect Effects 0.000 description 7
- 239000000562 conjugate Substances 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 7
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 6
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 6
- 102000015690 Proto-Oncogene Proteins c-bcr Human genes 0.000 description 6
- 108010024221 Proto-Oncogene Proteins c-bcr Proteins 0.000 description 6
- 108020004459 Small interfering RNA Proteins 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 6
- 229940093265 berberine Drugs 0.000 description 6
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 229940121647 egfr inhibitor Drugs 0.000 description 6
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 230000002246 oncogenic effect Effects 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- KNIFXFQDTOLZIJ-UHFFFAOYSA-N (2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamic acid Chemical compound N=1C2=CC(NC(=O)O)=CN=C2NC=1C1=CC=CC=C1 KNIFXFQDTOLZIJ-UHFFFAOYSA-N 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 5
- 101100218425 Gallus gallus BCL2L1 gene Proteins 0.000 description 5
- 102000003964 Histone deacetylase Human genes 0.000 description 5
- 108090000353 Histone deacetylase Proteins 0.000 description 5
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 5
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 5
- 102000008072 Lymphokines Human genes 0.000 description 5
- 108010074338 Lymphokines Proteins 0.000 description 5
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 5
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 5
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 5
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 5
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 230000002424 anti-apoptotic effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 125000002837 carbocyclic group Chemical group 0.000 description 5
- 229960001338 colchicine Drugs 0.000 description 5
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 5
- 230000003828 downregulation Effects 0.000 description 5
- 229960003722 doxycycline Drugs 0.000 description 5
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 5
- 239000000890 drug combination Substances 0.000 description 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 239000011737 fluorine Substances 0.000 description 5
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 5
- 229960002584 gefitinib Drugs 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 5
- 125000001183 hydrocarbyl group Chemical group 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 229960003966 nicotinamide Drugs 0.000 description 5
- 235000005152 nicotinamide Nutrition 0.000 description 5
- 239000011570 nicotinamide Substances 0.000 description 5
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 5
- 229960001346 nilotinib Drugs 0.000 description 5
- 231100000590 oncogenic Toxicity 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 230000004043 responsiveness Effects 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000004055 small Interfering RNA Substances 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CVCLJVVBHYOXDC-IAZSKANUSA-N (2z)-2-[(5z)-5-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole Chemical compound COC1=C\C(=C/2N=C3C=CC=CC3=C\2)N\C1=C/C=1NC(C)=CC=1C CVCLJVVBHYOXDC-IAZSKANUSA-N 0.000 description 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 4
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 4
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 4
- GMBQPNQUPKDATF-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(4-fluoroanilino)pyrido[2,3-d]pyrimidine-7-carboxylic acid Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)O)=NC2=NC=1NC1=CC=C(F)C=C1 GMBQPNQUPKDATF-UHFFFAOYSA-N 0.000 description 4
- 206010069754 Acquired gene mutation Diseases 0.000 description 4
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 4
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 4
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 4
- 102000043276 Oncogene Human genes 0.000 description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 4
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000001062 anti-nausea Effects 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 4
- 229940117893 apigenin Drugs 0.000 description 4
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 4
- 235000008714 apigenin Nutrition 0.000 description 4
- 229940120638 avastin Drugs 0.000 description 4
- 235000019445 benzyl alcohol Nutrition 0.000 description 4
- 229960004217 benzyl alcohol Drugs 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 229960003736 bosutinib Drugs 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 229940109262 curcumin Drugs 0.000 description 4
- 239000004148 curcumin Substances 0.000 description 4
- 235000012754 curcumin Nutrition 0.000 description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 4
- 230000002074 deregulated effect Effects 0.000 description 4
- 230000003831 deregulation Effects 0.000 description 4
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 4
- 229960005420 etoposide Drugs 0.000 description 4
- 229960002949 fluorouracil Drugs 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 229940045109 genistein Drugs 0.000 description 4
- 235000006539 genistein Nutrition 0.000 description 4
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 230000011132 hemopoiesis Effects 0.000 description 4
- 239000000367 immunologic factor Substances 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 4
- 108091005601 modified peptides Proteins 0.000 description 4
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 150000002924 oxiranes Chemical group 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 230000004850 protein–protein interaction Effects 0.000 description 4
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 4
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 230000037439 somatic mutation Effects 0.000 description 4
- 229960004964 temozolomide Drugs 0.000 description 4
- MHSKRLJMQQNJNC-UHFFFAOYSA-N terephthalamide Chemical compound NC(=O)C1=CC=C(C(N)=O)C=C1 MHSKRLJMQQNJNC-UHFFFAOYSA-N 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- TUCIOBMMDDOEMM-RIYZIHGNSA-N tyrphostin B42 Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NCC1=CC=CC=C1 TUCIOBMMDDOEMM-RIYZIHGNSA-N 0.000 description 4
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- JFJNVIPVOCESGZ-UHFFFAOYSA-N 2,3-dipyridin-2-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=CN=C1C1=CC=CC=N1 JFJNVIPVOCESGZ-UHFFFAOYSA-N 0.000 description 3
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 3
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 3
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 description 3
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 102100021906 Cyclin-O Human genes 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 102400001368 Epidermal growth factor Human genes 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 3
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 description 3
- HRYILSDLIGTCOP-UHFFFAOYSA-N N-benzoylurea Chemical compound NC(=O)NC(=O)C1=CC=CC=C1 HRYILSDLIGTCOP-UHFFFAOYSA-N 0.000 description 3
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- 108091007960 PI3Ks Proteins 0.000 description 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 3
- 102000052575 Proto-Oncogene Human genes 0.000 description 3
- 108700020978 Proto-Oncogene Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 206010042971 T-cell lymphoma Diseases 0.000 description 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- 108010017842 Telomerase Proteins 0.000 description 3
- 102100023132 Transcription factor Jun Human genes 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 229940122803 Vinca alkaloid Drugs 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 230000003474 anti-emetic effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000000340 anti-metabolite Effects 0.000 description 3
- 239000002111 antiemetic agent Substances 0.000 description 3
- 229940125683 antiemetic agent Drugs 0.000 description 3
- 229940100197 antimetabolite Drugs 0.000 description 3
- 239000002256 antimetabolite Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 230000005735 apoptotic response Effects 0.000 description 3
- 230000005756 apoptotic signaling Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 3
- 229960002707 bendamustine Drugs 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 3
- 229940127093 camptothecin Drugs 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000004452 carbocyclyl group Chemical group 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 230000004186 co-expression Effects 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 229960000684 cytarabine Drugs 0.000 description 3
- 230000002559 cytogenic effect Effects 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 229940082789 erbitux Drugs 0.000 description 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 3
- 229960001433 erlotinib Drugs 0.000 description 3
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 3
- 235000008191 folinic acid Nutrition 0.000 description 3
- 239000011672 folinic acid Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 229940022353 herceptin Drugs 0.000 description 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229960001691 leucovorin Drugs 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 229960003539 mitoguazone Drugs 0.000 description 3
- GCDZDXVTDCMNMN-UHFFFAOYSA-N n-(2-aminoethyl)methanesulfonamide Chemical compound CS(=O)(=O)NCCN GCDZDXVTDCMNMN-UHFFFAOYSA-N 0.000 description 3
- 208000004235 neutropenia Diseases 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 229950006584 obatoclax Drugs 0.000 description 3
- 102000027450 oncoproteins Human genes 0.000 description 3
- 108091008819 oncoproteins Proteins 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 210000004214 philadelphia chromosome Anatomy 0.000 description 3
- 230000010399 physical interaction Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 150000003057 platinum Chemical class 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 239000008389 polyethoxylated castor oil Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 239000003223 protective agent Substances 0.000 description 3
- 230000006916 protein interaction Effects 0.000 description 3
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000002626 targeted therapy Methods 0.000 description 3
- ZASCXWTVGGZQIZ-UHFFFAOYSA-N thieno[3,2-d]pyrimidin-2-amine Chemical compound NC1=NC=C2SC=CC2=N1 ZASCXWTVGGZQIZ-UHFFFAOYSA-N 0.000 description 3
- 206010043554 thrombocytopenia Diseases 0.000 description 3
- 239000003734 thymidylate synthase inhibitor Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 229940066958 treanda Drugs 0.000 description 3
- 125000004953 trihalomethyl group Chemical group 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- ISOCDPQFIXDIMS-QHCPKHFHSA-N (2s)-n-[4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]phenyl]pyrrolidine-2-carboxamide Chemical compound O=C([C@H]1NCCC1)NC(C=C1)=CC=C1C(N=1)=CC=NC=1NC(C=C1)=CC=C1N1CCOCC1 ISOCDPQFIXDIMS-QHCPKHFHSA-N 0.000 description 2
- VFUAJMPDXIRPKO-LQELWAHVSA-N (e)-3-(6-bromopyridin-2-yl)-2-cyano-n-[(1s)-1-phenylethyl]prop-2-enamide Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(=O)C(\C#N)=C\C1=CC=CC(Br)=N1 VFUAJMPDXIRPKO-LQELWAHVSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 2
- CXLPODKWPHSQEB-UHFFFAOYSA-N 2-(dimethylamino)-n-[4-[4-[(5-methyl-1h-pyrazol-3-yl)amino]-6-phenylpyrimidin-2-yl]sulfanylphenyl]acetamide Chemical compound C1=CC(NC(=O)CN(C)C)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=CC(C=2C=CC=CC=2)=N1 CXLPODKWPHSQEB-UHFFFAOYSA-N 0.000 description 2
- OKUQCAXYWXFGPK-UHFFFAOYSA-N 2-[(3,5-dimethoxyphenyl)methylsulfanyl]-n-(5-methyl-1h-pyrazol-3-yl)-6-morpholin-4-ylpyrimidin-4-amine Chemical compound COC1=CC(OC)=CC(CSC=2N=C(C=C(NC=3NN=C(C)C=3)N=2)N2CCOCC2)=C1 OKUQCAXYWXFGPK-UHFFFAOYSA-N 0.000 description 2
- XRAFMWYIOALWSA-UHFFFAOYSA-N 2-[(3,5-dimethoxyphenyl)methylsulfanyl]-n-(5-methyl-1h-pyrazol-3-yl)-6-pyrrolidin-3-ylpyrimidin-4-amine Chemical compound COC1=CC(OC)=CC(CSC=2N=C(C=C(NC=3NN=C(C)C=3)N=2)C2CNCC2)=C1 XRAFMWYIOALWSA-UHFFFAOYSA-N 0.000 description 2
- MPSNETNZTLYXIK-UHFFFAOYSA-N 2-[(3-chlorophenyl)methylsulfanyl]-6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical class C1CN(C)CCN1C1=CC(NC=2NN=C(C)C=2)=NC(SCC=2C=C(Cl)C=CC=2)=N1 MPSNETNZTLYXIK-UHFFFAOYSA-N 0.000 description 2
- LUJIOOSJBZJHHK-UHFFFAOYSA-N 2-[(3-chlorophenyl)methylsulfanyl]-6-n-(2-methoxyethyl)-4-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-4,6-diamine Chemical compound N=1C(SCC=2C=C(Cl)C=CC=2)=NC(NCCOC)=CC=1NC1=CC(C)=NN1 LUJIOOSJBZJHHK-UHFFFAOYSA-N 0.000 description 2
- VWRGZMRMYRYZGQ-UHFFFAOYSA-N 2-[(3-chlorophenyl)methylsulfanyl]-n-(5-methyl-1h-pyrazol-3-yl)-6-morpholin-4-ylpyrimidin-4-amine Chemical compound N1N=C(C)C=C1NC1=CC(N2CCOCC2)=NC(SCC=2C=C(Cl)C=CC=2)=N1 VWRGZMRMYRYZGQ-UHFFFAOYSA-N 0.000 description 2
- MSENMMQDNAUODA-UHFFFAOYSA-N 2-[(3-chlorophenyl)methylsulfanyl]-n-(5-methyl-1h-pyrazol-3-yl)-6-piperidin-1-ylpyrimidin-4-amine Chemical compound N1N=C(C)C=C1NC1=CC(N2CCCCC2)=NC(SCC=2C=C(Cl)C=CC=2)=N1 MSENMMQDNAUODA-UHFFFAOYSA-N 0.000 description 2
- JUPXIGULOXFQHK-UHFFFAOYSA-N 2-[(4-methoxyphenyl)methylsulfanyl]-6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical class C1=CC(OC)=CC=C1CSC1=NC(NC=2NN=C(C)C=2)=CC(N2CCN(C)CC2)=N1 JUPXIGULOXFQHK-UHFFFAOYSA-N 0.000 description 2
- WOGTVCHVDBTSJN-UHFFFAOYSA-N 2-benzylsulfanyl-6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound C1CN(C)CCN1C1=CC(NC=2NN=C(C)C=2)=NC(SCC=2C=CC=CC=2)=N1 WOGTVCHVDBTSJN-UHFFFAOYSA-N 0.000 description 2
- RHCLBIQUEJRCEF-UHFFFAOYSA-N 2-benzylsulfanyl-n-(5-methyl-1h-pyrazol-3-yl)-6-morpholin-4-ylpyrimidin-4-amine Chemical compound N1N=C(C)C=C1NC1=CC(N2CCOCC2)=NC(SCC=2C=CC=CC=2)=N1 RHCLBIQUEJRCEF-UHFFFAOYSA-N 0.000 description 2
- PHTBNWHHWXBUFX-UHFFFAOYSA-N 2-methyl-n-[4-[4-[(5-methyl-1h-pyrazol-3-yl)amino]-6-phenylpyrimidin-2-yl]sulfanylphenyl]propanamide Chemical compound C1=CC(NC(=O)C(C)C)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=CC(C=2C=CC=CC=2)=N1 PHTBNWHHWXBUFX-UHFFFAOYSA-N 0.000 description 2
- RZCJYMOBWVJQGV-UHFFFAOYSA-N 2-naphthyloxyacetic acid Chemical compound C1=CC=CC2=CC(OCC(=O)O)=CC=C21 RZCJYMOBWVJQGV-UHFFFAOYSA-N 0.000 description 2
- LPWXSUVGAPVCPY-UHFFFAOYSA-N 3-(2-bromophenyl)-7-[4-[2-(diethylamino)ethoxy]anilino]-1,4-dimethyl-4h-pyrimido[4,5-d]pyrimidin-2-one Chemical compound C1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C(C(C)N(C(=O)N2C)C=3C(=CC=CC=3)Br)C2=N1 LPWXSUVGAPVCPY-UHFFFAOYSA-N 0.000 description 2
- WEGYGNROSJDEIW-UHFFFAOYSA-N 3-Acetylpyridine Chemical compound CC(=O)C1=CC=CN=C1 WEGYGNROSJDEIW-UHFFFAOYSA-N 0.000 description 2
- FYAPZIAUATWNOR-UHFFFAOYSA-N 3-methyl-n-[4-[4-[(5-methyl-1h-pyrazol-3-yl)amino]-6-phenylpyrimidin-2-yl]sulfanylphenyl]butanamide Chemical compound C1=CC(NC(=O)CC(C)C)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=CC(C=2C=CC=CC=2)=N1 FYAPZIAUATWNOR-UHFFFAOYSA-N 0.000 description 2
- IBPVXAOOVUAOKJ-UHFFFAOYSA-N 4-[[2,6-difluoro-4-[3-(1-piperidin-4-ylpyrazol-4-yl)quinoxalin-5-yl]phenyl]methyl]morpholine Chemical compound FC1=CC(C=2C3=NC(=CN=C3C=CC=2)C2=CN(N=C2)C2CCNCC2)=CC(F)=C1CN1CCOCC1 IBPVXAOOVUAOKJ-UHFFFAOYSA-N 0.000 description 2
- IYLIRRZCLARWKQ-UHFFFAOYSA-N 4-anilinoquinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=CC=CC2=C1NC1=CC=CC=C1 IYLIRRZCLARWKQ-UHFFFAOYSA-N 0.000 description 2
- ZCCPLJOKGAACRT-UHFFFAOYSA-N 4-methyl-3-[[1-methyl-6-(3-pyridinyl)-4-pyrazolo[3,4-d]pyrimidinyl]amino]-N-[3-(trifluoromethyl)phenyl]benzamide Chemical compound CC1=CC=C(C(=O)NC=2C=C(C=CC=2)C(F)(F)F)C=C1NC(C=1C=NN(C)C=1N=1)=NC=1C1=CC=CN=C1 ZCCPLJOKGAACRT-UHFFFAOYSA-N 0.000 description 2
- RMSAJHYTPAICFG-UHFFFAOYSA-N 4-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-n-phenylquinazoline-2,4-diamine Chemical compound C1CC1C1=NNC(NC=2C3=CC=CC=C3N=C(NC=3C=CC=CC=3)N=2)=C1 RMSAJHYTPAICFG-UHFFFAOYSA-N 0.000 description 2
- PDOQBOJDRPLBQU-QMMMGPOBSA-N 5-chloro-2-n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1N=CC(F)=CN=1)C(N=1)=NC=C(Cl)C=1NC=1C=C(C)NN=1 PDOQBOJDRPLBQU-QMMMGPOBSA-N 0.000 description 2
- SUNXHXDJOIXABJ-NSHDSACASA-N 5-fluoro-2-[[(1s)-1-(4-fluorophenyl)ethyl]amino]-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(C(=CC=1F)C#N)=NC=1NC=1C=C(C)NN=1 SUNXHXDJOIXABJ-NSHDSACASA-N 0.000 description 2
- GOYHGLIVSBBDEG-UHFFFAOYSA-N 6-(2,6-dimethylphenyl)-n-(5-methyl-1h-pyrazol-3-yl)-2-naphthalen-2-ylsulfanylpyrimidin-4-amine Chemical compound N1N=C(C)C=C1NC1=CC(C=2C(=CC=CC=2C)C)=NC(SC=2C=C3C=CC=CC3=CC=2)=N1 GOYHGLIVSBBDEG-UHFFFAOYSA-N 0.000 description 2
- AIRMEXFVLJJUJE-UHFFFAOYSA-N 6-(2-methylphenyl)-n-(5-methyl-1h-pyrazol-3-yl)-2-naphthalen-2-ylsulfanylpyrimidin-4-amine Chemical compound N1N=C(C)C=C1NC1=CC(C=2C(=CC=CC=2)C)=NC(SC=2C=C3C=CC=CC3=CC=2)=N1 AIRMEXFVLJJUJE-UHFFFAOYSA-N 0.000 description 2
- QOEQKXHMJLFYIS-UHFFFAOYSA-N 6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)-2-[(4-morpholin-4-ylsulfonylphenyl)methylsulfanyl]pyrimidin-4-amine Chemical compound C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(SCC=2C=CC(=CC=2)S(=O)(=O)N2CCOCC2)=N1 QOEQKXHMJLFYIS-UHFFFAOYSA-N 0.000 description 2
- GYWKNWNEMVPCPW-UHFFFAOYSA-N 6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)-2-methylsulfanylpyrimidin-4-amine Chemical compound C=1C(N2CCN(C)CC2)=NC(SC)=NC=1NC1=CC(C)=NN1 GYWKNWNEMVPCPW-UHFFFAOYSA-N 0.000 description 2
- SBBORJVUTIKXAL-UHFFFAOYSA-N 6-ethyl-n-(5-methyl-1h-pyrazol-3-yl)-2-(2-phenylpropan-2-yl)pyrimidin-4-amine Chemical compound N=1C(C(C)(C)C=2C=CC=CC=2)=NC(CC)=CC=1NC1=CC(C)=NN1 SBBORJVUTIKXAL-UHFFFAOYSA-N 0.000 description 2
- HYUQZXHOCHTJGO-UHFFFAOYSA-N 6-n-(2-methoxyethyl)-4-n-(5-methyl-1h-pyrazol-3-yl)-2-[(4-morpholin-4-ylsulfonylphenyl)methylsulfanyl]pyrimidine-4,6-diamine Chemical compound N=1C(SCC=2C=CC(=CC=2)S(=O)(=O)N2CCOCC2)=NC(NCCOC)=CC=1NC=1C=C(C)NN=1 HYUQZXHOCHTJGO-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 108091012583 BCL2 Proteins 0.000 description 2
- 102100035656 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Human genes 0.000 description 2
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- SQSZANZGUXWJEA-UHFFFAOYSA-N Gandotinib Chemical compound N1C(C)=CC(NC2=NN3C(CC=4C(=CC(Cl)=CC=4)F)=C(C)N=C3C(CN3CCOCC3)=C2)=N1 SQSZANZGUXWJEA-UHFFFAOYSA-N 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 101000803294 Homo sapiens BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Proteins 0.000 description 2
- 101000798320 Homo sapiens Bcl-2 homologous antagonist/killer Proteins 0.000 description 2
- 101000634975 Homo sapiens Tripartite motif-containing protein 29 Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 2
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 206010048723 Multiple-drug resistance Diseases 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 102100025803 Progesterone receptor Human genes 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- 102000014400 SH2 domains Human genes 0.000 description 2
- 108050003452 SH2 domains Proteins 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- JVDOKQYTTYUYDV-UHFFFAOYSA-N TG101209 Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(C)C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)=N1 JVDOKQYTTYUYDV-UHFFFAOYSA-N 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 2
- 229960001686 afatinib Drugs 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 108700039689 bcl-2 Homologous Antagonist-Killer Proteins 0.000 description 2
- 108700000707 bcl-2-Associated X Proteins 0.000 description 2
- 102000055102 bcl-2-Associated X Human genes 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229940126600 bulk drug product Drugs 0.000 description 2
- ZRPZJWVJFYALFX-UHFFFAOYSA-N butyl 6-[(5-methyl-1h-pyrazol-3-yl)amino]-2-[4-(propanoylamino)phenyl]sulfanylpyrimidine-4-carboxylate Chemical compound N=1C(SC=2C=CC(NC(=O)CC)=CC=2)=NC(C(=O)OCCCC)=CC=1NC1=CC(C)=NN1 ZRPZJWVJFYALFX-UHFFFAOYSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 2
- 229950002205 dacomitinib Drugs 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 229940080856 gleevec Drugs 0.000 description 2
- 229940084910 gliadel Drugs 0.000 description 2
- OZBAVEKZGSOMOJ-MIUGBVLSSA-N glycitin Chemical compound COC1=CC(C(C(C=2C=CC(O)=CC=2)=CO2)=O)=C2C=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OZBAVEKZGSOMOJ-MIUGBVLSSA-N 0.000 description 2
- 229930000755 gossypol Natural products 0.000 description 2
- 229950005277 gossypol Drugs 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002743 insertional mutagenesis Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 150000002546 isoxazolidines Chemical class 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- FJIJAWAHGQDWTR-UHFFFAOYSA-N methyl 4-[4-(methoxymethyl)-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylbenzoate Chemical compound N=1C(SC=2C=CC(=CC=2)C(=O)OC)=NC(COC)=CC=1NC1=CC(C)=NN1 FJIJAWAHGQDWTR-UHFFFAOYSA-N 0.000 description 2
- UVFVPEIUGCVFRV-UHFFFAOYSA-N methyl 6-[(5-methyl-1h-pyrazol-3-yl)amino]-2-[4-(propanoylamino)phenyl]sulfanylpyrimidine-4-carboxylate Chemical compound C1=CC(NC(=O)CC)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=CC(C(=O)OC)=N1 UVFVPEIUGCVFRV-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N methyl cyanide Natural products CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 108040008770 methylated-DNA-[protein]-cysteine S-methyltransferase activity proteins Proteins 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N momelotinib Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000036457 multidrug resistance Effects 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- UMPNMWGCMVENOJ-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-naphthalen-2-ylsulfanyl-6-phenylpyrimidin-4-amine Chemical compound C1CC1C1=CC(NC=2N=C(SC=3C=C4C=CC=CC4=CC=3)N=C(C=2)C=2C=CC=CC=2)=NN1 UMPNMWGCMVENOJ-UHFFFAOYSA-N 0.000 description 2
- OWLHUABMKOEDDP-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-naphthalen-2-ylsulfanylpyrimidin-4-amine Chemical compound C1CC1C1=NNC(NC=2N=C(SC=3C=C4C=CC=CC4=CC=3)N=CC=2)=C1 OWLHUABMKOEDDP-UHFFFAOYSA-N 0.000 description 2
- HLZNMLOULICIDU-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-5,6-dimethyl-2-naphthalen-2-ylsulfanylpyrimidin-4-amine Chemical compound CC=1C(C)=NC(SC=2C=C3C=CC=CC3=CC=2)=NC=1NC(NN=1)=CC=1C1CC1 HLZNMLOULICIDU-UHFFFAOYSA-N 0.000 description 2
- QDLGURJHMBLUKW-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-5-methyl-2-naphthalen-2-ylsulfanylpyrimidin-4-amine Chemical compound CC1=CN=C(SC=2C=C3C=CC=CC3=CC=2)N=C1NC(NN=1)=CC=1C1CC1 QDLGURJHMBLUKW-UHFFFAOYSA-N 0.000 description 2
- BFCHWQNHLLJQKU-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-naphthalen-2-ylsulfanylpyrimidin-4-amine Chemical class C1CN(C)CCN1C1=CC(NC=2NN=C(C=2)C2CC2)=NC(SC=2C=C3C=CC=CC3=CC=2)=N1 BFCHWQNHLLJQKU-UHFFFAOYSA-N 0.000 description 2
- ZKSNPIJCWJYQSS-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-6-methyl-2-naphthalen-2-ylsulfanylpyrimidin-4-amine Chemical compound N=1C(SC=2C=C3C=CC=CC3=CC=2)=NC(C)=CC=1NC(NN=1)=CC=1C1CC1 ZKSNPIJCWJYQSS-UHFFFAOYSA-N 0.000 description 2
- MEQZKLFEMYIESN-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-6-morpholin-4-yl-2-naphthalen-2-ylsulfanylpyrimidin-4-amine Chemical compound C1CC1C1=NNC(NC=2N=C(SC=3C=C4C=CC=CC4=CC=3)N=C(C=2)N2CCOCC2)=C1 MEQZKLFEMYIESN-UHFFFAOYSA-N 0.000 description 2
- KXOKAYKGTCLIPO-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-2-naphthalen-2-ylsulfanyl-6-phenylpyrimidin-4-amine Chemical compound N1N=C(C)C=C1NC1=CC(C=2C=CC=CC=2)=NC(SC=2C=C3C=CC=CC3=CC=2)=N1 KXOKAYKGTCLIPO-UHFFFAOYSA-N 0.000 description 2
- CEZGBQYQEGPQHG-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-6-morpholin-4-yl-2-(naphthalen-2-ylmethylsulfanyl)pyrimidin-4-amine Chemical compound N1N=C(C)C=C1NC1=CC(N2CCOCC2)=NC(SCC=2C=C3C=CC=CC3=CC=2)=N1 CEZGBQYQEGPQHG-UHFFFAOYSA-N 0.000 description 2
- DYWSMDXSVIMMHS-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-6-morpholin-4-yl-2-[(4-morpholin-4-ylsulfonylphenyl)methylsulfanyl]pyrimidin-4-amine Chemical class N1C(C)=CC(NC=2N=C(SCC=3C=CC(=CC=3)S(=O)(=O)N3CCOCC3)N=C(C=2)N2CCOCC2)=N1 DYWSMDXSVIMMHS-UHFFFAOYSA-N 0.000 description 2
- RFZKSQIFOZZIAQ-UHFFFAOYSA-N n-[3-(4-methylpiperazin-1-yl)phenyl]-8-(4-methylsulfonylphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine Chemical compound C1CN(C)CCN1C1=CC=CC(NC2=NN3C=CC=C(C3=N2)C=2C=CC(=CC=2)S(C)(=O)=O)=C1 RFZKSQIFOZZIAQ-UHFFFAOYSA-N 0.000 description 2
- JRZGKUDOMQFGES-UHFFFAOYSA-N n-[4-[4-(3-acetamidophenyl)-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]acetamide Chemical class C1=CC(NC(=O)C)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=CC(C=2C=C(NC(C)=O)C=CC=2)=N1 JRZGKUDOMQFGES-UHFFFAOYSA-N 0.000 description 2
- RWEUEIUREFILDS-UHFFFAOYSA-N n-[4-[4-(4-methoxyphenyl)-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]acetamide Chemical compound C1=CC(OC)=CC=C1C1=CC(NC=2NN=C(C)C=2)=NC(SC=2C=CC(NC(C)=O)=CC=2)=N1 RWEUEIUREFILDS-UHFFFAOYSA-N 0.000 description 2
- WYIQXFOSEMJMAS-UHFFFAOYSA-N n-[4-[4-(hydroxymethyl)-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]propanamide Chemical compound C1=CC(NC(=O)CC)=CC=C1SC1=NC(CO)=CC(NC=2NN=C(C)C=2)=N1 WYIQXFOSEMJMAS-UHFFFAOYSA-N 0.000 description 2
- CJITVBOBWKKPLW-UHFFFAOYSA-N n-[4-[4-(methoxymethyl)-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]propanamide Chemical compound C1=CC(NC(=O)CC)=CC=C1SC1=NC(COC)=CC(NC=2NN=C(C)C=2)=N1 CJITVBOBWKKPLW-UHFFFAOYSA-N 0.000 description 2
- QUKPHHFZJNRUMP-UHFFFAOYSA-N n-[4-[4-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-6-phenylpyrimidin-2-yl]sulfanylphenyl]propanamide Chemical compound C1=CC(NC(=O)CC)=CC=C1SC1=NC(NC=2NN=C(C=2)C2CC2)=CC(C=2C=CC=CC=2)=N1 QUKPHHFZJNRUMP-UHFFFAOYSA-N 0.000 description 2
- NSJLOJLNMHXHFG-UHFFFAOYSA-N n-[4-[4-[(5-methyl-1h-pyrazol-3-yl)amino]-6-morpholin-4-ylpyrimidin-2-yl]sulfanylphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=CC(N2CCOCC2)=N1 NSJLOJLNMHXHFG-UHFFFAOYSA-N 0.000 description 2
- ZUOHNZIRNKHHJE-UHFFFAOYSA-N n-[4-[4-[(5-methyl-1h-pyrazol-3-yl)amino]-6-phenylpyrimidin-2-yl]sulfanylphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=CC(C=2C=CC=CC=2)=N1 ZUOHNZIRNKHHJE-UHFFFAOYSA-N 0.000 description 2
- GLXTXPWWOYBBCI-UHFFFAOYSA-N n-[4-[4-[(5-methyl-1h-pyrazol-3-yl)amino]-6-phenylpyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound N1N=C(C)C=C1NC1=CC(C=2C=CC=CC=2)=NC(SC=2C=CC(NC(=O)C3CC3)=CC=2)=N1 GLXTXPWWOYBBCI-UHFFFAOYSA-N 0.000 description 2
- NJPTZQZPKSHKNR-UHFFFAOYSA-N n-[4-[4-[(5-methyl-1h-pyrazol-3-yl)amino]-6-phenylpyrimidin-2-yl]sulfanylphenyl]ethanesulfonamide Chemical compound C1=CC(NS(=O)(=O)CC)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=CC(C=2C=CC=CC=2)=N1 NJPTZQZPKSHKNR-UHFFFAOYSA-N 0.000 description 2
- FNBGPMNXEGPANM-UHFFFAOYSA-N n-[4-[4-[(5-methyl-1h-pyrazol-3-yl)amino]-6-phenylpyrimidin-2-yl]sulfanylphenyl]propanamide Chemical compound C1=CC(NC(=O)CC)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=CC(C=2C=CC=CC=2)=N1 FNBGPMNXEGPANM-UHFFFAOYSA-N 0.000 description 2
- PUUPUZQGYNCCED-UHFFFAOYSA-N n-[4-[4-[(5-methyl-1h-pyrazol-3-yl)amino]-6-phenylpyrimidin-2-yl]sulfanylphenyl]propane-1-sulfonamide Chemical compound C1=CC(NS(=O)(=O)CCC)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=CC(C=2C=CC=CC=2)=N1 PUUPUZQGYNCCED-UHFFFAOYSA-N 0.000 description 2
- MNDVGQRXFSJZGA-UHFFFAOYSA-N n-[4-[4-[(5-methyl-1h-pyrazol-3-yl)amino]-6-phenylpyrimidin-2-yl]sulfanylphenyl]propane-2-sulfonamide Chemical compound C1=CC(NS(=O)(=O)C(C)C)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=CC(C=2C=CC=CC=2)=N1 MNDVGQRXFSJZGA-UHFFFAOYSA-N 0.000 description 2
- BGNRYQCGVJJPRI-UHFFFAOYSA-N n-[4-[4-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1SC1=NC=CC(NC=2NN=C(C)C=2)=N1 BGNRYQCGVJJPRI-UHFFFAOYSA-N 0.000 description 2
- PPKYLKQWCYTYOP-UHFFFAOYSA-N n-[4-[4-[4-[3-(dimethylamino)propoxy]phenyl]-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]acetamide Chemical compound C1=CC(OCCCN(C)C)=CC=C1C1=CC(NC=2NN=C(C)C=2)=NC(SC=2C=CC(NC(C)=O)=CC=2)=N1 PPKYLKQWCYTYOP-UHFFFAOYSA-N 0.000 description 2
- XGWCSXUNRMZLPZ-UHFFFAOYSA-N n-[4-[4-tert-butyl-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=CC(C(C)(C)C)=N1 XGWCSXUNRMZLPZ-UHFFFAOYSA-N 0.000 description 2
- YKDOQPKOCDSGNK-UHFFFAOYSA-N n-[4-[5-methyl-4-[(5-methyl-1h-pyrazol-3-yl)amino]-6-phenylpyrimidin-2-yl]sulfanylphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=C(C)C(C=2C=CC=CC=2)=N1 YKDOQPKOCDSGNK-UHFFFAOYSA-N 0.000 description 2
- 239000002159 nanocrystal Substances 0.000 description 2
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 2
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 2
- 231100001143 noxa Toxicity 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 229940069510 parthenolide Drugs 0.000 description 2
- KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N pentanal Chemical compound CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 2
- NDTYTMIUWGWIMO-UHFFFAOYSA-N perillyl alcohol Chemical compound CC(=C)C1CCC(CO)=CC1 NDTYTMIUWGWIMO-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- 239000003504 photosensitizing agent Substances 0.000 description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 108010056274 polo-like kinase 1 Proteins 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 2
- 229960003581 pyridoxal Drugs 0.000 description 2
- 235000008164 pyridoxal Nutrition 0.000 description 2
- 239000011674 pyridoxal Substances 0.000 description 2
- AUKXFNABVHIUAC-UHFFFAOYSA-N pyrrolidin-2-ylmethylamine Chemical compound NCC1CCCN1 AUKXFNABVHIUAC-UHFFFAOYSA-N 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- IOVJNINZHOJSDD-UHFFFAOYSA-N thieno[2,3-b]pyridine-5-carbonitrile Chemical compound N#CC1=CN=C2SC=CC2=C1 IOVJNINZHOJSDD-UHFFFAOYSA-N 0.000 description 2
- QYCIXUKZMDUDBK-UHFFFAOYSA-N thieno[3,2-b]pyridine-6-carbonitrile Chemical compound N#CC1=CN=C2C=CSC2=C1 QYCIXUKZMDUDBK-UHFFFAOYSA-N 0.000 description 2
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- 230000009452 underexpressoin Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 239000002525 vasculotropin inhibitor Substances 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 229930007631 (-)-perillyl alcohol Natural products 0.000 description 1
- KLOMFJDFOUPIJP-UHFFFAOYSA-N (2-chlorophenyl)methyl n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)carbamate Chemical compound ClC1=CC=CC=C1COC(=O)NC1=CN=C(NC(=C2)C=3C=CC=CC=3)C2=C1 KLOMFJDFOUPIJP-UHFFFAOYSA-N 0.000 description 1
- HPUOUTHIVTVOJL-UHFFFAOYSA-N (2-chlorophenyl)methyl n-[2-(3-acetamidophenyl)-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound CC(=O)NC1=CC=CC(C=2NC3=NC=C(NC(=O)OCC=4C(=CC=CC=4)Cl)C=C3C=2)=C1 HPUOUTHIVTVOJL-UHFFFAOYSA-N 0.000 description 1
- WMSJODTYOFJWQY-UHFFFAOYSA-N (2-chlorophenyl)methyl n-[2-[3-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound COCCOC1=CC=CC(C=2NC3=NC=C(NC(=O)OCC=4C(=CC=CC=4)Cl)C=C3C=2)=C1 WMSJODTYOFJWQY-UHFFFAOYSA-N 0.000 description 1
- FHSRUXRMSRJDQV-ZSOIEALJSA-N (3z)-2-oxo-3-(4,5,6,7-tetrahydro-1h-indol-2-ylmethylidene)-1h-indole-5-sulfonamide Chemical compound C1CCCC(N2)=C1C=C2\C=C1/C(=O)NC2=CC=C(S(=O)(=O)N)C=C21 FHSRUXRMSRJDQV-ZSOIEALJSA-N 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- UBJUKSAYDIAYLD-UHFFFAOYSA-N 1,1,1-trifluoropropan-2-yl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C(F)(F)F)=CN=C2NC=1C1=CC=CC=C1 UBJUKSAYDIAYLD-UHFFFAOYSA-N 0.000 description 1
- SWEICGMKXPNXNU-UHFFFAOYSA-N 1,2-dihydroindazol-3-one Chemical class C1=CC=C2C(O)=NNC2=C1 SWEICGMKXPNXNU-UHFFFAOYSA-N 0.000 description 1
- PYEVAXSVSVWERE-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-(9h-thioxanthen-9-yl)butane-1,3-dione Chemical compound C12=CC=CC=C2SC2=CC=CC=C2C1C(C(=O)C)C(=O)C1=CC=C(F)C=C1 PYEVAXSVSVWERE-UHFFFAOYSA-N 0.000 description 1
- ZRQPLIOJDVHTNM-UHFFFAOYSA-N 1-ethyl-3-[2-methoxy-4-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]urea Chemical compound C1=C(OC)C(NC(=O)NCC)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 ZRQPLIOJDVHTNM-UHFFFAOYSA-N 0.000 description 1
- TXPGVEQROBPCHN-UHFFFAOYSA-N 1-ethyl-3-[4-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]-2-(trifluoromethoxy)phenyl]urea Chemical compound C1=C(OC(F)(F)F)C(NC(=O)NCC)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 TXPGVEQROBPCHN-UHFFFAOYSA-N 0.000 description 1
- BNZPFJBUHRBLNB-UHFFFAOYSA-N 1-oxido-1,2,4-benzotriazin-1-ium Chemical compound C1=CC=C2[N+]([O-])=NC=NC2=C1 BNZPFJBUHRBLNB-UHFFFAOYSA-N 0.000 description 1
- PHTBBLCJUSOPTQ-UHFFFAOYSA-N 1-phenylethyl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound C=1C=CC=CC=1C(C)OC(=O)NC(C=C1N=2)=CN=C1NC=2C1=CC=CC=C1 PHTBBLCJUSOPTQ-UHFFFAOYSA-N 0.000 description 1
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- ZQEXIXXJFSQPNA-UHFFFAOYSA-N 1h-imidazole-5-carbaldehyde Chemical compound O=CC1=CNC=N1 ZQEXIXXJFSQPNA-UHFFFAOYSA-N 0.000 description 1
- RCWISWVYKNLXHC-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridin-4-amine Chemical compound NC1=CC=NC2=C1C=CN2 RCWISWVYKNLXHC-UHFFFAOYSA-N 0.000 description 1
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical group C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- BYHPYNMDJCZORZ-UHFFFAOYSA-N 2,2-dimethylpropyl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound N=1C2=CC(NC(=O)OCC(C)(C)C)=CN=C2NC=1C1=CC=CC=C1 BYHPYNMDJCZORZ-UHFFFAOYSA-N 0.000 description 1
- HPXNDPIHESDYPK-UHFFFAOYSA-N 2,2-dimethylpropyl n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)carbamate Chemical compound C=1C2=CC(NC(=O)OCC(C)(C)C)=CN=C2NC=1C1=CC=CC=C1 HPXNDPIHESDYPK-UHFFFAOYSA-N 0.000 description 1
- DKFVMUIYPLTEBS-UHFFFAOYSA-N 2,2-dimethylpropyl n-[2-(3-acetamidophenyl)-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound CC(=O)NC1=CC=CC(C=2NC3=NC=C(NC(=O)OCC(C)(C)C)C=C3C=2)=C1 DKFVMUIYPLTEBS-UHFFFAOYSA-N 0.000 description 1
- TZJIICRQRMTZEU-UHFFFAOYSA-N 2,2-dimethylpropyl n-[2-(4-acetamidophenyl)-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound C1=CC(NC(=O)C)=CC=C1C1=CC2=CC(NC(=O)OCC(C)(C)C)=CN=C2N1 TZJIICRQRMTZEU-UHFFFAOYSA-N 0.000 description 1
- ZIYBBNHVNXNGME-UHFFFAOYSA-N 2,2-dimethylpropyl n-[2-[3-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound COCCOC1=CC=CC(C=2NC3=NC=C(NC(=O)OCC(C)(C)C)C=C3C=2)=C1 ZIYBBNHVNXNGME-UHFFFAOYSA-N 0.000 description 1
- ZQMVDTJFDXBTJI-UHFFFAOYSA-N 2,4-dichloro-n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)benzamide Chemical compound ClC1=CC(Cl)=CC=C1C(=O)NC1=CN=C(NC(=C2)C=3C=CC=CC=3)C2=C1 ZQMVDTJFDXBTJI-UHFFFAOYSA-N 0.000 description 1
- RJDJISQHRUPWJL-UHFFFAOYSA-N 2,4-dichloro-n-[2-[3-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]benzamide Chemical compound COCCOC1=CC=CC(C=2NC3=NC=C(NC(=O)C=4C(=CC(Cl)=CC=4)Cl)C=C3C=2)=C1 RJDJISQHRUPWJL-UHFFFAOYSA-N 0.000 description 1
- ZXORINZVLXBEDD-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yloxy)-n-(5-methyl-1h-pyrazol-3-yl)quinazolin-4-amine Chemical compound N1N=C(C)C=C1NC1=NC(OC=2C=C3OCOC3=CC=2)=NC2=CC=CC=C12 ZXORINZVLXBEDD-UHFFFAOYSA-N 0.000 description 1
- AYKMXKNVEUMLFQ-UHFFFAOYSA-N 2-(1,8-naphthyridin-2-yl)phenol Chemical compound OC1=CC=CC=C1C1=CC=C(C=CC=N2)C2=N1 AYKMXKNVEUMLFQ-UHFFFAOYSA-N 0.000 description 1
- IMGVJNRSGWHSBQ-UHFFFAOYSA-N 2-(2-chlorophenyl)-4-n-(1h-indazol-3-yl)quinazoline-4,5-diamine Chemical compound N=1C(NC=2C3=CC=CC=C3NN=2)=C2C(N)=CC=CC2=NC=1C1=CC=CC=C1Cl IMGVJNRSGWHSBQ-UHFFFAOYSA-N 0.000 description 1
- DTOPQZPWUCXSCY-UHFFFAOYSA-N 2-(3,4-dimethoxyphenoxy)-n-(5-methyl-1h-pyrazol-3-yl)quinazolin-4-amine Chemical compound C1=C(OC)C(OC)=CC=C1OC1=NC(NC=2NN=C(C)C=2)=C(C=CC=C2)C2=N1 DTOPQZPWUCXSCY-UHFFFAOYSA-N 0.000 description 1
- AJJDFSQAFKDFIW-UHFFFAOYSA-N 2-(3-acetamidoanilino)-6-(2-bromophenyl)-n-[2-(methanesulfonamido)ethyl]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical class CC(=O)NC1=CC=CC(NC=2N=C3N=C(C(C=4C(=CC=CC=4)Br)=CC3=CN=2)C(=O)NCCNS(C)(=O)=O)=C1 AJJDFSQAFKDFIW-UHFFFAOYSA-N 0.000 description 1
- BEPBWBWMCGIRIH-UHFFFAOYSA-N 2-(3-acetamidoanilino)-n-(pyrrolidin-2-ylmethyl)-6-[2-(trifluoromethyl)phenyl]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound CC(=O)NC1=CC=CC(NC=2N=C3N=C(C(C=4C(=CC=CC=4)C(F)(F)F)=CC3=CN=2)C(=O)NCC2NCCC2)=C1 BEPBWBWMCGIRIH-UHFFFAOYSA-N 0.000 description 1
- RMHGCXBRKRTRRY-UHFFFAOYSA-N 2-(3-acetamidoanilino)-n-[2-(methanesulfonamido)ethyl]-6-[2-(trifluoromethyl)phenyl]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound CC(=O)NC1=CC=CC(NC=2N=C3N=C(C(C=4C(=CC=CC=4)C(F)(F)F)=CC3=CN=2)C(=O)NCCNS(C)(=O)=O)=C1 RMHGCXBRKRTRRY-UHFFFAOYSA-N 0.000 description 1
- LVWGCMDNLWPWFS-UHFFFAOYSA-N 2-(3-methoxyphenoxy)-n-(5-methyl-1h-pyrazol-3-yl)quinazolin-4-amine Chemical compound COC1=CC=CC(OC=2N=C3C=CC=CC3=C(NC=3NN=C(C)C=3)N=2)=C1 LVWGCMDNLWPWFS-UHFFFAOYSA-N 0.000 description 1
- ROLGHUJXQWSVPC-UHFFFAOYSA-N 2-(4-morpholin-4-ylphenyl)-1h-imidazo[4,5-b]pyridin-6-amine Chemical compound N=1C2=CC(N)=CN=C2NC=1C(C=C1)=CC=C1N1CCOCC1 ROLGHUJXQWSVPC-UHFFFAOYSA-N 0.000 description 1
- LYIOPCAMGKSTNU-UHFFFAOYSA-N 2-(n-[4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]anilino)ethanol Chemical compound N1N=C(C)C=C1NC1=NC(N(CCO)C=2C=CC=CC=2)=NC2=CC=CC=C12 LYIOPCAMGKSTNU-UHFFFAOYSA-N 0.000 description 1
- LDKIRLGURLNKRV-UHFFFAOYSA-N 2-[(2,6-dichlorophenyl)methyl]-5,6-dimethyl-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound N1N=C(C)C=C1NC1=NC(CC=2C(=CC=CC=2Cl)Cl)=NC(C)=C1C LDKIRLGURLNKRV-UHFFFAOYSA-N 0.000 description 1
- RCMQSFDLXYIJGY-UHFFFAOYSA-N 2-[(2,6-dichlorophenyl)methyl]-6-methyl-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound N1N=C(C)C=C1NC1=CC(C)=NC(CC=2C(=CC=CC=2Cl)Cl)=N1 RCMQSFDLXYIJGY-UHFFFAOYSA-N 0.000 description 1
- JUIGFRJJRJSFSF-UHFFFAOYSA-N 2-[(2,6-dichlorophenyl)methyl]-n-(5-methyl-1h-pyrazol-3-yl)-5,6,7,8-tetrahydroquinazolin-4-amine Chemical compound N1N=C(C)C=C1NC1=NC(CC=2C(=CC=CC=2Cl)Cl)=NC2=C1CCCC2 JUIGFRJJRJSFSF-UHFFFAOYSA-N 0.000 description 1
- ACDNKNZHJNPTTP-UHFFFAOYSA-N 2-[(2-chlorophenoxy)methyl]-6-methyl-n-(5-phenyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound N=1C(COC=2C(=CC=CC=2)Cl)=NC(C)=CC=1NC(NN=1)=CC=1C1=CC=CC=C1 ACDNKNZHJNPTTP-UHFFFAOYSA-N 0.000 description 1
- PQLIAUXPZVLZRF-UHFFFAOYSA-N 2-[(2-chlorophenoxy)methyl]-n-[5-(furan-2-yl)-1h-pyrazol-3-yl]-6-methylpyrimidin-4-amine Chemical compound N=1C(COC=2C(=CC=CC=2)Cl)=NC(C)=CC=1NC(NN=1)=CC=1C1=CC=CO1 PQLIAUXPZVLZRF-UHFFFAOYSA-N 0.000 description 1
- TVCOFKJGUVJBMQ-UHFFFAOYSA-N 2-[(4-chlorophenoxy)methyl]-6-(methoxymethyl)-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound N=1C(COC=2C=CC(Cl)=CC=2)=NC(COC)=CC=1NC=1C=C(C)NN=1 TVCOFKJGUVJBMQ-UHFFFAOYSA-N 0.000 description 1
- GZSSNMUAHPHZII-UHFFFAOYSA-N 2-[(4-chlorophenoxy)methyl]-6-methyl-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound N1C(C)=CC(NC=2N=C(COC=3C=CC(Cl)=CC=3)N=C(C)C=2)=N1 GZSSNMUAHPHZII-UHFFFAOYSA-N 0.000 description 1
- YYKXWDWIKSTBQS-UHFFFAOYSA-N 2-[(4-chlorophenoxy)methyl]-6-methyl-n-(5-phenyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound N=1C(COC=2C=CC(Cl)=CC=2)=NC(C)=CC=1NC(=NN1)C=C1C1=CC=CC=C1 YYKXWDWIKSTBQS-UHFFFAOYSA-N 0.000 description 1
- LQFHOYOJQCFPFL-UHFFFAOYSA-N 2-[(4-chlorophenoxy)methyl]-n-(5-methyl-1h-pyrazol-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-amine Chemical compound N1N=C(C)C=C1NC1=NC(COC=2C=CC(Cl)=CC=2)=NC2=C1CNCC2 LQFHOYOJQCFPFL-UHFFFAOYSA-N 0.000 description 1
- SXQNSXFKEQYMJR-UHFFFAOYSA-N 2-[(4-chlorophenoxy)methyl]-n-(5-methyl-1h-pyrazol-3-yl)-5,6,7,8-tetrahydroquinazolin-4-amine Chemical compound N1N=C(C)C=C1NC1=NC(COC=2C=CC(Cl)=CC=2)=NC2=C1CCCC2 SXQNSXFKEQYMJR-UHFFFAOYSA-N 0.000 description 1
- ULGJVTAIHIHXJE-UHFFFAOYSA-N 2-[(4-chlorophenoxy)methyl]-n-(5-methyl-1h-pyrazol-3-yl)-6,7,8,9-tetrahydro-5h-cyclohepta[d]pyrimidin-4-amine Chemical class N1N=C(C)C=C1NC1=NC(COC=2C=CC(Cl)=CC=2)=NC2=C1CCCCC2 ULGJVTAIHIHXJE-UHFFFAOYSA-N 0.000 description 1
- LIYRFXVJAVUVPN-UHFFFAOYSA-N 2-[(4-fluorophenoxy)methyl]-6-methyl-n-(5-phenyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound N=1C(COC=2C=CC(F)=CC=2)=NC(C)=CC=1NC(NN=1)=CC=1C1=CC=CC=C1 LIYRFXVJAVUVPN-UHFFFAOYSA-N 0.000 description 1
- DDSCNJHXPGHQND-UHFFFAOYSA-N 2-[(4-fluorophenoxy)methyl]-n-[5-(furan-2-yl)-1h-pyrazol-3-yl]-6-methylpyrimidin-4-amine Chemical compound N=1C(COC=2C=CC(F)=CC=2)=NC(C)=CC=1NC(NN=1)=CC=1C1=CC=CO1 DDSCNJHXPGHQND-UHFFFAOYSA-N 0.000 description 1
- DUODWRSOPCJVSC-UHFFFAOYSA-N 2-[(4-methylphenyl)sulfanylmethyl]-n-(5-methyl-1h-pyrazol-3-yl)-6,7,8,9-tetrahydro-5h-cyclohepta[d]pyrimidin-4-amine Chemical class N1N=C(C)C=C1NC1=NC(CSC=2C=CC(C)=CC=2)=NC2=C1CCCCC2 DUODWRSOPCJVSC-UHFFFAOYSA-N 0.000 description 1
- IYYCZMHOOMMAAJ-UHFFFAOYSA-N 2-[2-[[4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]amino]phenyl]ethanol Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C(=CC=CC=2)CCO)=NC2=CC=CC=C12 IYYCZMHOOMMAAJ-UHFFFAOYSA-N 0.000 description 1
- VIEMPZOLUBVFMA-UHFFFAOYSA-N 2-[2-methyl-4-[[4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]amino]phenyl]acetic acid Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=C(C)C(CC(O)=O)=CC=2)=NC2=CC=CC=C12 VIEMPZOLUBVFMA-UHFFFAOYSA-N 0.000 description 1
- KWIKIGJCOMVCPH-UHFFFAOYSA-N 2-[3-(2-methoxyethoxy)phenyl]-n-[(2-methylphenyl)methyl]-1h-pyrrolo[2,3-b]pyridin-5-amine Chemical compound COCCOC1=CC=CC(C=2NC3=NC=C(NCC=4C(=CC=CC=4)C)C=C3C=2)=C1 KWIKIGJCOMVCPH-UHFFFAOYSA-N 0.000 description 1
- HJHAKLUJSZLOIE-UHFFFAOYSA-N 2-[3-(methanesulfonamido)anilino]-n-(pyrrolidin-2-ylmethyl)-6-[2-(trifluoromethyl)phenyl]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound CS(=O)(=O)NC1=CC=CC(NC=2N=C3N=C(C(C=4C(=CC=CC=4)C(F)(F)F)=CC3=CN=2)C(=O)NCC2NCCC2)=C1 HJHAKLUJSZLOIE-UHFFFAOYSA-N 0.000 description 1
- ALJUIMZAAONJPW-UHFFFAOYSA-N 2-[4-[[4-(1h-indazol-3-ylamino)quinazolin-2-yl]amino]phenyl]acetonitrile Chemical compound C1=CC(CC#N)=CC=C1NC1=NC(NC=2C3=CC=CC=C3NN=2)=C(C=CC=C2)C2=N1 ALJUIMZAAONJPW-UHFFFAOYSA-N 0.000 description 1
- SNNUHUCBWBHPOF-UHFFFAOYSA-N 2-[4-[[4-(2h-pyrazolo[3,4-b]pyridin-3-ylamino)quinazolin-2-yl]amino]phenyl]acetonitrile Chemical compound C1=CC(CC#N)=CC=C1NC1=NC(NC=2C3=CC=CN=C3NN=2)=C(C=CC=C2)C2=N1 SNNUHUCBWBHPOF-UHFFFAOYSA-N 0.000 description 1
- UMGBPHWBESBIIL-UHFFFAOYSA-N 2-[4-[[4-[(4-fluoro-1h-indazol-3-yl)amino]quinazolin-2-yl]amino]phenyl]acetonitrile Chemical compound C1=2C(F)=CC=CC=2NN=C1NC(C1=CC=CC=C1N=1)=NC=1NC1=CC=C(CC#N)C=C1 UMGBPHWBESBIIL-UHFFFAOYSA-N 0.000 description 1
- GGTQWMLKKHJMBE-UHFFFAOYSA-N 2-[4-[[4-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-6-phenylpyrimidin-2-yl]amino]phenyl]acetonitrile Chemical compound C1=CC(CC#N)=CC=C1NC1=NC(NC=2NN=C(C=2)C2CC2)=CC(C=2C=CC=CC=2)=N1 GGTQWMLKKHJMBE-UHFFFAOYSA-N 0.000 description 1
- NMCUMRUQLGANIA-UHFFFAOYSA-N 2-[4-[[4-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]amino]phenoxy]acetic acid Chemical compound C1=CC(OCC(=O)O)=CC=C1NC1=NC(NC=2NN=C(C=2)C2CC2)=C(C=CC=C2)C2=N1 NMCUMRUQLGANIA-UHFFFAOYSA-N 0.000 description 1
- ZIOCSYFSFZGSKU-UHFFFAOYSA-N 2-[4-[[4-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]amino]phenyl]acetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1NC1=NC(NC=2NN=C(C=2)C2CC2)=C(C=CC=C2)C2=N1 ZIOCSYFSFZGSKU-UHFFFAOYSA-N 0.000 description 1
- BQVQZGZJNZFIJX-UHFFFAOYSA-N 2-[4-[[4-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]amino]phenyl]ethanol Chemical compound C1=CC(CCO)=CC=C1NC1=NC(NC=2NN=C(C=2)C2CC2)=C(C=CC=C2)C2=N1 BQVQZGZJNZFIJX-UHFFFAOYSA-N 0.000 description 1
- BTIRKRPJNUWTEK-UHFFFAOYSA-N 2-[4-[[4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]amino]phenyl]acetonitrile Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=CC(CC#N)=CC=2)=NC2=CC=CC=C12 BTIRKRPJNUWTEK-UHFFFAOYSA-N 0.000 description 1
- WWMBEHFXPLFIKW-UHFFFAOYSA-N 2-[6-(4-bromophenyl)-3-cyano-4-(trifluoromethyl)pyridin-2-yl]sulfanyl-2-phenylacetic acid Chemical compound C=1C=CC=CC=1C(C(=O)O)SC(C(=C(C=1)C(F)(F)F)C#N)=NC=1C1=CC=C(Br)C=C1 WWMBEHFXPLFIKW-UHFFFAOYSA-N 0.000 description 1
- VUXSEGVIYPPYHF-UHFFFAOYSA-N 2-[[4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]amino]-4a,10-dihydrobenzo[c]chromen-6-one Chemical compound N1C(C)=CC(NC=2C3=CC=CC=C3N=C(NC=3C=CC4OC(=O)C5=CC=CCC5=C4C=3)N=2)=N1 VUXSEGVIYPPYHF-UHFFFAOYSA-N 0.000 description 1
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical class C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 description 1
- POPPVIRYGJQIOF-UHFFFAOYSA-N 2-acetyloxyethyl(trimethyl)azanium;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound CC(=O)OCC[N+](C)(C)C.CN1CCCC1C1=CC=CN=C1 POPPVIRYGJQIOF-UHFFFAOYSA-N 0.000 description 1
- MVQXBXLDXSQURK-UHFFFAOYSA-N 2-aminoethanesulfonamide Chemical compound NCCS(N)(=O)=O MVQXBXLDXSQURK-UHFFFAOYSA-N 0.000 description 1
- LBRSYUWDDRBYEA-UHFFFAOYSA-N 2-benzyl-n-(5-cyclopropyl-1h-pyrazol-3-yl)quinazolin-4-amine Chemical compound N=1C(NC=2NN=C(C=2)C2CC2)=C2C=CC=CC2=NC=1CC1=CC=CC=C1 LBRSYUWDDRBYEA-UHFFFAOYSA-N 0.000 description 1
- ZSBYUVLZTZXHHR-UHFFFAOYSA-N 2-bromo-n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)benzamide Chemical compound BrC1=CC=CC=C1C(=O)NC1=CN=C(NC(=N2)C=3C=CC=CC=3)C2=C1 ZSBYUVLZTZXHHR-UHFFFAOYSA-N 0.000 description 1
- JKNWAFAZWXJCNI-UHFFFAOYSA-N 2-chloro-5-methoxy-n-[2-[3-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]benzamide Chemical compound COCCOC1=CC=CC(C=2NC3=NC=C(NC(=O)C=4C(=CC=C(OC)C=4)Cl)C=C3C=2)=C1 JKNWAFAZWXJCNI-UHFFFAOYSA-N 0.000 description 1
- IIECTRCWQXUIGH-UHFFFAOYSA-N 2-chloro-5-nitro-n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)benzamide Chemical compound [O-][N+](=O)C1=CC=C(Cl)C(C(=O)NC=2C=C3N=C(NC3=NC=2)C=2C=CC=CC=2)=C1 IIECTRCWQXUIGH-UHFFFAOYSA-N 0.000 description 1
- DGBSDJXTMKHAPM-UHFFFAOYSA-N 2-chloro-6-methyl-n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)benzamide Chemical compound CC1=CC=CC(Cl)=C1C(=O)NC1=CN=C(NC(=N2)C=3C=CC=CC=3)C2=C1 DGBSDJXTMKHAPM-UHFFFAOYSA-N 0.000 description 1
- QJKJYVUMPWSRNR-UHFFFAOYSA-N 2-chloro-6-methyl-n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)benzamide Chemical compound CC1=CC=CC(Cl)=C1C(=O)NC1=CN=C(NC(=C2)C=3C=CC=CC=3)C2=C1 QJKJYVUMPWSRNR-UHFFFAOYSA-N 0.000 description 1
- OBWDWNPGXHENEQ-UHFFFAOYSA-N 2-chloro-n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)benzamide Chemical compound ClC1=CC=CC=C1C(=O)NC1=CN=C(NC(=N2)C=3C=CC=CC=3)C2=C1 OBWDWNPGXHENEQ-UHFFFAOYSA-N 0.000 description 1
- UYOBNWAWIXFKKS-UHFFFAOYSA-N 2-chloro-n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)benzamide Chemical compound ClC1=CC=CC=C1C(=O)NC1=CN=C(NC(=C2)C=3C=CC=CC=3)C2=C1 UYOBNWAWIXFKKS-UHFFFAOYSA-N 0.000 description 1
- NROJMBSIKBHYAI-UHFFFAOYSA-N 2-chloro-n-(2-thiophen-2-yl-1h-imidazo[4,5-b]pyridin-6-yl)benzamide Chemical compound ClC1=CC=CC=C1C(=O)NC1=CN=C(NC(=N2)C=3SC=CC=3)C2=C1 NROJMBSIKBHYAI-UHFFFAOYSA-N 0.000 description 1
- WHVAFQFDTJQEBM-UHFFFAOYSA-N 2-chloro-n-(2-thiophen-3-yl-1h-imidazo[4,5-b]pyridin-6-yl)benzamide Chemical compound ClC1=CC=CC=C1C(=O)NC1=CN=C(NC(=N2)C3=CSC=C3)C2=C1 WHVAFQFDTJQEBM-UHFFFAOYSA-N 0.000 description 1
- XHTNMLWPNRMVDU-UHFFFAOYSA-N 2-chloro-n-[2-(2-methylpyridin-4-yl)-1h-imidazo[4,5-b]pyridin-6-yl]benzamide Chemical compound C1=NC(C)=CC(C=2NC3=NC=C(NC(=O)C=4C(=CC=CC=4)Cl)C=C3N=2)=C1 XHTNMLWPNRMVDU-UHFFFAOYSA-N 0.000 description 1
- PFXGLMSMNSOUEE-UHFFFAOYSA-N 2-chloro-n-[2-(3-methylsulfanylphenyl)-1h-imidazo[4,5-b]pyridin-6-yl]benzamide Chemical compound CSC1=CC=CC(C=2NC3=NC=C(NC(=O)C=4C(=CC=CC=4)Cl)C=C3N=2)=C1 PFXGLMSMNSOUEE-UHFFFAOYSA-N 0.000 description 1
- IPCOQHAOOMEMCC-UHFFFAOYSA-N 2-chloro-n-[2-(3-methylsulfinylphenyl)-1h-imidazo[4,5-b]pyridin-6-yl]benzamide Chemical compound CS(=O)C1=CC=CC(C=2NC3=NC=C(NC(=O)C=4C(=CC=CC=4)Cl)C=C3N=2)=C1 IPCOQHAOOMEMCC-UHFFFAOYSA-N 0.000 description 1
- VMVNRJMTLQGXDO-UHFFFAOYSA-N 2-chloro-n-[2-(3-nitrophenyl)-1h-imidazo[4,5-b]pyridin-6-yl]benzamide Chemical compound [O-][N+](=O)C1=CC=CC(C=2NC3=NC=C(NC(=O)C=4C(=CC=CC=4)Cl)C=C3N=2)=C1 VMVNRJMTLQGXDO-UHFFFAOYSA-N 0.000 description 1
- UWTKEPWMYSDCCW-UHFFFAOYSA-N 2-chloro-n-[2-(4-methylsulfanylphenyl)-1h-imidazo[4,5-b]pyridin-6-yl]benzamide Chemical compound C1=CC(SC)=CC=C1C1=NC2=CC(NC(=O)C=3C(=CC=CC=3)Cl)=CN=C2N1 UWTKEPWMYSDCCW-UHFFFAOYSA-N 0.000 description 1
- YPWOMZWDYGWXRE-UHFFFAOYSA-N 2-chloro-n-[2-(4-methylsulfonylphenyl)-1h-imidazo[4,5-b]pyridin-6-yl]benzamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=NC2=CC(NC(=O)C=3C(=CC=CC=3)Cl)=CN=C2N1 YPWOMZWDYGWXRE-UHFFFAOYSA-N 0.000 description 1
- IWMKTWSPHCCOSN-UHFFFAOYSA-N 2-chloro-n-[2-(4-morpholin-4-ylphenyl)-1h-imidazo[4,5-b]pyridin-6-yl]benzamide Chemical compound ClC1=CC=CC=C1C(=O)NC1=CN=C(NC(=N2)C=3C=CC(=CC=3)N3CCOCC3)C2=C1 IWMKTWSPHCCOSN-UHFFFAOYSA-N 0.000 description 1
- NAXUSWJQOJHNGO-UHFFFAOYSA-N 2-chloro-n-[2-(4-nitrophenyl)-1h-imidazo[4,5-b]pyridin-6-yl]benzamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1=NC2=CC(NC(=O)C=3C(=CC=CC=3)Cl)=CN=C2N1 NAXUSWJQOJHNGO-UHFFFAOYSA-N 0.000 description 1
- IPVQEFFKBOMQSF-UHFFFAOYSA-N 2-chloro-n-[2-(4-sulfamoylphenyl)-1h-imidazo[4,5-b]pyridin-6-yl]benzamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=NC2=CC(NC(=O)C=3C(=CC=CC=3)Cl)=CN=C2N1 IPVQEFFKBOMQSF-UHFFFAOYSA-N 0.000 description 1
- RASUKDABYPPEAM-UHFFFAOYSA-N 2-chloro-n-[2-(6-methylpyridin-3-yl)-1h-imidazo[4,5-b]pyridin-6-yl]benzamide Chemical compound C1=NC(C)=CC=C1C1=NC2=CC(NC(=O)C=3C(=CC=CC=3)Cl)=CN=C2N1 RASUKDABYPPEAM-UHFFFAOYSA-N 0.000 description 1
- PPSKOXBAMMWDEM-UHFFFAOYSA-N 2-chloro-n-[2-(6-morpholin-4-ylpyridin-3-yl)-1h-imidazo[4,5-b]pyridin-6-yl]benzamide Chemical compound ClC1=CC=CC=C1C(=O)NC1=CN=C(NC(=N2)C=3C=NC(=CC=3)N3CCOCC3)C2=C1 PPSKOXBAMMWDEM-UHFFFAOYSA-N 0.000 description 1
- DNEXQVPSBCFNBQ-UHFFFAOYSA-N 2-chloro-n-[2-[2-(3-methoxypropylamino)pyridin-4-yl]-1h-imidazo[4,5-b]pyridin-6-yl]benzamide Chemical compound C1=NC(NCCCOC)=CC(C=2NC3=NC=C(NC(=O)C=4C(=CC=CC=4)Cl)C=C3N=2)=C1 DNEXQVPSBCFNBQ-UHFFFAOYSA-N 0.000 description 1
- BQCXYQOBUQBNOS-UHFFFAOYSA-N 2-chloro-n-[2-[3-(1,3-dimethoxypropan-2-ylcarbamoyl)phenyl]-1h-imidazo[4,5-b]pyridin-6-yl]benzamide Chemical compound COCC(COC)NC(=O)C1=CC=CC(C=2NC3=NC=C(NC(=O)C=4C(=CC=CC=4)Cl)C=C3N=2)=C1 BQCXYQOBUQBNOS-UHFFFAOYSA-N 0.000 description 1
- ABMDHRWRBHOEFZ-UHFFFAOYSA-N 2-chloro-n-[2-[3-(2-hydroxyethyl)phenyl]-1h-imidazo[4,5-b]pyridin-6-yl]benzamide Chemical compound OCCC1=CC=CC(C=2NC3=NC=C(NC(=O)C=4C(=CC=CC=4)Cl)C=C3N=2)=C1 ABMDHRWRBHOEFZ-UHFFFAOYSA-N 0.000 description 1
- AYDGVVIMJZJDAS-UHFFFAOYSA-N 2-chloro-n-[2-[3-(2-methoxyethoxy)phenyl]-1h-imidazo[4,5-b]pyridin-6-yl]benzamide Chemical compound COCCOC1=CC=CC(C=2NC3=NC=C(NC(=O)C=4C(=CC=CC=4)Cl)C=C3N=2)=C1 AYDGVVIMJZJDAS-UHFFFAOYSA-N 0.000 description 1
- UREYTGOXKPZHBE-UHFFFAOYSA-N 2-chloro-n-[2-[3-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]benzamide Chemical compound COCCOC1=CC=CC(C=2NC3=NC=C(NC(=O)C=4C(=CC=CC=4)Cl)C=C3C=2)=C1 UREYTGOXKPZHBE-UHFFFAOYSA-N 0.000 description 1
- TZHRBBLXIVTIEZ-UHFFFAOYSA-N 2-chloro-n-[2-[3-(3-methoxypropanoylamino)phenyl]-1h-imidazo[4,5-b]pyridin-6-yl]benzamide Chemical compound COCCC(=O)NC1=CC=CC(C=2NC3=NC=C(NC(=O)C=4C(=CC=CC=4)Cl)C=C3N=2)=C1 TZHRBBLXIVTIEZ-UHFFFAOYSA-N 0.000 description 1
- WGROYOVAECCWRI-UHFFFAOYSA-N 2-chloro-n-[2-[3-(3-methoxypropylcarbamoyl)phenyl]-1h-imidazo[4,5-b]pyridin-6-yl]benzamide Chemical compound COCCCNC(=O)C1=CC=CC(C=2NC3=NC=C(NC(=O)C=4C(=CC=CC=4)Cl)C=C3N=2)=C1 WGROYOVAECCWRI-UHFFFAOYSA-N 0.000 description 1
- MFQJOKSMHPAQCW-UHFFFAOYSA-N 2-chloro-n-[2-[3-(propan-2-ylcarbamoyl)phenyl]-1h-imidazo[4,5-b]pyridin-6-yl]benzamide Chemical compound CC(C)NC(=O)C1=CC=CC(C=2NC3=NC=C(NC(=O)C=4C(=CC=CC=4)Cl)C=C3N=2)=C1 MFQJOKSMHPAQCW-UHFFFAOYSA-N 0.000 description 1
- HVJMQWCKXSUXOB-UHFFFAOYSA-N 2-chloro-n-[2-[4-(2-methoxyethoxy)phenyl]-1h-imidazo[4,5-b]pyridin-6-yl]benzamide Chemical compound C1=CC(OCCOC)=CC=C1C1=NC2=CC(NC(=O)C=3C(=CC=CC=3)Cl)=CN=C2N1 HVJMQWCKXSUXOB-UHFFFAOYSA-N 0.000 description 1
- VWOREXGUMIRVFK-UHFFFAOYSA-N 2-chloro-n-[2-[4-(4-methylpiperazin-1-yl)phenyl]-1h-imidazo[4,5-b]pyridin-6-yl]benzamide Chemical compound C1CN(C)CCN1C1=CC=C(C=2NC3=NC=C(NC(=O)C=4C(=CC=CC=4)Cl)C=C3N=2)C=C1 VWOREXGUMIRVFK-UHFFFAOYSA-N 0.000 description 1
- JPCXOAPPXSSUOG-UHFFFAOYSA-N 2-chloro-n-[2-[4-[2-(diethylamino)ethoxy]phenyl]-1h-imidazo[4,5-b]pyridin-6-yl]benzamide Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C1=NC2=CC(NC(=O)C=3C(=CC=CC=3)Cl)=CN=C2N1 JPCXOAPPXSSUOG-UHFFFAOYSA-N 0.000 description 1
- IFAQTUPIBHAALX-UHFFFAOYSA-N 2-cyano-n-[3-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]acetamide Chemical compound N#CCC(=O)NC1=CC=CC(C=2C3=NC(NC=4C=CC(=CC=4)N4CCOCC4)=NC=C3SC=2)=C1 IFAQTUPIBHAALX-UHFFFAOYSA-N 0.000 description 1
- DSLRZGXDJNTESO-UHFFFAOYSA-N 2-cyano-n-[4-methyl-3-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]acetamide Chemical compound CC1=CC=C(NC(=O)CC#N)C=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 DSLRZGXDJNTESO-UHFFFAOYSA-N 0.000 description 1
- MWOIPXLDGKWILQ-UHFFFAOYSA-N 2-methoxy-4-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenol Chemical compound C1=C(O)C(OC)=CC(C=2C3=NC(NC=4C=CC(=CC=4)N4CCOCC4)=NC=C3SC=2)=C1 MWOIPXLDGKWILQ-UHFFFAOYSA-N 0.000 description 1
- NXVQGMCWIORHSS-UHFFFAOYSA-N 2-methoxy-5-[(pyrido[2,3]thieno[2,4-d]pyrimidin-4-ylhydrazinylidene)methyl]phenol Chemical compound C1=C(O)C(OC)=CC=C1C=NNC1=NC=NC2=C1SC1=NC=CC=C12 NXVQGMCWIORHSS-UHFFFAOYSA-N 0.000 description 1
- VEGGHUCZRDIPBN-UHFFFAOYSA-N 2-methoxy-5-[[(7-methyl-6-phenylthieno[3,2-d]pyrimidin-4-yl)hydrazinylidene]methyl]phenol Chemical compound C1=C(O)C(OC)=CC=C1C=NNC1=NC=NC2=C1SC(C=1C=CC=CC=1)=C2C VEGGHUCZRDIPBN-UHFFFAOYSA-N 0.000 description 1
- XTCFBKIVOOQFOL-UHFFFAOYSA-N 2-methoxy-n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)benzamide Chemical compound COC1=CC=CC=C1C(=O)NC1=CN=C(NC(=C2)C=3C=CC=CC=3)C2=C1 XTCFBKIVOOQFOL-UHFFFAOYSA-N 0.000 description 1
- GQDSOMHUQVKGKG-UHFFFAOYSA-N 2-methoxy-n-[2-[4-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]benzamide Chemical compound C1=CC(OCCOC)=CC=C1C1=CC2=CC(NC(=O)C=3C(=CC=CC=3)OC)=CN=C2N1 GQDSOMHUQVKGKG-UHFFFAOYSA-N 0.000 description 1
- SETYDCSRABYHSW-UHFFFAOYSA-N 2-methyl-1-phenyl-4-pyridin-2-yl-2-(2-pyridin-2-ylethyl)butan-1-one Chemical compound C=1C=CC=NC=1CCC(C(=O)C=1C=CC=CC=1)(C)CCC1=CC=CC=N1 SETYDCSRABYHSW-UHFFFAOYSA-N 0.000 description 1
- XNPCMZQOWAOUJG-UHFFFAOYSA-N 2-methyl-5-nitro-n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)benzamide Chemical compound CC1=CC=C([N+]([O-])=O)C=C1C(=O)NC1=CN=C(NC(=N2)C=3C=CC=CC=3)C2=C1 XNPCMZQOWAOUJG-UHFFFAOYSA-N 0.000 description 1
- TURQCRWQWVIZHT-UHFFFAOYSA-N 2-methyl-n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)benzamide Chemical compound CC1=CC=CC=C1C(=O)NC1=CN=C(NC(=C2)C=3C=CC=CC=3)C2=C1 TURQCRWQWVIZHT-UHFFFAOYSA-N 0.000 description 1
- BSKNSMKKJJTTBC-UHFFFAOYSA-N 2-methyl-n-[4-[[4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]amino]phenyl]propanamide Chemical compound C1=CC(NC(=O)C(C)C)=CC=C1NC1=NC(NC=2NN=C(C)C=2)=C(C=CC=C2)C2=N1 BSKNSMKKJJTTBC-UHFFFAOYSA-N 0.000 description 1
- GAVKNRNMAYRKGF-UHFFFAOYSA-N 2-methylpropyl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound N=1C2=CC(NC(=O)OCC(C)C)=CN=C2NC=1C1=CC=CC=C1 GAVKNRNMAYRKGF-UHFFFAOYSA-N 0.000 description 1
- MIMJXSJUUSBBRB-UHFFFAOYSA-N 2-methylpropyl n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)carbamate Chemical compound C=1C2=CC(NC(=O)OCC(C)C)=CN=C2NC=1C1=CC=CC=C1 MIMJXSJUUSBBRB-UHFFFAOYSA-N 0.000 description 1
- RYBBEFMHXRQDHN-UHFFFAOYSA-N 2-methylpropyl n-[2-(3-acetamidophenyl)-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound C=1C2=CC(NC(=O)OCC(C)C)=CN=C2NC=1C1=CC=CC(NC(C)=O)=C1 RYBBEFMHXRQDHN-UHFFFAOYSA-N 0.000 description 1
- UKCDFOJVIJJIFR-UHFFFAOYSA-N 2-methylpropyl n-[2-[3-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound COCCOC1=CC=CC(C=2NC3=NC=C(NC(=O)OCC(C)C)C=C3C=2)=C1 UKCDFOJVIJJIFR-UHFFFAOYSA-N 0.000 description 1
- SQVGGCUCEJWTDH-UHFFFAOYSA-N 2-methylpropyl n-[2-[4-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound C1=CC(OCCOC)=CC=C1C1=CC2=CC(NC(=O)OCC(C)C)=CN=C2N1 SQVGGCUCEJWTDH-UHFFFAOYSA-N 0.000 description 1
- WGEUJIYMOQESGC-UHFFFAOYSA-N 2-n,4-n-bis(5-ethyl-1h-pyrazol-3-yl)quinazoline-2,4-diamine Chemical compound N1N=C(CC)C=C1NC1=NC(NC=2NN=C(CC)C=2)=C(C=CC=C2)C2=N1 WGEUJIYMOQESGC-UHFFFAOYSA-N 0.000 description 1
- DCLROPOFZBXTLJ-UHFFFAOYSA-N 2-n-(1,3-benzothiazol-6-yl)-4-n-(5-cyclopropyl-1h-pyrazol-3-yl)quinazoline-2,4-diamine Chemical compound C1CC1C1=NNC(NC=2C3=CC=CC=C3N=C(NC=3C=C4SC=NC4=CC=3)N=2)=C1 DCLROPOFZBXTLJ-UHFFFAOYSA-N 0.000 description 1
- HASSNJXFHPQHNY-UHFFFAOYSA-N 2-n-(1,3-benzothiazol-6-yl)-4-n-(5-methyl-1h-pyrazol-3-yl)quinazoline-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=C3SC=NC3=CC=2)=NC2=CC=CC=C12 HASSNJXFHPQHNY-UHFFFAOYSA-N 0.000 description 1
- IBOIYDXLUJSBBN-UHFFFAOYSA-N 2-n-(1h-benzimidazol-2-yl)-6-(methoxymethyl)-4-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound N=1C(NC=2NC3=CC=CC=C3N=2)=NC(COC)=CC=1NC1=CC(C)=NN1 IBOIYDXLUJSBBN-UHFFFAOYSA-N 0.000 description 1
- DTIDHLNJZPTOCE-UHFFFAOYSA-N 2-n-(1h-benzimidazol-2-yl)-6-benzyl-4-n-(5-methyl-1h-pyrazol-3-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidine-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NC=2NC3=CC=CC=C3N=2)=NC2=C1CN(CC=1C=CC=CC=1)CC2 DTIDHLNJZPTOCE-UHFFFAOYSA-N 0.000 description 1
- MEXYHPROPVQLKK-UHFFFAOYSA-N 2-n-(1h-benzimidazol-2-yl)-7-benzyl-4-n-(5-methyl-1h-pyrazol-3-yl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NC=2NC3=CC=CC=C3N=2)=NC2=C1CCN(CC=1C=CC=CC=1)C2 MEXYHPROPVQLKK-UHFFFAOYSA-N 0.000 description 1
- SSJOYZCCXZRBGS-UHFFFAOYSA-N 2-n-(1h-indazol-6-yl)-4-n-(5-methyl-1h-pyrazol-3-yl)quinazoline-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=C3NN=CC3=CC=2)=NC2=CC=CC=C12 SSJOYZCCXZRBGS-UHFFFAOYSA-N 0.000 description 1
- ONVGNVGJJMIKNF-UHFFFAOYSA-N 2-n-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-n-(5-methyl-1h-pyrazol-3-yl)quinazoline-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=C3OCCOC3=CC=2)=NC2=CC=CC=C12 ONVGNVGJJMIKNF-UHFFFAOYSA-N 0.000 description 1
- CIDHZWTYEWSOTG-UHFFFAOYSA-N 2-n-(2-adamantyl)-4-n-(1h-indazol-3-yl)quinazoline-2,4-diamine Chemical compound C1=CC=CC2=NC(NC3C4CC5CC3CC(C4)C5)=NC(NC=3C4=CC=CC=C4NN=3)=C21 CIDHZWTYEWSOTG-UHFFFAOYSA-N 0.000 description 1
- ZPUUGJPXWWNHSP-UHFFFAOYSA-N 2-n-(2-chloro-5-methylphenyl)-4-n-(5-methyl-1h-pyrazol-3-yl)quinazoline-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C(=CC=C(C)C=2)Cl)=NC2=CC=CC=C12 ZPUUGJPXWWNHSP-UHFFFAOYSA-N 0.000 description 1
- DJLTUQSEMZTBLT-UHFFFAOYSA-N 2-n-(2-cyclohexylethyl)-4-n-(5-cyclopropyl-1h-pyrazol-3-yl)quinazoline-2,4-diamine Chemical compound N=1C(NC=2NN=C(C=2)C2CC2)=C2C=CC=CC2=NC=1NCCC1CCCCC1 DJLTUQSEMZTBLT-UHFFFAOYSA-N 0.000 description 1
- GXFKALIDTAKOJE-UHFFFAOYSA-N 2-n-(3,4-dimethylphenyl)-4-n-(5-methyl-1h-pyrazol-3-yl)quinazoline-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=C(C)C(C)=CC=2)=NC2=CC=CC=C12 GXFKALIDTAKOJE-UHFFFAOYSA-N 0.000 description 1
- QFJPVWJKWACZJQ-UHFFFAOYSA-N 2-n-(3-chlorophenyl)-4-n-(5-methyl-1h-pyrazol-3-yl)-6-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine Chemical compound COC1=C(OC)C(OC)=CC(C=2N=C(NC=3C=C(Cl)C=CC=3)N=C(NC=3NN=C(C)C=3)C=2)=C1 QFJPVWJKWACZJQ-UHFFFAOYSA-N 0.000 description 1
- PLUKVZCOKMZJDI-UHFFFAOYSA-N 2-n-(3-chlorophenyl)-4-n-(5-methyl-1h-pyrazol-3-yl)-6-(3-nitrophenyl)pyrimidine-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=CC(C=2C=C(C=CC=2)[N+]([O-])=O)=NC(NC=2C=C(Cl)C=CC=2)=N1 PLUKVZCOKMZJDI-UHFFFAOYSA-N 0.000 description 1
- JMMLYBACNATHAI-UHFFFAOYSA-N 2-n-(3-chlorophenyl)-4-n-(5-methyl-1h-pyrazol-3-yl)quinazoline-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=C(Cl)C=CC=2)=NC2=CC=CC=C12 JMMLYBACNATHAI-UHFFFAOYSA-N 0.000 description 1
- IJSRTFJVVRBSIZ-UHFFFAOYSA-N 2-n-(3-chlorophenyl)-6-(3-nitrophenyl)-4-n-(5-phenyl-1h-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound [O-][N+](=O)C1=CC=CC(C=2N=C(NC=3C=C(Cl)C=CC=3)N=C(NC=3NN=C(C=3)C=3C=CC=CC=3)C=2)=C1 IJSRTFJVVRBSIZ-UHFFFAOYSA-N 0.000 description 1
- RELMGGYGFNCOTI-UHFFFAOYSA-N 2-n-(3-ethylphenyl)-4-n-(5-methyl-1h-pyrazol-3-yl)quinazoline-2,4-diamine Chemical compound CCC1=CC=CC(NC=2N=C3C=CC=CC3=C(NC=3NN=C(C)C=3)N=2)=C1 RELMGGYGFNCOTI-UHFFFAOYSA-N 0.000 description 1
- NRFBZTISTRZZSJ-UHFFFAOYSA-N 2-n-(3-methoxyphenyl)-4-n-(5-methyl-1h-pyrazol-3-yl)quinazoline-2,4-diamine Chemical compound COC1=CC=CC(NC=2N=C3C=CC=CC3=C(NC=3NN=C(C)C=3)N=2)=C1 NRFBZTISTRZZSJ-UHFFFAOYSA-N 0.000 description 1
- IIDFTKCQZIEPRI-UHFFFAOYSA-N 2-n-(3-methylphenyl)-4-n-(5-methyl-1h-pyrazol-3-yl)quinazoline-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=C(C)C=CC=2)=NC2=CC=CC=C12 IIDFTKCQZIEPRI-UHFFFAOYSA-N 0.000 description 1
- IWAAJBNIWOYYDO-UHFFFAOYSA-N 2-n-(4-aminophenyl)-4-n-(5-methyl-1h-pyrazol-3-yl)quinazoline-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=CC(N)=CC=2)=NC2=CC=CC=C12 IWAAJBNIWOYYDO-UHFFFAOYSA-N 0.000 description 1
- TZUWXSYPJXGQSU-UHFFFAOYSA-N 2-n-(4-bromophenyl)-4-n-(5-methyl-1h-pyrazol-3-yl)quinazoline-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=CC(Br)=CC=2)=NC2=CC=CC=C12 TZUWXSYPJXGQSU-UHFFFAOYSA-N 0.000 description 1
- NHGSMDHQOWIPNE-UHFFFAOYSA-N 2-n-(4-chloro-3-methylphenyl)-4-n-(5-cyclopropyl-1h-pyrazol-3-yl)quinazoline-2,4-diamine Chemical compound C1=C(Cl)C(C)=CC(NC=2N=C3C=CC=CC3=C(NC=3NN=C(C=3)C3CC3)N=2)=C1 NHGSMDHQOWIPNE-UHFFFAOYSA-N 0.000 description 1
- IZJQZMHHUOQCLA-UHFFFAOYSA-N 2-n-(4-chlorophenyl)-4-n-(5-methyl-1h-pyrazol-3-yl)quinazoline-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=CC(Cl)=CC=2)=NC2=CC=CC=C12 IZJQZMHHUOQCLA-UHFFFAOYSA-N 0.000 description 1
- MCKQFIYONNWMAQ-UHFFFAOYSA-N 2-n-(4-chlorophenyl)-5,6-dimethyl-4-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=CC(Cl)=CC=2)=NC(C)=C1C MCKQFIYONNWMAQ-UHFFFAOYSA-N 0.000 description 1
- QPDOXHISZYSROD-UHFFFAOYSA-N 2-n-(4-chlorophenyl)-6-(methoxymethyl)-4-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound N=1C(NC=2C=CC(Cl)=CC=2)=NC(COC)=CC=1NC1=CC(C)=NN1 QPDOXHISZYSROD-UHFFFAOYSA-N 0.000 description 1
- UQHSUJAJNCDBDL-UHFFFAOYSA-N 2-n-(4-chlorophenyl)-6-ethyl-4-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound N=1C(NC=2C=CC(Cl)=CC=2)=NC(CC)=CC=1NC1=CC(C)=NN1 UQHSUJAJNCDBDL-UHFFFAOYSA-N 0.000 description 1
- QADYFEPNCIZGRA-UHFFFAOYSA-N 2-n-(4-methoxy-3-phenylphenyl)-4-n-(5-methyl-1h-pyrazol-3-yl)quinazoline-2,4-diamine Chemical compound C1=C(C=2C=CC=CC=2)C(OC)=CC=C1NC(N=C1C=CC=CC1=1)=NC=1NC1=CC(C)=NN1 QADYFEPNCIZGRA-UHFFFAOYSA-N 0.000 description 1
- WKINCHQAJSVMRX-UHFFFAOYSA-N 2-n-(4-morpholin-4-ylphenyl)-7-n-(2-propan-2-ylphenyl)thieno[3,2-d]pyrimidine-2,7-diamine Chemical compound CC(C)C1=CC=CC=C1NC(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 WKINCHQAJSVMRX-UHFFFAOYSA-N 0.000 description 1
- ZESYSFLCEWUXLD-UHFFFAOYSA-N 2-n-(4-morpholin-4-ylphenyl)-7-n-(4-propan-2-ylphenyl)thieno[3,2-d]pyrimidine-2,7-diamine Chemical compound C1=CC(C(C)C)=CC=C1NC(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 ZESYSFLCEWUXLD-UHFFFAOYSA-N 0.000 description 1
- WEIDSMUWFCGLLC-UHFFFAOYSA-N 2-n-(cyclohexylmethyl)-4-n-(5-methyl-1h-pyrazol-3-yl)quinazoline-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NCC2CCCCC2)=NC2=CC=CC=C12 WEIDSMUWFCGLLC-UHFFFAOYSA-N 0.000 description 1
- ZFJPECUVCWNWGO-UHFFFAOYSA-N 2-n-[(4-fluorophenyl)methyl]-4-n-(5-methyl-1h-pyrazol-3-yl)quinazoline-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NCC=2C=CC(F)=CC=2)=NC2=CC=CC=C12 ZFJPECUVCWNWGO-UHFFFAOYSA-N 0.000 description 1
- VVLIINHMOCWFKZ-UHFFFAOYSA-N 2-n-benzyl-4-n-(5-methyl-1h-pyrazol-3-yl)quinazoline-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NCC=2C=CC=CC=2)=NC2=CC=CC=C12 VVLIINHMOCWFKZ-UHFFFAOYSA-N 0.000 description 1
- WWHDRANZCNAOED-UHFFFAOYSA-N 2-n-cyclohexyl-4-n-(5-methyl-1h-pyrazol-3-yl)quinazoline-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NC2CCCCC2)=NC2=CC=CC=C12 WWHDRANZCNAOED-UHFFFAOYSA-N 0.000 description 1
- OLKMOZXQBMINOD-UHFFFAOYSA-N 2-n-methyl-4-n-(5-methyl-1h-pyrazol-3-yl)-2-n-(pyridin-3-ylmethyl)quinazoline-2,4-diamine Chemical compound N=1C(NC=2NN=C(C)C=2)=C2C=CC=CC2=NC=1N(C)CC1=CC=CN=C1 OLKMOZXQBMINOD-UHFFFAOYSA-N 0.000 description 1
- HVHBXBDAWFYVOJ-UHFFFAOYSA-N 2-n-methyl-4-n-(5-methyl-1h-pyrazol-3-yl)-2-n-phenylquinazoline-2,4-diamine Chemical compound N=1C(NC=2NN=C(C)C=2)=C2C=CC=CC2=NC=1N(C)C1=CC=CC=C1 HVHBXBDAWFYVOJ-UHFFFAOYSA-N 0.000 description 1
- LAWQRONLLORGGJ-UHFFFAOYSA-N 2-oxo-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylidene)-1H-indole-5-sulfonic acid Chemical compound O=C1NC2=CC=C(C=C2C1=CC=1NC=2CCCCC2C1)S(=O)(=O)O LAWQRONLLORGGJ-UHFFFAOYSA-N 0.000 description 1
- ZQVDLGSARPZTIJ-UHFFFAOYSA-N 2-phenyl-n-(1-phenylethyl)-1h-imidazo[4,5-b]pyridin-6-amine Chemical compound C=1C=CC=CC=1C(C)NC(C=C1N=2)=CN=C1NC=2C1=CC=CC=C1 ZQVDLGSARPZTIJ-UHFFFAOYSA-N 0.000 description 1
- ARQZZLMERXMLMS-UHFFFAOYSA-N 2-tert-butyl-3-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]benzenesulfonamide Chemical compound C1=CC=C(S(N)(=O)=O)C(C(C)(C)C)=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 ARQZZLMERXMLMS-UHFFFAOYSA-N 0.000 description 1
- FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 description 1
- ZZVDXRCAGGQFAK-UHFFFAOYSA-N 2h-oxazaphosphinine Chemical class N1OC=CC=P1 ZZVDXRCAGGQFAK-UHFFFAOYSA-N 0.000 description 1
- JSIAIROWMJGMQZ-UHFFFAOYSA-N 2h-triazol-4-amine Chemical class NC1=CNN=N1 JSIAIROWMJGMQZ-UHFFFAOYSA-N 0.000 description 1
- PSHIWTSFJFBAPB-UHFFFAOYSA-N 3,5-dimethoxy-n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)benzamide Chemical compound COC1=CC(OC)=CC(C(=O)NC=2C=C3C=C(NC3=NC=2)C=2C=CC=CC=2)=C1 PSHIWTSFJFBAPB-UHFFFAOYSA-N 0.000 description 1
- RGNQQYKNWHKCES-UHFFFAOYSA-N 3-(2-hydroxyphenyl)-3-phenyl-n,n-dipropylpropanamide Chemical compound C=1C=CC=C(O)C=1C(CC(=O)N(CCC)CCC)C1=CC=CC=C1 RGNQQYKNWHKCES-UHFFFAOYSA-N 0.000 description 1
- PEQAQVCHUDMZPB-UHFFFAOYSA-N 3-(4,5,6,7-tetrahydro-1h-indol-2-ylmethylidene)-1h-indol-2-one Chemical class C1CCCC(N2)=C1C=C2C=C1C2=CC=CC=C2NC1=O PEQAQVCHUDMZPB-UHFFFAOYSA-N 0.000 description 1
- PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 1
- XVBFEXFNHLUXCJ-UHFFFAOYSA-N 3-[2-[4-(2-pyrrolidin-1-ylethoxy)anilino]thieno[3,2-d]pyrimidin-7-yl]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC(C=2C3=NC(NC=4C=CC(OCCN5CCCC5)=CC=4)=NC=C3SC=2)=C1 XVBFEXFNHLUXCJ-UHFFFAOYSA-N 0.000 description 1
- FNNLPTYQRNVYRT-UHFFFAOYSA-N 3-[5-[(4-oxo-4-phenylbutan-2-ylidene)amino]pentylimino]-1-phenylbutan-1-one Chemical compound C=1C=CC=CC=1C(=O)CC(C)=NCCCCCN=C(C)CC(=O)C1=CC=CC=C1 FNNLPTYQRNVYRT-UHFFFAOYSA-N 0.000 description 1
- VYQUIYSWCNUIBL-UHFFFAOYSA-N 3-[6-(propan-2-yloxycarbonylamino)-1h-imidazo[4,5-b]pyridin-2-yl]benzoic acid Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=CC(C(O)=O)=C1 VYQUIYSWCNUIBL-UHFFFAOYSA-N 0.000 description 1
- UPCWHMYPOBLJJC-UHFFFAOYSA-N 3-[6-[(2-chlorobenzoyl)amino]-1h-imidazo[4,5-b]pyridin-2-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2NC3=NC=C(NC(=O)C=4C(=CC=CC=4)Cl)C=C3N=2)=C1 UPCWHMYPOBLJJC-UHFFFAOYSA-N 0.000 description 1
- HEXFFYQBBGRUKE-UHFFFAOYSA-N 3-[[(7-methylthieno[3,2-d]pyrimidin-4-yl)hydrazinylidene]methyl]benzoic acid Chemical compound N1=CN=C2C(C)=CSC2=C1NN=CC1=CC=CC(C(O)=O)=C1 HEXFFYQBBGRUKE-UHFFFAOYSA-N 0.000 description 1
- LOPRJHOLWKJBAP-UHFFFAOYSA-N 3-[[(7-methylthieno[3,2-d]pyrimidin-4-yl)hydrazinylidene]methyl]phenol Chemical compound N1=CN=C2C(C)=CSC2=C1NN=CC1=CC=CC(O)=C1 LOPRJHOLWKJBAP-UHFFFAOYSA-N 0.000 description 1
- XDDICUDIYRKLDF-UHFFFAOYSA-N 3-[[4-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]amino]benzoic acid Chemical compound OC(=O)C1=CC=CC(NC=2N=C3C=CC=CC3=C(NC=3NN=C(C=3)C3CC3)N=2)=C1 XDDICUDIYRKLDF-UHFFFAOYSA-N 0.000 description 1
- ULRVXSMHIHDXQN-UHFFFAOYSA-N 3-[[4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]amino]phenol Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=C(O)C=CC=2)=NC2=CC=CC=C12 ULRVXSMHIHDXQN-UHFFFAOYSA-N 0.000 description 1
- FSGGEXBJTHFCHP-UHFFFAOYSA-N 3-amino-2-(2-chloro-5-hydroxyphenyl)-7-(2-morpholin-4-ylethoxy)-5H-pyrazolo[4,3-c]quinolin-4-one Chemical compound NC=1N(C=2C(=CC=C(O)C=2)Cl)N=C(C2=CC=3)C=1C(=O)NC2=CC=3OCCN1CCOCC1 FSGGEXBJTHFCHP-UHFFFAOYSA-N 0.000 description 1
- AKEYKEPZDYXZOH-UHFFFAOYSA-N 3-amino-2-(2-chloro-5-hydroxyphenyl)-7-(3-morpholin-4-ylpropoxy)-5H-pyrazolo[4,3-c]quinolin-4-one Chemical compound NC=1N(C=2C(=CC=C(O)C=2)Cl)N=C(C2=CC=3)C=1C(=O)NC2=CC=3OCCCN1CCOCC1 AKEYKEPZDYXZOH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- JCRWHBZYRHDRNX-UHFFFAOYSA-N 3-bromo-7-(2,4-dichloro-5-methoxyanilino)thieno[3,2-b]pyridine-6-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C=3SC=C(Br)C=3N=CC=2C#N)=C1Cl JCRWHBZYRHDRNX-UHFFFAOYSA-N 0.000 description 1
- PXSGRWNXASCGTJ-UHFFFAOYSA-N 3-methyl-5-propan-2-yl-2-(1,4,6,7-tetrahydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)naphthalene-1,4,6,7-tetrone Chemical compound CC(C)c1c(O)c(O)cc2c(O)c(c(C)c(O)c12)-c1c(C)c(=O)c2c(C(C)C)c(=O)c(=O)cc2c1=O PXSGRWNXASCGTJ-UHFFFAOYSA-N 0.000 description 1
- BTKZNPLSNZGUGX-UHFFFAOYSA-N 3-methylbutan-2-yl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C(C)C)=CN=C2NC=1C1=CC=CC=C1 BTKZNPLSNZGUGX-UHFFFAOYSA-N 0.000 description 1
- MEYPDIZQUOKSNV-UHFFFAOYSA-N 3-n-(7-iodothieno[3,2-d]pyrimidin-2-yl)benzene-1,3-diamine Chemical compound NC1=CC=CC(NC=2N=C3C(I)=CSC3=CN=2)=C1 MEYPDIZQUOKSNV-UHFFFAOYSA-N 0.000 description 1
- YFQIRHIHDGHORF-UHFFFAOYSA-N 3-n-[7-(2-ethylphenyl)thieno[3,2-d]pyrimidin-2-yl]benzene-1,3-diamine Chemical compound CCC1=CC=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=CC(N)=C1 YFQIRHIHDGHORF-UHFFFAOYSA-N 0.000 description 1
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 1
- WCXVZXSLSCQTGU-UHFFFAOYSA-N 4-(2,4-dichloro-5-ethoxyanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OCC)=CC(NC=2C3=CC(OC)=C(OCC4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl WCXVZXSLSCQTGU-UHFFFAOYSA-N 0.000 description 1
- NPTUGALLOCBPCM-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-ethoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCC3CCN(C)CC3)C(OCC)=CC2=C1NC1=CC(OC)=C(Cl)C=C1Cl NPTUGALLOCBPCM-UHFFFAOYSA-N 0.000 description 1
- JQGPWNQWNMMMAS-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-ethoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCCC3CCN(C)CC3)C(OCC)=CC2=C1NC1=CC(OC)=C(Cl)C=C1Cl JQGPWNQWNMMMAS-UHFFFAOYSA-N 0.000 description 1
- PCSXTJQETYJEOI-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-ethoxy-7-[2-(4-methylpiperazin-1-yl)ethoxy]quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCCN3CCN(C)CC3)C(OCC)=CC2=C1NC1=CC(OC)=C(Cl)C=C1Cl PCSXTJQETYJEOI-UHFFFAOYSA-N 0.000 description 1
- OSJKQGUEJYZHQM-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-ethoxy-7-[3-(1-methylpiperidin-4-yl)propoxy]quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCCCC3CCN(C)CC3)C(OCC)=CC2=C1NC1=CC(OC)=C(Cl)C=C1Cl OSJKQGUEJYZHQM-UHFFFAOYSA-N 0.000 description 1
- FEPWXPAVJHFWGS-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-ethoxy-7-[3-(4-ethylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCCCN3CCN(CC)CC3)C(OCC)=CC2=C1NC1=CC(OC)=C(Cl)C=C1Cl FEPWXPAVJHFWGS-UHFFFAOYSA-N 0.000 description 1
- SNJXHAGNHXWXDO-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-ethoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCCCN3CCN(C)CC3)C(OCC)=CC2=C1NC1=CC(OC)=C(Cl)C=C1Cl SNJXHAGNHXWXDO-UHFFFAOYSA-N 0.000 description 1
- TXAYKQMEBQBGLR-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCC4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl TXAYKQMEBQBGLR-UHFFFAOYSA-N 0.000 description 1
- FCIILWHQWNLPJU-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCC4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl FCIILWHQWNLPJU-UHFFFAOYSA-N 0.000 description 1
- UNVLTPQRCHRNDB-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[2-(4-methylpiperazin-1-yl)ethoxy]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UNVLTPQRCHRNDB-UHFFFAOYSA-N 0.000 description 1
- QXWCRBMAGJJKTO-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(1-methylpiperidin-4-yl)propoxy]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCC4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl QXWCRBMAGJJKTO-UHFFFAOYSA-N 0.000 description 1
- SUGCHLACYQMXHH-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-propylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile Chemical compound C1CN(CCC)CCN1CCCOC1=CC2=NC=C(C#N)C(NC=3C(=CC(Cl)=C(OC)C=3)Cl)=C2C=C1OC SUGCHLACYQMXHH-UHFFFAOYSA-N 0.000 description 1
- JQQHEQAFJISPAT-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[5-(piperidin-1-ylmethyl)furan-3-yl]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(C=4C=C(CN5CCCCC5)OC=4)C=C3N=CC=2C#N)=C1Cl JQQHEQAFJISPAT-UHFFFAOYSA-N 0.000 description 1
- AQYRUJMLNNGSET-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[5-(pyrrolidin-1-ylmethyl)furan-3-yl]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(C=4C=C(CN5CCCC5)OC=4)C=C3N=CC=2C#N)=C1Cl AQYRUJMLNNGSET-UHFFFAOYSA-N 0.000 description 1
- AXMGNVQNQXEDNZ-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[5-(thiomorpholin-4-ylmethyl)furan-3-yl]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(C=4C=C(CN5CCSCC5)OC=4)C=C3N=CC=2C#N)=C1Cl AXMGNVQNQXEDNZ-UHFFFAOYSA-N 0.000 description 1
- NKHRSGROVDEDGV-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[5-[(4-methyl-1,4-diazepan-1-yl)methyl]furan-3-yl]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(C=4C=C(CN5CCN(C)CCC5)OC=4)C=C3N=CC=2C#N)=C1Cl NKHRSGROVDEDGV-UHFFFAOYSA-N 0.000 description 1
- ANUHLKPVOXDYSK-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[5-[(4-methylpiperazin-1-yl)methyl]furan-3-yl]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(C=4C=C(CN5CCN(C)CC5)OC=4)C=C3N=CC=2C#N)=C1Cl ANUHLKPVOXDYSK-UHFFFAOYSA-N 0.000 description 1
- HBMCAYMASSWIBL-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[5-[(4-phenylpiperazin-1-yl)methyl]furan-3-yl]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(C=4C=C(CN5CCN(CC5)C=5C=CC=CC=5)OC=4)C=C3N=CC=2C#N)=C1Cl HBMCAYMASSWIBL-UHFFFAOYSA-N 0.000 description 1
- WBNWCYXNLDZBFG-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[5-[(4-pyridin-4-ylpiperazin-1-yl)methyl]furan-3-yl]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(C=4C=C(CN5CCN(CC5)C=5C=CN=CC=5)OC=4)C=C3N=CC=2C#N)=C1Cl WBNWCYXNLDZBFG-UHFFFAOYSA-N 0.000 description 1
- AXKNHMDAYUBEPW-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[5-[(4-pyrrolidin-1-ylpiperidin-1-yl)methyl]furan-3-yl]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(C=4C=C(CN5CCC(CC5)N5CCCC5)OC=4)C=C3N=CC=2C#N)=C1Cl AXKNHMDAYUBEPW-UHFFFAOYSA-N 0.000 description 1
- IGKMQVDQRXQZED-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[5-[[4-(1-methylpiperidin-4-yl)piperazin-1-yl]methyl]furan-3-yl]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(C=4C=C(CN5CCN(CC5)C5CCN(C)CC5)OC=4)C=C3N=CC=2C#N)=C1Cl IGKMQVDQRXQZED-UHFFFAOYSA-N 0.000 description 1
- AEAIFONYAIOFML-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[5-[[4-(2-methoxyethyl)piperazin-1-yl]methyl]furan-3-yl]quinoline-3-carbonitrile Chemical compound C1CN(CCOC)CCN1CC1=CC(C=2C(=CC3=C(NC=4C(=CC(Cl)=C(OC)C=4)Cl)C(C#N)=CN=C3C=2)OC)=CO1 AEAIFONYAIOFML-UHFFFAOYSA-N 0.000 description 1
- MQCHTVYPBGSHON-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[5-[[4-(2-morpholin-4-ylethyl)piperazin-1-yl]methyl]furan-3-yl]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(C=4C=C(CN5CCN(CCN6CCOCC6)CC5)OC=4)C=C3N=CC=2C#N)=C1Cl MQCHTVYPBGSHON-UHFFFAOYSA-N 0.000 description 1
- OOOJUKFDBMKZNA-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[5-[[4-(2-phenylethyl)piperazin-1-yl]methyl]furan-3-yl]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(C=4C=C(CN5CCN(CCC=6C=CC=CC=6)CC5)OC=4)C=C3N=CC=2C#N)=C1Cl OOOJUKFDBMKZNA-UHFFFAOYSA-N 0.000 description 1
- MOBRUQWPCPWABB-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[5-[[4-(4-methoxyphenyl)piperazin-1-yl]methyl]furan-3-yl]quinoline-3-carbonitrile Chemical compound C1=CC(OC)=CC=C1N1CCN(CC=2OC=C(C=2)C=2C(=CC3=C(NC=4C(=CC(Cl)=C(OC)C=4)Cl)C(C#N)=CN=C3C=2)OC)CC1 MOBRUQWPCPWABB-UHFFFAOYSA-N 0.000 description 1
- LZYSTEBTUAIRFE-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[5-[[4-(4-methylphenyl)piperazin-1-yl]methyl]furan-3-yl]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(C=4C=C(CN5CCN(CC5)C=5C=CC(C)=CC=5)OC=4)C=C3N=CC=2C#N)=C1Cl LZYSTEBTUAIRFE-UHFFFAOYSA-N 0.000 description 1
- BQZFXYKINZSMJQ-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[5-[[4-(pyridin-4-ylmethyl)piperazin-1-yl]methyl]furan-3-yl]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(C=4C=C(CN5CCN(CC=6C=CN=CC=6)CC5)OC=4)C=C3N=CC=2C#N)=C1Cl BQZFXYKINZSMJQ-UHFFFAOYSA-N 0.000 description 1
- WHYXOCUUXKVQTI-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[5-[[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]methyl]furan-3-yl]quinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(C=4C=C(CN5CCN(CC5)C=5C=CC(=CC=5)C(F)(F)F)OC=4)C=C3N=CC=2C#N)=C1Cl WHYXOCUUXKVQTI-UHFFFAOYSA-N 0.000 description 1
- HOHWAQXKWAAULM-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-7-[(1-ethylpiperidin-4-yl)methoxy]-6-methoxyquinoline-3-carbonitrile Chemical compound C1CN(CC)CCC1COC1=CC2=NC=C(C#N)C(NC=3C(=CC(Cl)=C(OC)C=3)Cl)=C2C=C1OC HOHWAQXKWAAULM-UHFFFAOYSA-N 0.000 description 1
- JYNBIMGGLJKDLR-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-7-[2-(4-ethylpiperazin-1-yl)ethoxy]-6-methoxyquinoline-3-carbonitrile Chemical compound C1CN(CC)CCN1CCOC1=CC2=NC=C(C#N)C(NC=3C(=CC(Cl)=C(OC)C=3)Cl)=C2C=C1OC JYNBIMGGLJKDLR-UHFFFAOYSA-N 0.000 description 1
- BIEFBSIFAKMKOT-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-7-[3-(4-ethylpiperazin-1-yl)propoxy]-6-methoxyquinoline-3-carbonitrile Chemical compound C1CN(CC)CCN1CCCOC1=CC2=NC=C(C#N)C(NC=3C(=CC(Cl)=C(OC)C=3)Cl)=C2C=C1OC BIEFBSIFAKMKOT-UHFFFAOYSA-N 0.000 description 1
- PZNNYHNRBANRAT-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-7-[5-(diethylaminomethyl)furan-3-yl]-6-methoxyquinoline-3-carbonitrile Chemical compound O1C(CN(CC)CC)=CC(C=2C(=CC3=C(NC=4C(=CC(Cl)=C(OC)C=4)Cl)C(C#N)=CN=C3C=2)OC)=C1 PZNNYHNRBANRAT-UHFFFAOYSA-N 0.000 description 1
- FBSFVGSFCHWHAH-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-7-[5-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]furan-3-yl]-6-methoxyquinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(C=4C=C(CN5CCS(=O)(=O)CC5)OC=4)C=C3N=CC=2C#N)=C1Cl FBSFVGSFCHWHAH-UHFFFAOYSA-N 0.000 description 1
- GPTHVGOIWRCTOM-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-7-[5-[(dipropylamino)methyl]furan-3-yl]-6-methoxyquinoline-3-carbonitrile Chemical compound O1C(CN(CCC)CCC)=CC(C=2C(=CC3=C(NC=4C(=CC(Cl)=C(OC)C=4)Cl)C(C#N)=CN=C3C=2)OC)=C1 GPTHVGOIWRCTOM-UHFFFAOYSA-N 0.000 description 1
- QVFYMGFPEFXYPN-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-7-[5-[[2-(dimethylamino)ethyl-methylamino]methyl]furan-3-yl]-6-methoxyquinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(C=4C=C(CN(C)CCN(C)C)OC=4)C=C3N=CC=2C#N)=C1Cl QVFYMGFPEFXYPN-UHFFFAOYSA-N 0.000 description 1
- SLNBYHMRTBFNPQ-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-7-[5-[[4-(2,4-dimethoxyphenyl)piperazin-1-yl]methyl]furan-3-yl]-6-methoxyquinoline-3-carbonitrile Chemical compound COC1=CC(OC)=CC=C1N1CCN(CC=2OC=C(C=2)C=2C(=CC3=C(NC=4C(=CC(Cl)=C(OC)C=4)Cl)C(C#N)=CN=C3C=2)OC)CC1 SLNBYHMRTBFNPQ-UHFFFAOYSA-N 0.000 description 1
- PHWFLUHXRLQXDK-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-7-[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]furan-3-yl]-6-methoxyquinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(C=4C=C(CN5CCN(CCO)CC5)OC=4)C=C3N=CC=2C#N)=C1Cl PHWFLUHXRLQXDK-UHFFFAOYSA-N 0.000 description 1
- MUQZCEYAAPUICE-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-7-[5-[[4-(4-hydroxyphenyl)piperazin-1-yl]methyl]furan-3-yl]-6-methoxyquinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(C=4C=C(CN5CCN(CC5)C=5C=CC(O)=CC=5)OC=4)C=C3N=CC=2C#N)=C1Cl MUQZCEYAAPUICE-UHFFFAOYSA-N 0.000 description 1
- XUMQGSLZFCAQEF-UHFFFAOYSA-N 4-(2,4-dichloro-5-methoxyanilino)-7-[5-[[4-[3-(diethylamino)propyl]piperazin-1-yl]methyl]furan-3-yl]-6-methoxyquinoline-3-carbonitrile Chemical compound C1CN(CCCN(CC)CC)CCN1CC1=CC(C=2C(=CC3=C(NC=4C(=CC(Cl)=C(OC)C=4)Cl)C(C#N)=CN=C3C=2)OC)=CO1 XUMQGSLZFCAQEF-UHFFFAOYSA-N 0.000 description 1
- ONVKFNZGEFTWQD-UHFFFAOYSA-N 4-(2,4-dichloroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCC3CCN(C)CC3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1Cl ONVKFNZGEFTWQD-UHFFFAOYSA-N 0.000 description 1
- YCFQNCQMGGRGHM-UHFFFAOYSA-N 4-(2,4-dimethylanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCC3CCN(C)CC3)C(OC)=CC2=C1NC1=CC=C(C)C=C1C YCFQNCQMGGRGHM-UHFFFAOYSA-N 0.000 description 1
- ZPKGDYKWVKCDJQ-UHFFFAOYSA-N 4-(2-chloro-5-methoxyanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinoline-3-carbonitrile Chemical compound COC1=CC=C(Cl)C(NC=2C3=CC(OC)=C(OCC4CCN(C)CC4)C=C3N=CC=2C#N)=C1 ZPKGDYKWVKCDJQ-UHFFFAOYSA-N 0.000 description 1
- MHJBZVSGOZTKRH-IZHYLOQSSA-N 4-Hydroxy-N-desmethyltamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCNC)=CC=1)/C1=CC=C(O)C=C1 MHJBZVSGOZTKRH-IZHYLOQSSA-N 0.000 description 1
- KRCUAJDZUQDXRN-FQEVSTJZSA-N 4-[(1s)-6,7-diethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]benzonitrile Chemical compound C1([C@@H]2NCCC=3C=C(C(=CC=32)OCC)OCC)=CC=C(C#N)C=C1 KRCUAJDZUQDXRN-FQEVSTJZSA-N 0.000 description 1
- RUROLFBHCHFKNE-UHFFFAOYSA-N 4-[(8-thia-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaen-6-ylhydrazinylidene)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C=NNC1=NC=NC2=C1SC1=NC=CC=C12 RUROLFBHCHFKNE-UHFFFAOYSA-N 0.000 description 1
- NCZFXISZNVYLCF-UHFFFAOYSA-N 4-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 NCZFXISZNVYLCF-UHFFFAOYSA-N 0.000 description 1
- URDGHUPHWFDFHZ-UHFFFAOYSA-N 4-[2-[(4-carboxyphenyl)methylidene]hydrazinyl]-7-methylthieno[3,2-d]pyrimidine-6-carboxylic acid Chemical compound N1=CN=C2C(C)=C(C(O)=O)SC2=C1NN=CC1=CC=C(C(O)=O)C=C1 URDGHUPHWFDFHZ-UHFFFAOYSA-N 0.000 description 1
- QKYHREMIFMPIOZ-UHFFFAOYSA-N 4-[5-methyl-2-(4-morpholin-4-ylanilino)pyrrolo[3,2-d]pyrimidin-7-yl]benzenesulfonamide Chemical compound C12=NC(NC=3C=CC(=CC=3)N3CCOCC3)=NC=C2N(C)C=C1C1=CC=C(S(N)(=O)=O)C=C1 QKYHREMIFMPIOZ-UHFFFAOYSA-N 0.000 description 1
- XOXLRHOUBGXBSI-UHFFFAOYSA-N 4-[[(6-iodo-7-methylthieno[3,2-d]pyrimidin-4-yl)hydrazinylidene]methyl]benzoic acid Chemical compound N1=CN=C2C(C)=C(I)SC2=C1NN=CC1=CC=C(C(O)=O)C=C1 XOXLRHOUBGXBSI-UHFFFAOYSA-N 0.000 description 1
- YZSXJUGAWFFZCP-UHFFFAOYSA-N 4-[[(6-iodothieno[3,2-d]pyrimidin-4-yl)hydrazinylidene]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C=NNC1=NC=NC2=C1SC(I)=C2 YZSXJUGAWFFZCP-UHFFFAOYSA-N 0.000 description 1
- SJZHHRGQDXFPID-UHFFFAOYSA-N 4-[[(7-methyl-6-phenylthieno[3,2-d]pyrimidin-4-yl)hydrazinylidene]methyl]benzoic acid Chemical compound N1=CN=C2C(C)=C(C=3C=CC=CC=3)SC2=C1NN=CC1=CC=C(C(O)=O)C=C1 SJZHHRGQDXFPID-UHFFFAOYSA-N 0.000 description 1
- BAKXJKBQQFNGEM-UHFFFAOYSA-N 4-[[(7-methylthieno[3,2-d]pyrimidin-4-yl)hydrazinylidene]methyl]benzene-1,2-diol Chemical compound Cc1csc2c(NN=Cc3ccc(O)c(O)c3)ncnc12 BAKXJKBQQFNGEM-UHFFFAOYSA-N 0.000 description 1
- LNCBMCGJQSROBB-UHFFFAOYSA-N 4-[[4-(1h-indazol-3-ylamino)quinazolin-2-yl]amino]benzonitrile Chemical compound C1=CC(C#N)=CC=C1NC1=NC(NC=2C3=CC=CC=C3NN=2)=C(C=CC=C2)C2=N1 LNCBMCGJQSROBB-UHFFFAOYSA-N 0.000 description 1
- BAELVIMBCBALND-UHFFFAOYSA-N 4-[[4-[(5-methyl-1h-pyrazol-3-yl)amino]-6-(3,4,5-trimethoxyphenyl)pyrimidin-2-yl]amino]benzenesulfonamide Chemical class COC1=C(OC)C(OC)=CC(C=2N=C(NC=3C=CC(=CC=3)S(N)(=O)=O)N=C(NC=3NN=C(C)C=3)C=2)=C1 BAELVIMBCBALND-UHFFFAOYSA-N 0.000 description 1
- WPIBIZSPDLUCKE-UHFFFAOYSA-N 4-[[4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]amino]benzonitrile Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=CC(=CC=2)C#N)=NC2=CC=CC=C12 WPIBIZSPDLUCKE-UHFFFAOYSA-N 0.000 description 1
- RUNVSNVGKWTWFA-UHFFFAOYSA-N 4-[[[4-(1h-indazol-3-ylamino)quinazolin-2-yl]amino]methyl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1CNC1=NC(NC=2C3=CC=CC=C3NN=2)=C(C=CC=C2)C2=N1 RUNVSNVGKWTWFA-UHFFFAOYSA-N 0.000 description 1
- MQRKLTVBYGUEEB-UHFFFAOYSA-N 4-[[[4-(2h-pyrazolo[3,4-b]pyridin-3-ylamino)quinazolin-2-yl]amino]methyl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1CNC1=NC(NC=2C3=CC=CN=C3NN=2)=C(C=CC=C2)C2=N1 MQRKLTVBYGUEEB-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- GIRAGORHKOLKLO-UHFFFAOYSA-N 4-methoxy-n-[2-[3-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]benzamide Chemical compound COCCOC1=CC=CC(C=2NC3=NC=C(NC(=O)C=4C=CC(OC)=CC=4)C=C3C=2)=C1 GIRAGORHKOLKLO-UHFFFAOYSA-N 0.000 description 1
- KNRAJGWTBJKPFE-UHFFFAOYSA-N 4-methylpentan-2-yl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)CC(C)C)=CN=C2NC=1C1=CC=CC=C1 KNRAJGWTBJKPFE-UHFFFAOYSA-N 0.000 description 1
- QRVYABWJVXXOTN-UHFFFAOYSA-N 4-methylsulfanylbenzaldehyde Chemical compound CSC1=CC=C(C=O)C=C1 QRVYABWJVXXOTN-UHFFFAOYSA-N 0.000 description 1
- ALHQBGAZODZYIN-UHFFFAOYSA-N 4-n-(1h-indazol-3-yl)-2-n-[2-(trifluoromethyl)phenyl]quinazoline-2,4-diamine Chemical compound FC(F)(F)C1=CC=CC=C1NC1=NC(NC=2C3=CC=CC=C3NN=2)=C(C=CC=C2)C2=N1 ALHQBGAZODZYIN-UHFFFAOYSA-N 0.000 description 1
- HJNIQVRJAQTIHL-UHFFFAOYSA-N 4-n-(1h-indazol-3-yl)-2-n-[3-(trifluoromethyl)phenyl]quinazoline-2,4-diamine Chemical compound FC(F)(F)C1=CC=CC(NC=2N=C3C=CC=CC3=C(NC=3C4=CC=CC=C4NN=3)N=2)=C1 HJNIQVRJAQTIHL-UHFFFAOYSA-N 0.000 description 1
- ZBKGWPQCYLPBMA-UHFFFAOYSA-N 4-n-(1h-indazol-3-yl)-2-n-[4-(trifluoromethyl)phenyl]quinazoline-2,4-diamine Chemical compound C1=CC(C(F)(F)F)=CC=C1NC1=NC(NC=2C3=CC=CC=C3NN=2)=C(C=CC=C2)C2=N1 ZBKGWPQCYLPBMA-UHFFFAOYSA-N 0.000 description 1
- ZGPBGXPUNTYDAK-UHFFFAOYSA-N 4-n-(1h-indazol-3-yl)-2-n-phenylquinazoline-2,4-diamine Chemical compound N=1NC2=CC=CC=C2C=1NC(C1=CC=CC=C1N=1)=NC=1NC1=CC=CC=C1 ZGPBGXPUNTYDAK-UHFFFAOYSA-N 0.000 description 1
- ROZRHKKPJWWVOJ-UHFFFAOYSA-N 4-n-(1h-indazol-3-yl)-5-(2-methylphenyl)quinazoline-2,4-diamine Chemical compound CC1=CC=CC=C1C1=CC=CC2=NC(N)=NC(NC=3C4=CC=CC=C4NN=3)=C12 ROZRHKKPJWWVOJ-UHFFFAOYSA-N 0.000 description 1
- LRACMIDLSWCJHK-UHFFFAOYSA-N 4-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-n,6-diphenylpyrimidine-2,4-diamine Chemical compound C1CC1C1=NNC(NC=2N=C(NC=3C=CC=CC=3)N=C(C=2)C=2C=CC=CC=2)=C1 LRACMIDLSWCJHK-UHFFFAOYSA-N 0.000 description 1
- HYJCZEQDFBEQIO-UHFFFAOYSA-N 4-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-n-(1h-indazol-5-yl)quinazoline-2,4-diamine Chemical compound C1CC1C1=NNC(NC=2C3=CC=CC=C3N=C(NC=3C=C4C=NNC4=CC=3)N=2)=C1 HYJCZEQDFBEQIO-UHFFFAOYSA-N 0.000 description 1
- JKNFXJPVHPNVNL-UHFFFAOYSA-N 4-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-n-(1h-indol-6-yl)quinazoline-2,4-diamine Chemical compound C1CC1C1=NNC(NC=2C3=CC=CC=C3N=C(NC=3C=C4NC=CC4=CC=3)N=2)=C1 JKNFXJPVHPNVNL-UHFFFAOYSA-N 0.000 description 1
- SSWZEQWKYNCAGQ-UHFFFAOYSA-N 4-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-n-(2,3-dihydro-1h-inden-2-yl)quinazoline-2,4-diamine Chemical compound C1CC1C1=NNC(NC=2C3=CC=CC=C3N=C(NC3CC4=CC=CC=C4C3)N=2)=C1 SSWZEQWKYNCAGQ-UHFFFAOYSA-N 0.000 description 1
- SRRKNKSERRHKCJ-UHFFFAOYSA-N 4-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-n-(2,3-dihydro-1h-inden-5-yl)quinazoline-2,4-diamine Chemical compound C1CC1C1=NNC(NC=2C3=CC=CC=C3N=C(NC=3C=C4CCCC4=CC=3)N=2)=C1 SRRKNKSERRHKCJ-UHFFFAOYSA-N 0.000 description 1
- DANKPRSNHKCBCO-UHFFFAOYSA-N 4-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-n-(2,3-dimethylphenyl)quinazoline-2,4-diamine Chemical compound CC1=CC=CC(NC=2N=C3C=CC=CC3=C(NC=3NN=C(C=3)C3CC3)N=2)=C1C DANKPRSNHKCBCO-UHFFFAOYSA-N 0.000 description 1
- PXHCKVGYGVOCOW-UHFFFAOYSA-N 4-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-n-(2-phenoxyethyl)quinazoline-2,4-diamine Chemical compound N=1C(NC=2NN=C(C=2)C2CC2)=C2C=CC=CC2=NC=1NCCOC1=CC=CC=C1 PXHCKVGYGVOCOW-UHFFFAOYSA-N 0.000 description 1
- JSBAZGUBPSVZNI-UHFFFAOYSA-N 4-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-n-(3,4-dimethoxyphenyl)quinazoline-2,4-diamine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC(NC=2NN=C(C=2)C2CC2)=C(C=CC=C2)C2=N1 JSBAZGUBPSVZNI-UHFFFAOYSA-N 0.000 description 1
- QJZGYMMKCNSDCH-UHFFFAOYSA-N 4-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-n-(3,4-dimethylphenyl)quinazoline-2,4-diamine Chemical compound C1=C(C)C(C)=CC=C1NC1=NC(NC=2NN=C(C=2)C2CC2)=C(C=CC=C2)C2=N1 QJZGYMMKCNSDCH-UHFFFAOYSA-N 0.000 description 1
- VEBJMJGJGLIRDY-UHFFFAOYSA-N 4-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-n-(3-ethylphenyl)quinazoline-2,4-diamine Chemical compound CCC1=CC=CC(NC=2N=C3C=CC=CC3=C(NC=3NN=C(C=3)C3CC3)N=2)=C1 VEBJMJGJGLIRDY-UHFFFAOYSA-N 0.000 description 1
- OZGUZABGHJXIQY-UHFFFAOYSA-N 4-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-n-(3-methoxyphenyl)quinazoline-2,4-diamine Chemical compound COC1=CC=CC(NC=2N=C3C=CC=CC3=C(NC=3NN=C(C=3)C3CC3)N=2)=C1 OZGUZABGHJXIQY-UHFFFAOYSA-N 0.000 description 1
- IJZTYXNAWIOYGR-UHFFFAOYSA-N 4-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-n-(3-methylphenyl)-6-phenylpyrimidine-2,4-diamine Chemical compound CC1=CC=CC(NC=2N=C(C=C(NC=3NN=C(C=3)C3CC3)N=2)C=2C=CC=CC=2)=C1 IJZTYXNAWIOYGR-UHFFFAOYSA-N 0.000 description 1
- ARJLZWXNCDAWMX-UHFFFAOYSA-N 4-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-n-(3-methylphenyl)quinazoline-2,4-diamine Chemical compound CC1=CC=CC(NC=2N=C3C=CC=CC3=C(NC=3NN=C(C=3)C3CC3)N=2)=C1 ARJLZWXNCDAWMX-UHFFFAOYSA-N 0.000 description 1
- ZIPIGJRDYVUMGG-UHFFFAOYSA-N 4-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-n-(3-phenylphenyl)quinazoline-2,4-diamine Chemical compound C1CC1C1=NNC(NC=2C3=CC=CC=C3N=C(NC=3C=C(C=CC=3)C=3C=CC=CC=3)N=2)=C1 ZIPIGJRDYVUMGG-UHFFFAOYSA-N 0.000 description 1
- FOBLLALNHZDKKW-UHFFFAOYSA-N 4-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-n-(3-phenylpropyl)quinazoline-2,4-diamine Chemical compound C=1C=CC=CC=1CCCNC(N=C1C=CC=CC1=1)=NC=1NC(NN=1)=CC=1C1CC1 FOBLLALNHZDKKW-UHFFFAOYSA-N 0.000 description 1
- UJYJLEWSKNGXGF-UHFFFAOYSA-N 4-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-n-(4-ethylphenyl)quinazoline-2,4-diamine Chemical compound C1=CC(CC)=CC=C1NC1=NC(NC=2NN=C(C=2)C2CC2)=C(C=CC=C2)C2=N1 UJYJLEWSKNGXGF-UHFFFAOYSA-N 0.000 description 1
- DWEAWCPUIURCQD-UHFFFAOYSA-N 4-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-n-(4-propylphenyl)quinazoline-2,4-diamine Chemical compound C1=CC(CCC)=CC=C1NC1=NC(NC=2NN=C(C=2)C2CC2)=C(C=CC=C2)C2=N1 DWEAWCPUIURCQD-UHFFFAOYSA-N 0.000 description 1
- RIWNVKWGRFIRLW-UHFFFAOYSA-N 4-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-n-(6-methoxypyridin-3-yl)quinazoline-2,4-diamine Chemical compound C1=NC(OC)=CC=C1NC1=NC(NC=2NN=C(C=2)C2CC2)=C(C=CC=C2)C2=N1 RIWNVKWGRFIRLW-UHFFFAOYSA-N 0.000 description 1
- LACPVBWVLKYJHA-UHFFFAOYSA-N 4-n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-n-(pyridin-3-ylmethyl)quinazoline-2,4-diamine Chemical compound C=1C=CN=CC=1CNC(N=C1C=CC=CC1=1)=NC=1NC(NN=1)=CC=1C1CC1 LACPVBWVLKYJHA-UHFFFAOYSA-N 0.000 description 1
- WRWBZPHBOXTUHG-UHFFFAOYSA-N 4-n-(5-cyclopropyl-1h-pyrazol-3-yl)-6-phenyl-2-n-(pyridin-3-ylmethyl)pyrimidine-2,4-diamine Chemical compound C=1C=CN=CC=1CNC(N=C(C=1)C=2C=CC=CC=2)=NC=1NC(NN=1)=CC=1C1CC1 WRWBZPHBOXTUHG-UHFFFAOYSA-N 0.000 description 1
- DPRGICRKHDEMAP-UHFFFAOYSA-N 4-n-(5-methyl-1h-pyrazol-3-yl)-2-n-(3-phenylphenyl)quinazoline-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=C(C=CC=2)C=2C=CC=CC=2)=NC2=CC=CC=C12 DPRGICRKHDEMAP-UHFFFAOYSA-N 0.000 description 1
- RCBHCMLALOQPFS-UHFFFAOYSA-N 4-n-(5-methyl-1h-pyrazol-3-yl)-2-n-(pyridin-3-ylmethyl)quinazoline-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NCC=2C=NC=CC=2)=NC2=CC=CC=C12 RCBHCMLALOQPFS-UHFFFAOYSA-N 0.000 description 1
- LDHVXZBHYGHUJG-UHFFFAOYSA-N 4-n-(5-methyl-1h-pyrazol-3-yl)-2-n-phenyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=CC=CC=2)=NC2=C1CCNC2 LDHVXZBHYGHUJG-UHFFFAOYSA-N 0.000 description 1
- FMEKCTPHORFCAQ-UHFFFAOYSA-N 4-n-(5-methyl-1h-pyrazol-3-yl)-2-n-phenyl-6,7,8,9-tetrahydro-5h-cyclohepta[d]pyrimidine-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=CC=CC=2)=NC2=C1CCCCC2 FMEKCTPHORFCAQ-UHFFFAOYSA-N 0.000 description 1
- MAIYDNZVOBREIJ-UHFFFAOYSA-N 4-n-(5-methyl-1h-pyrazol-3-yl)-2-n-phenylquinazoline-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=CC=CC=2)=NC2=CC=CC=C12 MAIYDNZVOBREIJ-UHFFFAOYSA-N 0.000 description 1
- NUPWYKBBNYGZGV-UHFFFAOYSA-N 4-n-(5-tert-butyl-1h-pyrazol-3-yl)-2-n-(3-chlorophenyl)-6-(3-nitrophenyl)pyrimidine-2,4-diamine Chemical compound N1N=C(C(C)(C)C)C=C1NC1=CC(C=2C=C(C=CC=2)[N+]([O-])=O)=NC(NC=2C=C(Cl)C=CC=2)=N1 NUPWYKBBNYGZGV-UHFFFAOYSA-N 0.000 description 1
- DDLGKYQTGUWEJS-UHFFFAOYSA-N 4-n-[5-(furan-2-yl)-1h-pyrazol-3-yl]-2-n,6-diphenylpyrimidine-2,4-diamine Chemical compound C=1C(C=2C=CC=CC=2)=NC(NC=2C=CC=CC=2)=NC=1NC(NN=1)=CC=1C1=CC=CO1 DDLGKYQTGUWEJS-UHFFFAOYSA-N 0.000 description 1
- TXCMFODSFLTCNK-UHFFFAOYSA-N 5,6-dimethyl-4-n-(5-methyl-1h-pyrazol-3-yl)-2-n-phenylpyrimidine-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=CC=CC=2)=NC(C)=C1C TXCMFODSFLTCNK-UHFFFAOYSA-N 0.000 description 1
- SAPCUZGFJUFXGF-UHFFFAOYSA-N 5,7-diphenylpyrrolo[2,3-d]pyrimidine Chemical class C12=CN=CN=C2N(C=2C=CC=CC=2)C=C1C1=CC=CC=C1 SAPCUZGFJUFXGF-UHFFFAOYSA-N 0.000 description 1
- RNXUJXQDDPFKPD-UHFFFAOYSA-N 5-[[(6-iodo-7-methylthieno[3,2-d]pyrimidin-4-yl)hydrazinylidene]methyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C=NNC1=NC=NC2=C1SC(I)=C2C RNXUJXQDDPFKPD-UHFFFAOYSA-N 0.000 description 1
- IDYJQGNYZPATLU-UHFFFAOYSA-N 5-[[(6-iodothieno[3,2-d]pyrimidin-4-yl)hydrazinylidene]methyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C=NNC1=NC=NC2=C1SC(I)=C2 IDYJQGNYZPATLU-UHFFFAOYSA-N 0.000 description 1
- LGHZTFVKQYWWNK-UHFFFAOYSA-N 5-[[[6-(hydroxymethyl)-7-methylthieno[3,2-d]pyrimidin-4-yl]hydrazinylidene]methyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C=NNC1=NC=NC2=C1SC(CO)=C2C LGHZTFVKQYWWNK-UHFFFAOYSA-N 0.000 description 1
- TYKANBAOZCXMIE-UHFFFAOYSA-N 5-amino-2-methyl-n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)benzamide Chemical compound CC1=CC=C(N)C=C1C(=O)NC1=CN=C(NC(=N2)C=3C=CC=CC=3)C2=C1 TYKANBAOZCXMIE-UHFFFAOYSA-N 0.000 description 1
- IVADEYIFFKRQRZ-UHFFFAOYSA-N 5-bromo-3-hydroxy-3-[2-oxo-2-(5,6,7,8-tetrahydronaphthalen-2-yl)ethyl]-1h-indol-2-one Chemical compound O=C1NC2=CC=C(Br)C=C2C1(O)CC(=O)C1=CC=C(CCCC2)C2=C1 IVADEYIFFKRQRZ-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- GSEXIRHLJSYGNG-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-2-[3-(2-hydroxyethylsulfanyl)anilino]-n-[2-(methanesulfonamido)ethyl]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3Cl)Cl)C(C(=O)NCCNS(=O)(=O)C)=NC2=NC=1NC1=CC=CC(SCCO)=C1 GSEXIRHLJSYGNG-UHFFFAOYSA-N 0.000 description 1
- PLMCDOCWWFGLPQ-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-2-[4-(2-hydroxyethoxy)anilino]-n-[2-(methanesulfonamido)ethyl]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3Cl)Cl)C(C(=O)NCCNS(=O)(=O)C)=NC2=NC=1NC1=CC=C(OCCO)C=C1 PLMCDOCWWFGLPQ-UHFFFAOYSA-N 0.000 description 1
- BRJZESSSHVDRAE-UHFFFAOYSA-N 6-(2,6-dichlorophenyl)-n-[2-(methanesulfonamido)ethyl]-2-(4-morpholin-4-ylanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3Cl)Cl)C(C(=O)NCCNS(=O)(=O)C)=NC2=NC=1NC(C=C1)=CC=C1N1CCOCC1 BRJZESSSHVDRAE-UHFFFAOYSA-N 0.000 description 1
- PJDBVLDFJICXRK-SFHVURJKSA-N 6-(2-bromophenyl)-2-(3-methylsulfanylanilino)-n-[(3s)-piperidin-3-yl]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound CSC1=CC=CC(NC=2N=C3N=C(C(C=4C(=CC=CC=4)Br)=CC3=CN=2)C(=O)N[C@@H]2CNCCC2)=C1 PJDBVLDFJICXRK-SFHVURJKSA-N 0.000 description 1
- IAHSPWZAKGBTST-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(3-methylsulfanylanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound CSC1=CC=CC(NC=2N=C3N=C(C(=CC3=CN=2)C=2C(=CC=CC=2)Br)C(N)=O)=C1 IAHSPWZAKGBTST-UHFFFAOYSA-N 0.000 description 1
- GNGYDHYFPXOPQQ-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(3-methylsulfanylanilino)pyrido[2,3-d]pyrimidine-7-carboxylic acid Chemical compound CSC1=CC=CC(NC=2N=C3N=C(C(=CC3=CN=2)C=2C(=CC=CC=2)Br)C(O)=O)=C1 GNGYDHYFPXOPQQ-UHFFFAOYSA-N 0.000 description 1
- WMVYQUNXAXBFGA-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(3-methylsulfinylanilino)-n-(2-sulfamoylethyl)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical class CS(=O)C1=CC=CC(NC=2N=C3N=C(C(=CC3=CN=2)C=2C(=CC=CC=2)Br)C(=O)NCCS(N)(=O)=O)=C1 WMVYQUNXAXBFGA-UHFFFAOYSA-N 0.000 description 1
- DSTFQCDMOGZMQE-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(3-methylsulfinylanilino)pyrido[2,3-d]pyrimidine-7-carbonitrile Chemical compound CS(=O)C1=CC=CC(NC=2N=C3N=C(C(C=4C(=CC=CC=4)Br)=CC3=CN=2)C#N)=C1 DSTFQCDMOGZMQE-UHFFFAOYSA-N 0.000 description 1
- KYSSHVRQLNFHIC-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(3-methylsulfonylanilino)-n-(2-sulfamoylethyl)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical class CS(=O)(=O)C1=CC=CC(NC=2N=C3N=C(C(=CC3=CN=2)C=2C(=CC=CC=2)Br)C(=O)NCCS(N)(=O)=O)=C1 KYSSHVRQLNFHIC-UHFFFAOYSA-N 0.000 description 1
- OMSXYMXGZGSYIG-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(3-methylsulfonylanilino)pyrido[2,3-d]pyrimidine-7-carbonitrile Chemical compound CS(=O)(=O)C1=CC=CC(NC=2N=C3N=C(C(C=4C(=CC=CC=4)Br)=CC3=CN=2)C#N)=C1 OMSXYMXGZGSYIG-UHFFFAOYSA-N 0.000 description 1
- VLYPNIQSYBSVKI-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(3-methylsulfonylanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound CS(=O)(=O)C1=CC=CC(NC=2N=C3N=C(C(C=4C(=CC=CC=4)Br)=CC3=CN=2)C(N)=O)=C1 VLYPNIQSYBSVKI-UHFFFAOYSA-N 0.000 description 1
- NSKPWIUWVOZSOA-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(4-fluoroanilino)-n-(1h-pyrazol-5-yl)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical class C1=CC(F)=CC=C1NC1=NC=C(C=C(C=2C(=CC=CC=2)Br)C(=N2)C(=O)NC3=NNC=C3)C2=N1 NSKPWIUWVOZSOA-UHFFFAOYSA-N 0.000 description 1
- ASOACAUODMDSFS-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(4-fluoroanilino)-n-(2-hydroxyethyl)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCCO)=NC2=NC=1NC1=CC=C(F)C=C1 ASOACAUODMDSFS-UHFFFAOYSA-N 0.000 description 1
- RZIMSQNGBHCRQZ-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(4-fluoroanilino)-n-(2-methoxyethyl)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCCOC)=NC2=NC=1NC1=CC=C(F)C=C1 RZIMSQNGBHCRQZ-UHFFFAOYSA-N 0.000 description 1
- NJGMCYWZJBXFDB-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(4-fluoroanilino)-n-(2-methylpyrazol-3-yl)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound CN1N=CC=C1NC(=O)C1=NC2=NC(NC=3C=CC(F)=CC=3)=NC=C2C=C1C1=CC=CC=C1Br NJGMCYWZJBXFDB-UHFFFAOYSA-N 0.000 description 1
- UJONIIMPIFRFRR-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(4-fluoroanilino)-n-(2-methylsulfinylethyl)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical class N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCCS(=O)C)=NC2=NC=1NC1=CC=C(F)C=C1 UJONIIMPIFRFRR-UHFFFAOYSA-N 0.000 description 1
- CKQTZLOJZACYRV-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(4-fluoroanilino)-n-(2-morpholin-4-ylethyl)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound C1=CC(F)=CC=C1NC1=NC=C(C=C(C=2C(=CC=CC=2)Br)C(=N2)C(=O)NCCN3CCOCC3)C2=N1 CKQTZLOJZACYRV-UHFFFAOYSA-N 0.000 description 1
- HAPNTFYRXOHYCY-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(4-fluoroanilino)-n-(2-sulfamoylethyl)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCCS(=O)(=O)N)=NC2=NC=1NC1=CC=C(F)C=C1 HAPNTFYRXOHYCY-UHFFFAOYSA-N 0.000 description 1
- OJMXAGKIUHTEHI-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(4-fluoroanilino)-n-(3-hydroxypropyl)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCCCO)=NC2=NC=1NC1=CC=C(F)C=C1 OJMXAGKIUHTEHI-UHFFFAOYSA-N 0.000 description 1
- NLMBDQLXECXIIC-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(4-fluoroanilino)-n-(3-morpholin-4-ylpropyl)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound C1=CC(F)=CC=C1NC1=NC=C(C=C(C=2C(=CC=CC=2)Br)C(=N2)C(=O)NCCCN3CCOCC3)C2=N1 NLMBDQLXECXIIC-UHFFFAOYSA-N 0.000 description 1
- JXWVYBDSQRHNOO-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(4-fluoroanilino)-n-(piperidin-2-ylmethyl)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical class C1=CC(F)=CC=C1NC1=NC=C(C=C(C=2C(=CC=CC=2)Br)C(=N2)C(=O)NCC3NCCCC3)C2=N1 JXWVYBDSQRHNOO-UHFFFAOYSA-N 0.000 description 1
- DOLKDKWUIOAUOD-GOSISDBHSA-N 6-(2-bromophenyl)-2-(4-fluoroanilino)-n-[(3r)-piperidin-3-yl]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound C1=CC(F)=CC=C1NC1=NC=C(C=C(C=2C(=CC=CC=2)Br)C(=N2)C(=O)N[C@H]3CNCCC3)C2=N1 DOLKDKWUIOAUOD-GOSISDBHSA-N 0.000 description 1
- IJZMZAFWNZUGTE-QGZVFWFLSA-N 6-(2-bromophenyl)-2-(4-fluoroanilino)-n-[(3r)-pyrrolidin-3-yl]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound C1=CC(F)=CC=C1NC1=NC=C(C=C(C=2C(=CC=CC=2)Br)C(=N2)C(=O)N[C@H]3CNCC3)C2=N1 IJZMZAFWNZUGTE-QGZVFWFLSA-N 0.000 description 1
- DOLKDKWUIOAUOD-SFHVURJKSA-N 6-(2-bromophenyl)-2-(4-fluoroanilino)-n-[(3s)-piperidin-3-yl]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound C1=CC(F)=CC=C1NC1=NC=C(C=C(C=2C(=CC=CC=2)Br)C(=N2)C(=O)N[C@@H]3CNCCC3)C2=N1 DOLKDKWUIOAUOD-SFHVURJKSA-N 0.000 description 1
- IJZMZAFWNZUGTE-KRWDZBQOSA-N 6-(2-bromophenyl)-2-(4-fluoroanilino)-n-[(3s)-pyrrolidin-3-yl]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound C1=CC(F)=CC=C1NC1=NC=C(C=C(C=2C(=CC=CC=2)Br)C(=N2)C(=O)N[C@@H]3CNCC3)C2=N1 IJZMZAFWNZUGTE-KRWDZBQOSA-N 0.000 description 1
- ZIIZCFTWBAMBIG-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(4-fluoroanilino)-n-[2-(methylamino)-2-oxoethyl]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCC(=O)NC)=NC2=NC=1NC1=CC=C(F)C=C1 ZIIZCFTWBAMBIG-UHFFFAOYSA-N 0.000 description 1
- CPXXQCFUJBBPKN-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(4-fluoroanilino)-n-[2-(methylamino)ethyl]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCCNC)=NC2=NC=1NC1=CC=C(F)C=C1 CPXXQCFUJBBPKN-UHFFFAOYSA-N 0.000 description 1
- HSGTXZRTNMDYNK-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(4-fluoroanilino)-n-[3-(methylamino)propyl]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCCCNC)=NC2=NC=1NC1=CC=C(F)C=C1 HSGTXZRTNMDYNK-UHFFFAOYSA-N 0.000 description 1
- DYSYMKVIODGXDO-GOSISDBHSA-N 6-(2-bromophenyl)-2-(4-fluoroanilino)-n-[[(2r)-pyrrolidin-2-yl]methyl]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound C1=CC(F)=CC=C1NC1=NC=C(C=C(C=2C(=CC=CC=2)Br)C(=N2)C(=O)NC[C@@H]3NCCC3)C2=N1 DYSYMKVIODGXDO-GOSISDBHSA-N 0.000 description 1
- DYSYMKVIODGXDO-SFHVURJKSA-N 6-(2-bromophenyl)-2-(4-fluoroanilino)-n-[[(2s)-pyrrolidin-2-yl]methyl]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound C1=CC(F)=CC=C1NC1=NC=C(C=C(C=2C(=CC=CC=2)Br)C(=N2)C(=O)NC[C@H]3NCCC3)C2=N1 DYSYMKVIODGXDO-SFHVURJKSA-N 0.000 description 1
- UBVZUMCOQDNULE-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(4-fluoroanilino)-n-piperidin-4-ylpyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound C1=CC(F)=CC=C1NC1=NC=C(C=C(C=2C(=CC=CC=2)Br)C(=N2)C(=O)NC3CCNCC3)C2=N1 UBVZUMCOQDNULE-UHFFFAOYSA-N 0.000 description 1
- VCVJRGLIGKHRCD-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(4-methylsulfinylanilino)-n-(2-sulfamoylethyl)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical class C1=CC(S(=O)C)=CC=C1NC1=NC=C(C=C(C(=N2)C(=O)NCCS(N)(=O)=O)C=3C(=CC=CC=3)Br)C2=N1 VCVJRGLIGKHRCD-UHFFFAOYSA-N 0.000 description 1
- XRDDHDSERGTKFE-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(4-morpholin-4-ylanilino)-n-(2-sulfamoylethyl)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCCS(=O)(=O)N)=NC2=NC=1NC(C=C1)=CC=C1N1CCOCC1 XRDDHDSERGTKFE-UHFFFAOYSA-N 0.000 description 1
- UFUSSZKGWQKENL-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(4-morpholin-4-ylanilino)-n-piperidin-4-ylpyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound BrC1=CC=CC=C1C(C(=NC1=N2)C(=O)NC3CCNCC3)=CC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 UFUSSZKGWQKENL-UHFFFAOYSA-N 0.000 description 1
- XFCVWRFECKQYPH-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(4-morpholin-4-ylanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)N)=NC2=NC=1NC(C=C1)=CC=C1N1CCOCC1 XFCVWRFECKQYPH-UHFFFAOYSA-N 0.000 description 1
- MURNLDISINKNGX-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(4-morpholin-4-ylanilino)pyrido[2,3-d]pyrimidine-7-carboxylic acid Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)O)=NC2=NC=1NC(C=C1)=CC=C1N1CCOCC1 MURNLDISINKNGX-UHFFFAOYSA-N 0.000 description 1
- JUJMAMPJNZNVTJ-UHFFFAOYSA-N 6-(2-bromophenyl)-2-(4-sulfamoylanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)N)=NC2=NC=1NC1=CC=C(S(N)(=O)=O)C=C1 JUJMAMPJNZNVTJ-UHFFFAOYSA-N 0.000 description 1
- WXWGUMHGUGMRHI-UHFFFAOYSA-N 6-(2-bromophenyl)-2-[3-(2-hydroxyethylsulfanyl)anilino]-n-[2-(methanesulfonamido)ethyl]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCCNS(=O)(=O)C)=NC2=NC=1NC1=CC=CC(SCCO)=C1 WXWGUMHGUGMRHI-UHFFFAOYSA-N 0.000 description 1
- IBLNQDPJYWDYEZ-UHFFFAOYSA-N 6-(2-bromophenyl)-2-[3-(2-hydroxyethylsulfonyl)anilino]pyrido[2,3-d]pyrimidine-7-carbonitrile Chemical compound OCCS(=O)(=O)C1=CC=CC(NC=2N=C3N=C(C(=CC3=CN=2)C=2C(=CC=CC=2)Br)C#N)=C1 IBLNQDPJYWDYEZ-UHFFFAOYSA-N 0.000 description 1
- PGGUZUWCSUBXNC-UHFFFAOYSA-N 6-(2-bromophenyl)-2-[3-(2-hydroxyethylsulfonyl)anilino]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)N)=NC2=NC=1NC1=CC=CC(S(=O)(=O)CCO)=C1 PGGUZUWCSUBXNC-UHFFFAOYSA-N 0.000 description 1
- XKBJCEYMIIUKPS-UHFFFAOYSA-N 6-(2-bromophenyl)-2-[3-(hydroxymethyl)anilino]-n-(2-sulfamoylethyl)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical class N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCCS(=O)(=O)N)=NC2=NC=1NC1=CC=CC(CO)=C1 XKBJCEYMIIUKPS-UHFFFAOYSA-N 0.000 description 1
- ZLGXPKBLOHRDHR-UHFFFAOYSA-N 6-(2-bromophenyl)-2-[3-(methanesulfonamido)anilino]-n-[2-(methanesulfonamido)ethyl]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCCNS(=O)(=O)C)=NC2=NC=1NC1=CC=CC(NS(C)(=O)=O)=C1 ZLGXPKBLOHRDHR-UHFFFAOYSA-N 0.000 description 1
- ZYIGLUZDVCCTKZ-UHFFFAOYSA-N 6-(2-bromophenyl)-2-[3-(methylsulfamoylmethyl)anilino]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound CNS(=O)(=O)CC1=CC=CC(NC=2N=C3N=C(C(=CC3=CN=2)C=2C(=CC=CC=2)Br)C(N)=O)=C1 ZYIGLUZDVCCTKZ-UHFFFAOYSA-N 0.000 description 1
- GCSVRYQZGYPLND-UHFFFAOYSA-N 6-(2-bromophenyl)-2-[4-(2-hydroxyethoxy)anilino]-n-(2-sulfamoylethyl)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCCS(=O)(=O)N)=NC2=NC=1NC1=CC=C(OCCO)C=C1 GCSVRYQZGYPLND-UHFFFAOYSA-N 0.000 description 1
- UHYSCZYLTBUAQY-UHFFFAOYSA-N 6-(2-bromophenyl)-2-[4-(2-hydroxyethoxy)anilino]-n-[2-(methanesulfonamido)ethyl]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCCNS(=O)(=O)C)=NC2=NC=1NC1=CC=C(OCCO)C=C1 UHYSCZYLTBUAQY-UHFFFAOYSA-N 0.000 description 1
- XHNNRYWEPRYBBR-UHFFFAOYSA-N 6-(2-bromophenyl)-2-[4-(2-hydroxyethoxy)anilino]pyrido[2,3-d]pyrimidine-7-carbonitrile Chemical compound C1=CC(OCCO)=CC=C1NC1=NC=C(C=C(C(=N2)C#N)C=3C(=CC=CC=3)Br)C2=N1 XHNNRYWEPRYBBR-UHFFFAOYSA-N 0.000 description 1
- POESFJMOFZQTKG-UHFFFAOYSA-N 6-(2-bromophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-n-[2-(dimethylamino)ethyl]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound C1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C(C=C(C=2C(=CC=CC=2)Br)C(=N2)C(=O)NCCN(C)C)C2=N1 POESFJMOFZQTKG-UHFFFAOYSA-N 0.000 description 1
- ZNCKOMYOXVQTHV-UHFFFAOYSA-N 6-(2-bromophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]pyrido[2,3-d]pyrimidine-7-carbonitrile Chemical compound C1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C(C=C(C(=N2)C#N)C=3C(=CC=CC=3)Br)C2=N1 ZNCKOMYOXVQTHV-UHFFFAOYSA-N 0.000 description 1
- OMCJFGUZQAKQSF-UHFFFAOYSA-N 6-(2-bromophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound C1=CC(OCCN(CC)CC)=CC=C1NC1=NC=C(C=C(C=2C(=CC=CC=2)Br)C(=N2)C(N)=O)C2=N1 OMCJFGUZQAKQSF-UHFFFAOYSA-N 0.000 description 1
- ZDZROEUWXZIIEA-UHFFFAOYSA-N 6-(2-bromophenyl)-2-[4-[2-(ethylamino)ethoxy]anilino]pyrido[2,3-d]pyrimidine-7-carbonitrile Chemical compound C1=CC(OCCNCC)=CC=C1NC1=NC=C(C=C(C(=N2)C#N)C=3C(=CC=CC=3)Br)C2=N1 ZDZROEUWXZIIEA-UHFFFAOYSA-N 0.000 description 1
- LOFVTHGTJSBUSM-UHFFFAOYSA-N 6-(2-bromophenyl)-n'-[2-(dimethylamino)acetyl]-2-(4-fluoroanilino)pyrido[2,3-d]pyrimidine-7-carbohydrazide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NNC(=O)CN(C)C)=NC2=NC=1NC1=CC=C(F)C=C1 LOFVTHGTJSBUSM-UHFFFAOYSA-N 0.000 description 1
- QWXVWRASHVYUFB-UHFFFAOYSA-N 6-(2-bromophenyl)-n-(2-hydroxyethyl)-2-(3-methylsulfinylanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical class CS(=O)C1=CC=CC(NC=2N=C3N=C(C(=CC3=CN=2)C=2C(=CC=CC=2)Br)C(=O)NCCO)=C1 QWXVWRASHVYUFB-UHFFFAOYSA-N 0.000 description 1
- NTSQWSCZSHVYOX-UHFFFAOYSA-N 6-(2-bromophenyl)-n-(2-hydroxyethyl)-2-(4-methylsulfinylanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical class C1=CC(S(=O)C)=CC=C1NC1=NC=C(C=C(C(=N2)C(=O)NCCO)C=3C(=CC=CC=3)Br)C2=N1 NTSQWSCZSHVYOX-UHFFFAOYSA-N 0.000 description 1
- LXSAFYHHPPKCAO-UHFFFAOYSA-N 6-(2-bromophenyl)-n-(2-hydroxyethyl)-2-(4-morpholin-4-ylanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCCO)=NC2=NC=1NC(C=C1)=CC=C1N1CCOCC1 LXSAFYHHPPKCAO-UHFFFAOYSA-N 0.000 description 1
- QDWGABFYHPTEKH-UHFFFAOYSA-N 6-(2-bromophenyl)-n-(2-hydroxyethyl)-2-[3-(2-hydroxyethylsulfamoyl)anilino]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCCO)=NC2=NC=1NC1=CC=CC(S(=O)(=O)NCCO)=C1 QDWGABFYHPTEKH-UHFFFAOYSA-N 0.000 description 1
- AFQINFVOKVAQIX-UHFFFAOYSA-N 6-(2-bromophenyl)-n-(2-hydroxyethyl)-2-[3-(hydroxymethyl)anilino]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical class N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCCO)=NC2=NC=1NC1=CC=CC(CO)=C1 AFQINFVOKVAQIX-UHFFFAOYSA-N 0.000 description 1
- DKPLECAUJMCVHL-UHFFFAOYSA-N 6-(2-bromophenyl)-n-(2-hydroxyethyl)-2-[4-(2-hydroxyethylsulfamoyl)anilino]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCCO)=NC2=NC=1NC1=CC=C(S(=O)(=O)NCCO)C=C1 DKPLECAUJMCVHL-UHFFFAOYSA-N 0.000 description 1
- MEWSEHIAGRPYID-MRXNPFEDSA-N 6-(2-bromophenyl)-n-[(2r)-2,3-dihydroxypropyl]-2-(4-fluoroanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NC[C@@H](O)CO)=NC2=NC=1NC1=CC=C(F)C=C1 MEWSEHIAGRPYID-MRXNPFEDSA-N 0.000 description 1
- MEWSEHIAGRPYID-INIZCTEOSA-N 6-(2-bromophenyl)-n-[(2s)-2,3-dihydroxypropyl]-2-(4-fluoroanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NC[C@H](O)CO)=NC2=NC=1NC1=CC=C(F)C=C1 MEWSEHIAGRPYID-INIZCTEOSA-N 0.000 description 1
- CLLPEGWDSUSZGB-UHFFFAOYSA-N 6-(2-bromophenyl)-n-[1-(dimethylamino)propan-2-yl]-2-(4-fluoroanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NC(CN(C)C)C)=NC2=NC=1NC1=CC=C(F)C=C1 CLLPEGWDSUSZGB-UHFFFAOYSA-N 0.000 description 1
- HEMJBHYJDRIIAP-UHFFFAOYSA-N 6-(2-bromophenyl)-n-[2-(1h-imidazol-5-yl)ethyl]-2-(4-morpholin-4-ylanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound BrC1=CC=CC=C1C(C(=NC1=N2)C(=O)NCCC=3NC=NC=3)=CC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 HEMJBHYJDRIIAP-UHFFFAOYSA-N 0.000 description 1
- WVVMGOODSSTVJR-UHFFFAOYSA-N 6-(2-bromophenyl)-n-[2-(dimethylamino)-2-oxoethyl]-2-(4-fluoroanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCC(=O)N(C)C)=NC2=NC=1NC1=CC=C(F)C=C1 WVVMGOODSSTVJR-UHFFFAOYSA-N 0.000 description 1
- RHNIWLLPYVUXFF-UHFFFAOYSA-N 6-(2-bromophenyl)-n-[2-(dimethylamino)ethyl]-2-(3-methylsulfanylanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical class CSC1=CC=CC(NC=2N=C3N=C(C(C=4C(=CC=CC=4)Br)=CC3=CN=2)C(=O)NCCN(C)C)=C1 RHNIWLLPYVUXFF-UHFFFAOYSA-N 0.000 description 1
- NYMNALJDHHAVKF-UHFFFAOYSA-N 6-(2-bromophenyl)-n-[2-(dimethylamino)ethyl]-2-(4-fluoroanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCCN(C)C)=NC2=NC=1NC1=CC=C(F)C=C1 NYMNALJDHHAVKF-UHFFFAOYSA-N 0.000 description 1
- FVLAJCUKMMXPNC-UHFFFAOYSA-N 6-(2-bromophenyl)-n-[2-(dimethylamino)ethyl]-2-(4-morpholin-4-ylanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCCN(C)C)=NC2=NC=1NC(C=C1)=CC=C1N1CCOCC1 FVLAJCUKMMXPNC-UHFFFAOYSA-N 0.000 description 1
- NVDRLGQGLILSCK-UHFFFAOYSA-N 6-(2-bromophenyl)-n-[2-(dimethylamino)propyl]-2-(4-fluoroanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCC(C)N(C)C)=NC2=NC=1NC1=CC=C(F)C=C1 NVDRLGQGLILSCK-UHFFFAOYSA-N 0.000 description 1
- SMIYOGZGSHJZHA-UHFFFAOYSA-N 6-(2-bromophenyl)-n-[2-(methanesulfonamido)ethyl]-2-(3-methoxyanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical class COC1=CC=CC(NC=2N=C3N=C(C(=CC3=CN=2)C=2C(=CC=CC=2)Br)C(=O)NCCNS(C)(=O)=O)=C1 SMIYOGZGSHJZHA-UHFFFAOYSA-N 0.000 description 1
- PGXSTZVCQYYDPL-UHFFFAOYSA-N 6-(2-bromophenyl)-n-[2-(methanesulfonamido)ethyl]-2-(4-morpholin-4-ylanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCCNS(=O)(=O)C)=NC2=NC=1NC(C=C1)=CC=C1N1CCOCC1 PGXSTZVCQYYDPL-UHFFFAOYSA-N 0.000 description 1
- FBVSYVYNWVJXSA-UHFFFAOYSA-N 6-(2-bromophenyl)-n-[2-(methanesulfonamido)ethyl]-2-[4-(4-methylpiperazin-1-yl)anilino]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=C(C=2C(=CC=CC=2)Br)C(=N2)C(=O)NCCNS(C)(=O)=O)C2=N1 FBVSYVYNWVJXSA-UHFFFAOYSA-N 0.000 description 1
- KBRLEAMHSILKNF-UHFFFAOYSA-N 6-(2-bromophenyl)-n-[2-(methylamino)ethyl]-2-(3-methylsulfanylanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical class N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCCNC)=NC2=NC=1NC1=CC=CC(SC)=C1 KBRLEAMHSILKNF-UHFFFAOYSA-N 0.000 description 1
- OBXYRFZNFSPMKW-UHFFFAOYSA-N 6-(2-bromophenyl)-n-[2-(methylamino)ethyl]-2-(4-morpholin-4-ylanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCCNC)=NC2=NC=1NC(C=C1)=CC=C1N1CCOCC1 OBXYRFZNFSPMKW-UHFFFAOYSA-N 0.000 description 1
- IZBHAHWHVJIGLM-UHFFFAOYSA-N 6-(2-bromophenyl)-n-[3-(dimethylamino)-2,2-dimethylpropyl]-2-(4-fluoroanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCC(C)(C)CN(C)C)=NC2=NC=1NC1=CC=C(F)C=C1 IZBHAHWHVJIGLM-UHFFFAOYSA-N 0.000 description 1
- XBAXXAJELQCNGZ-UHFFFAOYSA-N 6-(2-bromophenyl)-n-[3-(dimethylamino)propyl]-2-(4-fluoroanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCCCN(C)C)=NC2=NC=1NC1=CC=C(F)C=C1 XBAXXAJELQCNGZ-UHFFFAOYSA-N 0.000 description 1
- CNXWBASJVBMCHD-UHFFFAOYSA-N 6-(methoxymethyl)-4-n-(5-methyl-1h-pyrazol-3-yl)-2-n-phenylpyrimidine-2,4-diamine Chemical compound N=1C(NC=2C=CC=CC=2)=NC(COC)=CC=1NC1=CC(C)=NN1 CNXWBASJVBMCHD-UHFFFAOYSA-N 0.000 description 1
- DUBPGEJGGVZKDD-UHFFFAOYSA-N 6-O-acetylglycitin Natural products COC1=CC(C(C(C=2C=CC(O)=CC=2)=CO2)=O)=C2C=C1OC1OC(COC(C)=O)C(O)C(O)C1O DUBPGEJGGVZKDD-UHFFFAOYSA-N 0.000 description 1
- GCFKABFWXHSSLC-UHFFFAOYSA-N 6-benzyl-2-[(4-chlorophenoxy)methyl]-n-(5-methyl-1h-pyrazol-3-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-amine Chemical compound N1N=C(C)C=C1NC1=NC(COC=2C=CC(Cl)=CC=2)=NC2=C1CN(CC=1C=CC=CC=1)CC2 GCFKABFWXHSSLC-UHFFFAOYSA-N 0.000 description 1
- RJIUWPVZGMYFSE-UHFFFAOYSA-N 6-benzyl-2-n-(4-chlorophenyl)-4-n-(5-methyl-1h-pyrazol-3-yl)-7,8-dihydro-5h-pyrido[4,3-d]pyrimidine-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=CC(Cl)=CC=2)=NC2=C1CN(CC=1C=CC=CC=1)CC2 RJIUWPVZGMYFSE-UHFFFAOYSA-N 0.000 description 1
- KQPCRCXYTMOUBO-UHFFFAOYSA-N 6-benzyl-4-n-(5-methyl-1h-pyrazol-3-yl)-2-n-phenyl-7,8-dihydro-5h-pyrido[4,3-d]pyrimidine-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=CC=CC=2)=NC2=C1CN(CC=1C=CC=CC=1)CC2 KQPCRCXYTMOUBO-UHFFFAOYSA-N 0.000 description 1
- YPWZVKBXBHSXJR-UHFFFAOYSA-N 6-bromo-n-(pyridin-3-ylmethylideneamino)thieno[3,2-d]pyrimidin-4-amine Chemical compound C=12SC(Br)=CC2=NC=NC=1NN=CC1=CC=CN=C1 YPWZVKBXBHSXJR-UHFFFAOYSA-N 0.000 description 1
- NHPUKJZAMBNZRB-UHFFFAOYSA-N 6-ethyl-2-[(4-fluorophenoxy)methyl]-n-(5-methyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound N=1C(COC=2C=CC(F)=CC=2)=NC(CC)=CC=1NC1=CC(C)=NN1 NHPUKJZAMBNZRB-UHFFFAOYSA-N 0.000 description 1
- QWEKKTIAYZMRDA-UHFFFAOYSA-N 6-ethyl-n-(5-methyl-1h-pyrazol-3-yl)-2-(2-phenylbutan-2-yl)pyrimidin-4-amine Chemical compound N=1C(C(C)(CC)C=2C=CC=CC=2)=NC(CC)=CC=1NC=1C=C(C)NN=1 QWEKKTIAYZMRDA-UHFFFAOYSA-N 0.000 description 1
- NFVWCMOBXXSLKV-UHFFFAOYSA-N 6-ethyl-n-(5-methyl-1h-pyrazol-3-yl)-2-(phenoxymethyl)pyrimidin-4-amine Chemical compound N=1C(COC=2C=CC=CC=2)=NC(CC)=CC=1NC1=CC(C)=NN1 NFVWCMOBXXSLKV-UHFFFAOYSA-N 0.000 description 1
- CNUBFAOHKRFGQL-UHFFFAOYSA-N 6-ethyl-n-(5-methyl-1h-pyrazol-3-yl)-2-(phenylsulfanylmethyl)pyrimidin-4-amine Chemical compound N=1C(CSC=2C=CC=CC=2)=NC(CC)=CC=1NC1=CC(C)=NN1 CNUBFAOHKRFGQL-UHFFFAOYSA-N 0.000 description 1
- FBXWZGUXNBEQGN-UHFFFAOYSA-N 6-hydroxy-7-oxobenzo[e]perimidine-4-sulfonic acid Chemical compound N1=CN=C2C3=CC=CC=C3C(=O)C3=C2C1=C(S(O)(=O)=O)C=C3O FBXWZGUXNBEQGN-UHFFFAOYSA-N 0.000 description 1
- VVNOGCPUDPDRAQ-UHFFFAOYSA-N 6-iodo-7-methyl-N-(pyridin-3-ylmethylideneamino)thieno[3,2-d]pyrimidin-4-amine Chemical compound N1=CN=C2C(C)=C(I)SC2=C1NN=CC1=CC=CN=C1 VVNOGCPUDPDRAQ-UHFFFAOYSA-N 0.000 description 1
- ZVJGVGZVJOQTAY-UHFFFAOYSA-N 6-iodo-7-methyl-n-(thiophen-2-ylmethylideneamino)thieno[3,2-d]pyrimidin-4-amine Chemical compound N1=CN=C2C(C)=C(I)SC2=C1NN=CC1=CC=CS1 ZVJGVGZVJOQTAY-UHFFFAOYSA-N 0.000 description 1
- OCKGNHJJOXBMSU-UHFFFAOYSA-N 6-iodo-n-(pyridin-3-ylmethylideneamino)thieno[3,2-d]pyrimidin-4-amine Chemical compound C=12SC(I)=CC2=NC=NC=1NN=CC1=CC=CN=C1 OCKGNHJJOXBMSU-UHFFFAOYSA-N 0.000 description 1
- RFQLOANFLWFATP-UHFFFAOYSA-N 6-iodo-n-(thiophen-2-ylmethylideneamino)thieno[3,2-d]pyrimidin-4-amine Chemical compound C=12SC(I)=CC2=NC=NC=1NN=CC1=CC=CS1 RFQLOANFLWFATP-UHFFFAOYSA-N 0.000 description 1
- YAFBWUKWKZZPIF-UHFFFAOYSA-N 6-methoxy-4-(5-methoxy-2,4-dimethylanilino)-7-[(1-methylpiperidin-4-yl)methoxy]quinoline-3-carbonitrile Chemical compound C1=C(C)C(OC)=CC(NC=2C3=CC(OC)=C(OCC4CCN(C)CC4)C=C3N=CC=2C#N)=C1C YAFBWUKWKZZPIF-UHFFFAOYSA-N 0.000 description 1
- YQWRDEHPSFGGHV-UHFFFAOYSA-N 6-methoxy-4-(5-methoxy-2-methylanilino)-7-[(1-methylpiperidin-4-yl)methoxy]quinoline-3-carbonitrile Chemical compound COC1=CC=C(C)C(NC=2C3=CC(OC)=C(OCC4CCN(C)CC4)C=C3N=CC=2C#N)=C1 YQWRDEHPSFGGHV-UHFFFAOYSA-N 0.000 description 1
- BWLSIYJKVFXNFV-UHFFFAOYSA-N 6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-(3,4,5-trimethoxyanilino)quinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(OCC3CCN(C)CC3)C(OC)=CC2=C1NC1=CC(OC)=C(OC)C(OC)=C1 BWLSIYJKVFXNFV-UHFFFAOYSA-N 0.000 description 1
- XRLACMRIGOEBPO-UHFFFAOYSA-N 6-methyl-2-(phenoxymethyl)-n-(5-phenyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound N=1C(COC=2C=CC=CC=2)=NC(C)=CC=1NC(NN=1)=CC=1C1=CC=CC=C1 XRLACMRIGOEBPO-UHFFFAOYSA-N 0.000 description 1
- ICWSHZQBLJBXOV-UHFFFAOYSA-N 6-methyl-2-[(4-methylphenyl)sulfanylmethyl]-n-(5-phenyl-1h-pyrazol-3-yl)pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1SCC1=NC(C)=CC(NC=2NN=C(C=2)C=2C=CC=CC=2)=N1 ICWSHZQBLJBXOV-UHFFFAOYSA-N 0.000 description 1
- JZECDBIXRMIMDK-UHFFFAOYSA-N 6-methyl-n-(5-methyl-1h-pyrazol-3-yl)-2-(1-phenylcyclopropyl)pyrimidin-4-amine Chemical compound N1C(C)=CC(NC=2N=C(N=C(C)C=2)C2(CC2)C=2C=CC=CC=2)=N1 JZECDBIXRMIMDK-UHFFFAOYSA-N 0.000 description 1
- BVXPTQBIEZMVJF-UHFFFAOYSA-N 6-methyl-n-(5-methyl-1h-pyrazol-3-yl)-2-(2-phenylpropan-2-yl)pyrimidin-4-amine Chemical compound N1C(C)=CC(NC=2N=C(N=C(C)C=2)C(C)(C)C=2C=CC=CC=2)=N1 BVXPTQBIEZMVJF-UHFFFAOYSA-N 0.000 description 1
- OMDUQDBNROSVLS-UHFFFAOYSA-N 6-phenyl-N-(pyridin-4-ylmethylideneamino)thieno[3,2-d]pyrimidin-4-amine Chemical compound N=1C=NC=2C=C(C=3C=CC=CC=3)SC=2C=1NN=CC1=CC=NC=C1 OMDUQDBNROSVLS-UHFFFAOYSA-N 0.000 description 1
- NVFGROYOFKDYPB-UHFFFAOYSA-N 7-(1,3-benzodioxol-5-yl)-n-[4-(morpholin-4-ylmethyl)phenyl]thieno[3,2-d]pyrimidin-2-amine Chemical compound C=1C=C(NC=2N=C3C(C=4C=C5OCOC5=CC=4)=CSC3=CN=2)C=CC=1CN1CCOCC1 NVFGROYOFKDYPB-UHFFFAOYSA-N 0.000 description 1
- PBHIXZSYHUEFMT-UHFFFAOYSA-N 7-(2,4-dichloro-5-methoxyanilino)-3-(4-formylphenyl)thieno[3,2-b]pyridine-6-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C=3SC=C(C=3N=CC=2C#N)C=2C=CC(C=O)=CC=2)=C1Cl PBHIXZSYHUEFMT-UHFFFAOYSA-N 0.000 description 1
- CPDDSFULZQYBPA-UHFFFAOYSA-N 7-(2,4-dichloro-5-methoxyanilino)-3-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]thieno[3,2-b]pyridine-6-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C=3SC=C(C=3N=CC=2C#N)C=2C=CC(CN3CCN(C)CC3)=CC=2)=C1Cl CPDDSFULZQYBPA-UHFFFAOYSA-N 0.000 description 1
- RIRSLQWRXYSMCQ-UHFFFAOYSA-N 7-(2,4-dichloro-5-methoxyanilino)-3-[4-[(dimethylamino)methyl]phenyl]thieno[3,2-b]pyridine-6-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C=3SC=C(C=3N=CC=2C#N)C=2C=CC(CN(C)C)=CC=2)=C1Cl RIRSLQWRXYSMCQ-UHFFFAOYSA-N 0.000 description 1
- GWZOURQFOXBJDY-UHFFFAOYSA-N 7-(2-aminopyrimidin-5-yl)-n-(3,4-dimethoxyphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(SC=C2C=3C=NC(N)=NC=3)C2=N1 GWZOURQFOXBJDY-UHFFFAOYSA-N 0.000 description 1
- FVLDKKBZEPCRSZ-UHFFFAOYSA-N 7-(2-aminopyrimidin-5-yl)-n-[4-(morpholin-4-ylmethyl)phenyl]thieno[3,2-d]pyrimidin-2-amine Chemical compound C1=NC(N)=NC=C1C(C1=N2)=CSC1=CN=C2NC(C=C1)=CC=C1CN1CCOCC1 FVLDKKBZEPCRSZ-UHFFFAOYSA-N 0.000 description 1
- RMDPEJUOCPZKEC-UHFFFAOYSA-N 7-(2-ethylphenyl)-n-(4-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound CCC1=CC=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 RMDPEJUOCPZKEC-UHFFFAOYSA-N 0.000 description 1
- NFZPTELINVMKMR-UHFFFAOYSA-N 7-(2-methoxypyridin-3-yl)-n-(4-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound COC1=NC=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 NFZPTELINVMKMR-UHFFFAOYSA-N 0.000 description 1
- ZVQHOLKTOFURIS-UHFFFAOYSA-N 7-(3-aminophenyl)-n-(4-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound NC1=CC=CC(C=2C3=NC(NC=4C=CC(=CC=4)N4CCOCC4)=NC=C3SC=2)=C1 ZVQHOLKTOFURIS-UHFFFAOYSA-N 0.000 description 1
- GAMSCKKWZQHVAL-UHFFFAOYSA-N 7-(3-chloro-4-fluorophenyl)-n-[4-(2-pyrrolidin-1-ylethoxy)phenyl]thieno[3,2-d]pyrimidin-2-amine Chemical class C1=C(Cl)C(F)=CC=C1C(C1=N2)=CSC1=CN=C2NC(C=C1)=CC=C1OCCN1CCCC1 GAMSCKKWZQHVAL-UHFFFAOYSA-N 0.000 description 1
- GPVTXRKZDLMLOL-UHFFFAOYSA-N 7-(4-amino-3-methoxyphenyl)-n-(4-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound C1=C(N)C(OC)=CC(C=2C3=NC(NC=4C=CC(=CC=4)N4CCOCC4)=NC=C3SC=2)=C1 GPVTXRKZDLMLOL-UHFFFAOYSA-N 0.000 description 1
- LSVRDFWXFIOTPD-UHFFFAOYSA-N 7-(4-amino-3-nitrophenyl)-n-(3,4-dimethoxyphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(SC=C2C=3C=C(C(N)=CC=3)[N+]([O-])=O)C2=N1 LSVRDFWXFIOTPD-UHFFFAOYSA-N 0.000 description 1
- BNZDPWAUHORUCL-UHFFFAOYSA-N 7-(4-amino-3-nitrophenyl)-n-(4-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound C1=C([N+]([O-])=O)C(N)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 BNZDPWAUHORUCL-UHFFFAOYSA-N 0.000 description 1
- PAUFNAVZOJBUAW-UHFFFAOYSA-N 7-(4-aminophenyl)-n-(4-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound C1=CC(N)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 PAUFNAVZOJBUAW-UHFFFAOYSA-N 0.000 description 1
- SHZFPYXFYPIPLR-UHFFFAOYSA-N 7-(5-amino-2-methylphenyl)-n-(4-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound CC1=CC=C(N)C=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 SHZFPYXFYPIPLR-UHFFFAOYSA-N 0.000 description 1
- HQYFNRUBVMRJHK-UHFFFAOYSA-N 7-[4-(4-methylpiperazin-1-yl)phenyl]-n-[4-(morpholin-4-ylmethyl)phenyl]thieno[3,2-d]pyrimidin-2-amine Chemical compound C1CN(C)CCN1C1=CC=C(C=2C3=NC(NC=4C=CC(CN5CCOCC5)=CC=4)=NC=C3SC=2)C=C1 HQYFNRUBVMRJHK-UHFFFAOYSA-N 0.000 description 1
- ZIUVZAUZRMYGTO-UHFFFAOYSA-N 7-[4-(aminomethyl)phenyl]-n-[4-(morpholin-4-ylmethyl)phenyl]thieno[3,2-d]pyrimidin-2-amine Chemical compound C1=CC(CN)=CC=C1C(C1=N2)=CSC1=CN=C2NC(C=C1)=CC=C1CN1CCOCC1 ZIUVZAUZRMYGTO-UHFFFAOYSA-N 0.000 description 1
- ZRSLVQISLPSOLF-UHFFFAOYSA-N 7-[4-amino-3-(trifluoromethoxy)phenyl]-n-(4-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound C1=C(OC(F)(F)F)C(N)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 ZRSLVQISLPSOLF-UHFFFAOYSA-N 0.000 description 1
- WGNACIUUOCKRHS-UHFFFAOYSA-N 7-[5-[(4-benzylpiperazin-1-yl)methyl]furan-3-yl]-4-(2,4-dichloro-5-methoxyanilino)-6-methoxyquinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(C=4C=C(CN5CCN(CC=6C=CC=CC=6)CC5)OC=4)C=C3N=CC=2C#N)=C1Cl WGNACIUUOCKRHS-UHFFFAOYSA-N 0.000 description 1
- SRBZQUXCCNVUDQ-UHFFFAOYSA-N 7-[5-[(4-butylpiperazin-1-yl)methyl]furan-3-yl]-4-(2,4-dichloro-5-methoxyanilino)-6-methoxyquinoline-3-carbonitrile Chemical compound C1CN(CCCC)CCN1CC1=CC(C=2C(=CC3=C(NC=4C(=CC(Cl)=C(OC)C=4)Cl)C(C#N)=CN=C3C=2)OC)=CO1 SRBZQUXCCNVUDQ-UHFFFAOYSA-N 0.000 description 1
- OLHJUGFREXOUQL-UHFFFAOYSA-N 7-[5-[(4-cyclohexylpiperazin-1-yl)methyl]furan-3-yl]-4-(2,4-dichloro-5-methoxyanilino)-6-methoxyquinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(C=4C=C(CN5CCN(CC5)C5CCCCC5)OC=4)C=C3N=CC=2C#N)=C1Cl OLHJUGFREXOUQL-UHFFFAOYSA-N 0.000 description 1
- FIJKZAFWCOQIIE-UHFFFAOYSA-N 7-[5-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]furan-3-yl]-4-(2,4-dichloro-5-methoxyanilino)-6-methoxyquinoline-3-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(C=4C=C(CN5CCN(CC5)C=5C=CC(Cl)=CC=5)OC=4)C=C3N=CC=2C#N)=C1Cl FIJKZAFWCOQIIE-UHFFFAOYSA-N 0.000 description 1
- CYIDJABEPJZXGC-UHFFFAOYSA-N 7-[6-(2-morpholin-4-ylethylamino)pyridin-3-yl]-n-(3,4,5-trimethoxyphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C3C(C=4C=NC(NCCN5CCOCC5)=CC=4)=CSC3=CN=2)=C1 CYIDJABEPJZXGC-UHFFFAOYSA-N 0.000 description 1
- BWNKBAPXJKAQJR-UHFFFAOYSA-N 7-benzyl-2-[(2,6-dichlorophenyl)methyl]-n-(5-methyl-1h-pyrazol-3-yl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-4-amine Chemical compound N1N=C(C)C=C1NC1=NC(CC=2C(=CC=CC=2Cl)Cl)=NC2=C1CCN(CC=1C=CC=CC=1)C2 BWNKBAPXJKAQJR-UHFFFAOYSA-N 0.000 description 1
- KILQEKOOQRRWJQ-UHFFFAOYSA-N 7-benzyl-4-n-(5-methyl-1h-pyrazol-3-yl)-2-n-phenyl-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-2,4-diamine Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=CC=CC=2)=NC2=C1CCN(CC=1C=CC=CC=1)C2 KILQEKOOQRRWJQ-UHFFFAOYSA-N 0.000 description 1
- AVDORUKLIOLRRM-UHFFFAOYSA-N 7-bromo-n-(3,4,5-trimethoxyphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C3C(Br)=CSC3=CN=2)=C1 AVDORUKLIOLRRM-UHFFFAOYSA-N 0.000 description 1
- UAXLIAFJSCHPKS-UHFFFAOYSA-N 7-bromo-n-(3,4-dimethoxyphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(SC=C2Br)C2=N1 UAXLIAFJSCHPKS-UHFFFAOYSA-N 0.000 description 1
- KTXBGBIBFVAPBD-UHFFFAOYSA-N 7-bromo-n-(4-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound N1=C2C(Br)=CSC2=CN=C1NC(C=C1)=CC=C1N1CCOCC1 KTXBGBIBFVAPBD-UHFFFAOYSA-N 0.000 description 1
- BTIJYOTXEXMWCD-UHFFFAOYSA-N 7-bromo-n-[4-(2-pyrrolidin-1-ylethoxy)phenyl]thieno[3,2-d]pyrimidin-2-amine Chemical compound N1=C2C(Br)=CSC2=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 BTIJYOTXEXMWCD-UHFFFAOYSA-N 0.000 description 1
- FZLPMBULBHSJGD-UHFFFAOYSA-N 7-bromo-n-[4-[(4-ethylpiperazin-1-yl)methyl]phenyl]thieno[3,2-d]pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=C1)=CC=C1NC1=NC=C(SC=C2Br)C2=N1 FZLPMBULBHSJGD-UHFFFAOYSA-N 0.000 description 1
- MAWBDDBDDYIMOK-UHFFFAOYSA-N 7-ethoxyindeno[1,2-b]quinoxalin-11-one Chemical compound C1=CC=C2C3=NC4=CC(OCC)=CC=C4N=C3C(=O)C2=C1 MAWBDDBDDYIMOK-UHFFFAOYSA-N 0.000 description 1
- HSWCWWGRZFYCJM-UHFFFAOYSA-N 7-ethyl-N-(pyridin-3-ylmethylideneamino)thieno[3,2-d]pyrimidin-4-amine Chemical compound N1=CN=C2C(CC)=CSC2=C1NN=CC1=CC=CN=C1 HSWCWWGRZFYCJM-UHFFFAOYSA-N 0.000 description 1
- CRVCMLQVHOKQBS-UHFFFAOYSA-N 7-iodo-n-(3-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound N1=C2C(I)=CSC2=CN=C1NC(C=1)=CC=CC=1N1CCOCC1 CRVCMLQVHOKQBS-UHFFFAOYSA-N 0.000 description 1
- ZTRUDXLYAWTYHT-UHFFFAOYSA-N 7-iodo-n-(3-nitrophenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound [O-][N+](=O)C1=CC=CC(NC=2N=C3C(I)=CSC3=CN=2)=C1 ZTRUDXLYAWTYHT-UHFFFAOYSA-N 0.000 description 1
- JBECAGFSWOUDBK-UHFFFAOYSA-N 7-iodo-n-(4-morpholin-4-ylphenyl)-5h-pyrrolo[3,2-d]pyrimidin-2-amine Chemical compound N1=C2C(I)=CNC2=CN=C1NC(C=C1)=CC=C1N1CCOCC1 JBECAGFSWOUDBK-UHFFFAOYSA-N 0.000 description 1
- MOAKLJKOGYJRNX-UHFFFAOYSA-N 7-iodo-n-(4-morpholin-4-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound N1=C2C(I)=CSC2=CN=C1NC(C=C1)=CC=C1N1CCOCC1 MOAKLJKOGYJRNX-UHFFFAOYSA-N 0.000 description 1
- BIUXMWARCYGKBI-UHFFFAOYSA-N 7-iodo-n-[4-(morpholin-4-ylmethyl)phenyl]thieno[3,2-d]pyrimidin-2-amine Chemical compound N1=C2C(I)=CSC2=CN=C1NC(C=C1)=CC=C1CN1CCOCC1 BIUXMWARCYGKBI-UHFFFAOYSA-N 0.000 description 1
- WHSBSHLMDWFBMF-UHFFFAOYSA-N 7-methyl-4-[2-(pyridin-3-ylmethylidene)hydrazinyl]thieno[3,2-d]pyrimidine-6-carboxylic acid Chemical compound N1=CN=C2C(C)=C(C(O)=O)SC2=C1NN=CC1=CC=CN=C1 WHSBSHLMDWFBMF-UHFFFAOYSA-N 0.000 description 1
- AXRYWHGOVYOUOF-UHFFFAOYSA-N 7-methyl-4-[2-(thiophen-2-ylmethylidene)hydrazinyl]thieno[3,2-d]pyrimidine-6-carboxylic acid Chemical compound N1=CN=C2C(C)=C(C(O)=O)SC2=C1NN=CC1=CC=CS1 AXRYWHGOVYOUOF-UHFFFAOYSA-N 0.000 description 1
- KREPHSVZIMYUBD-UHFFFAOYSA-N 7-methyl-6-phenyl-n-(pyridin-3-ylmethylideneamino)thieno[3,2-d]pyrimidin-4-amine Chemical compound N1=CN=C2C(C)=C(C=3C=CC=CC=3)SC2=C1NN=CC1=CC=CN=C1 KREPHSVZIMYUBD-UHFFFAOYSA-N 0.000 description 1
- LDTPEFMJGGTDAB-UHFFFAOYSA-N 7-methyl-6-phenyl-n-(thiophen-2-ylmethylideneamino)thieno[3,2-d]pyrimidin-4-amine Chemical compound N1=CN=C2C(C)=C(C=3C=CC=CC=3)SC2=C1NN=CC1=CC=CS1 LDTPEFMJGGTDAB-UHFFFAOYSA-N 0.000 description 1
- QSAPBJDZNRQPBA-UHFFFAOYSA-N 7-methyl-N-(1H-pyrrol-2-ylmethylideneamino)thieno[3,2-d]pyrimidin-4-amine Chemical compound Cc1csc2c(NN=Cc3ccc[nH]3)ncnc12 QSAPBJDZNRQPBA-UHFFFAOYSA-N 0.000 description 1
- PJTITAAFFRJHGM-UHFFFAOYSA-N 7-methyl-n-(1,3-thiazol-2-ylmethylideneamino)thieno[3,2-d]pyrimidin-4-amine Chemical compound N1=CN=C2C(C)=CSC2=C1NN=CC1=NC=CS1 PJTITAAFFRJHGM-UHFFFAOYSA-N 0.000 description 1
- IDYJHSINZARXMG-UHFFFAOYSA-N 7-methyl-n-(2-phenylethylideneamino)thieno[3,2-d]pyrimidin-4-amine Chemical compound N1=CN=C2C(C)=CSC2=C1NN=CCC1=CC=CC=C1 IDYJHSINZARXMG-UHFFFAOYSA-N 0.000 description 1
- LTOUZBGGZPFVCR-UHFFFAOYSA-N 7-methyl-n-(oxolan-3-ylmethylideneamino)thieno[3,2-d]pyrimidin-4-amine Chemical compound N1=CN=C2C(C)=CSC2=C1NN=CC1CCOC1 LTOUZBGGZPFVCR-UHFFFAOYSA-N 0.000 description 1
- AAKJQPDSJSZPEX-UHFFFAOYSA-N 7-methyl-n-(pyridin-3-ylmethylideneamino)thieno[3,2-d]pyrimidin-4-amine Chemical compound N1=CN=C2C(C)=CSC2=C1NN=CC1=CC=CN=C1 AAKJQPDSJSZPEX-UHFFFAOYSA-N 0.000 description 1
- GAGFFUPLCLLBQH-UHFFFAOYSA-N 7-methyl-n-(pyridin-4-ylmethylideneamino)thieno[3,2-d]pyrimidin-4-amine Chemical compound N1=CN=C2C(C)=CSC2=C1NN=CC1=CC=NC=C1 GAGFFUPLCLLBQH-UHFFFAOYSA-N 0.000 description 1
- BUEIQNUGWBFECI-UHFFFAOYSA-N 7-methyl-n-(thiophen-2-ylmethylideneamino)thieno[3,2-d]pyrimidin-4-amine Chemical compound N1=CN=C2C(C)=CSC2=C1NN=CC1=CC=CS1 BUEIQNUGWBFECI-UHFFFAOYSA-N 0.000 description 1
- ZYAIIGPFKXYEMV-UHFFFAOYSA-N 7-methyl-n-[(3-methylthiophen-2-yl)methylideneamino]thieno[3,2-d]pyrimidin-4-amine Chemical compound C1=CSC(C=NNC=2C=3SC=C(C)C=3N=CN=2)=C1C ZYAIIGPFKXYEMV-UHFFFAOYSA-N 0.000 description 1
- LAVDBDFGFICATB-UHFFFAOYSA-N 7-methyl-n-[(3-propoxyphenyl)methylideneamino]thieno[3,2-d]pyrimidin-4-amine Chemical compound CCCOC1=CC=CC(C=NNC=2C=3SC=C(C)C=3N=CN=2)=C1 LAVDBDFGFICATB-UHFFFAOYSA-N 0.000 description 1
- CYGCYFLDOSZZNH-UHFFFAOYSA-N 7-methyl-n-[(4-propoxyphenyl)methylideneamino]thieno[3,2-d]pyrimidin-4-amine Chemical compound C1=CC(OCCC)=CC=C1C=NNC1=NC=NC2=C1SC=C2C CYGCYFLDOSZZNH-UHFFFAOYSA-N 0.000 description 1
- LFSXKZVNSZIYDZ-UHFFFAOYSA-N 7-propyl-N-(pyridin-3-ylmethylideneamino)thieno[3,2-d]pyrimidin-4-amine Chemical compound N1=CN=C2C(CCC)=CSC2=C1NN=CC1=CC=CN=C1 LFSXKZVNSZIYDZ-UHFFFAOYSA-N 0.000 description 1
- HALYIFFLOBGDNN-UHFFFAOYSA-N 7h-pyrido[3,4-d]pyrimidin-8-one Chemical class N1=CN=C2C(=O)NC=CC2=C1 HALYIFFLOBGDNN-UHFFFAOYSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 241000714175 Abelson murine leukemia virus Species 0.000 description 1
- 229940121683 Acetylcholine receptor antagonist Drugs 0.000 description 1
- 102000006772 Acid Ceramidase Human genes 0.000 description 1
- 108020005296 Acid Ceramidase Proteins 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 229940123786 Adenosine A3 receptor antagonist Drugs 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- 108010087905 Adenovirus E1B Proteins Proteins 0.000 description 1
- 101000783817 Agaricus bisporus lectin Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102100025674 Angiopoietin-related protein 4 Human genes 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 101100020619 Arabidopsis thaliana LATE gene Proteins 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 208000032800 BCR-ABL1 positive blast phase chronic myelogenous leukemia Diseases 0.000 description 1
- 108091007065 BIRCs Proteins 0.000 description 1
- 101000796998 Bacillus subtilis (strain 168) Methylated-DNA-protein-cysteine methyltransferase, inducible Proteins 0.000 description 1
- 102100021971 Bcl-2-interacting killer Human genes 0.000 description 1
- 101150008012 Bcl2l1 gene Proteins 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000004860 Blast Crisis Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000010183 Bradykinin receptor Human genes 0.000 description 1
- 108050001736 Bradykinin receptor Proteins 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- OBHFGNSNNKOLSO-UHFFFAOYSA-N CS(=O)(=O)C(N)CNC(=O)C1=NC2=NC(NC=3C=C4OC(CO)COC4=CC=3)=NC=C2C=C1C1=CC=CC=C1Br Chemical compound CS(=O)(=O)C(N)CNC(=O)C1=NC2=NC(NC=3C=C4OC(CO)COC4=CC=3)=NC=C2C=C1C1=CC=CC=C1Br OBHFGNSNNKOLSO-UHFFFAOYSA-N 0.000 description 1
- 108010001789 Calcitonin Receptors Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000052052 Casein Kinase II Human genes 0.000 description 1
- 108010010919 Casein Kinase II Proteins 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 description 1
- 108010018888 Choline kinase Proteins 0.000 description 1
- 102100031065 Choline kinase alpha Human genes 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- 208000003311 Cytochrome P-450 Enzyme Inhibitors Diseases 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 description 1
- 101710101225 Diablo IAP-binding mitochondrial protein Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 244000133098 Echinacea angustifolia Species 0.000 description 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 1
- 102100028471 Eosinophil peroxidase Human genes 0.000 description 1
- 108010060374 FSH Receptors Proteins 0.000 description 1
- 102000008175 FSH Receptors Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 102000052874 Gastrin receptors Human genes 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 108010063919 Glucagon Receptors Proteins 0.000 description 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- XJTZHGNBKZYODI-UHFFFAOYSA-N Glycitin Natural products OCC1OC(Oc2ccc3OC=C(C(=O)c3c2CO)c4ccc(O)cc4)C(O)C(O)C1O XJTZHGNBKZYODI-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 1
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 1
- MCSPBPXATWBACD-GAYQJXMFSA-N Guanabenz acetate Chemical compound CC(O)=O.NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl MCSPBPXATWBACD-GAYQJXMFSA-N 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 208000006050 Hemangiopericytoma Diseases 0.000 description 1
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 1
- 101710184069 Hepatocyte growth factor receptor Proteins 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000693076 Homo sapiens Angiopoietin-related protein 4 Proteins 0.000 description 1
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 description 1
- 101000588130 Homo sapiens Microsomal triglyceride transfer protein large subunit Proteins 0.000 description 1
- 101000785063 Homo sapiens Serine-protein kinase ATM Proteins 0.000 description 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000010790 Interleukin-3 Receptors Human genes 0.000 description 1
- 108010038452 Interleukin-3 Receptors Proteins 0.000 description 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
- 241000713321 Intracisternal A-particles Species 0.000 description 1
- 108010024121 Janus Kinases Proteins 0.000 description 1
- 102000015617 Janus Kinases Human genes 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 108010021290 LHRH Receptors Proteins 0.000 description 1
- 102000008238 LHRH Receptors Human genes 0.000 description 1
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000035561 Leukaemic infiltration brain Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 101100269444 Mus musculus Ahi1 gene Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 1
- 108050002826 Neuropeptide Y Receptor Proteins 0.000 description 1
- 102000012301 Neuropeptide Y receptor Human genes 0.000 description 1
- 101150056950 Ntrk2 gene Proteins 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010049358 Oncogene Protein p65(gag-jun) Proteins 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 102000004279 Oxytocin receptors Human genes 0.000 description 1
- 108090000876 Oxytocin receptors Proteins 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108010058828 Parathyroid Hormone Receptors Proteins 0.000 description 1
- 102000006461 Parathyroid Hormone Receptors Human genes 0.000 description 1
- 208000032721 Philadelphia Chromosome Diseases 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 101710132457 Protein A1 Proteins 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 102000009096 Proto-Oncogene Proteins c-myb Human genes 0.000 description 1
- 108010087776 Proto-Oncogene Proteins c-myb Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- OOPDAHSJBRZRPH-UHFFFAOYSA-L Pyrvinium pamoate Chemical compound C1=CC2=CC(N(C)C)=CC=C2[N+](C)=C1C=CC(=C1C)C=C(C)N1C1=CC=CC=C1.C1=CC2=CC(N(C)C)=CC=C2[N+](C)=C1C=CC(=C1C)C=C(C)N1C1=CC=CC=C1.C12=CC=CC=C2C=C(C([O-])=O)C(O)=C1CC1=C(O)C(C([O-])=O)=CC2=CC=CC=C12 OOPDAHSJBRZRPH-UHFFFAOYSA-L 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000713810 Rat sarcoma virus Species 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 102000016983 Releasing hormones receptors Human genes 0.000 description 1
- 108070000025 Releasing hormones receptors Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 101150099493 STAT3 gene Proteins 0.000 description 1
- 101150058731 STAT5A gene Proteins 0.000 description 1
- 101150063267 STAT5B gene Proteins 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 102100020824 Serine-protein kinase ATM Human genes 0.000 description 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108050001286 Somatostatin Receptor Proteins 0.000 description 1
- 102000011096 Somatostatin receptor Human genes 0.000 description 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 229940122149 Thymidylate synthase inhibitor Drugs 0.000 description 1
- 108090000253 Thyrotropin Receptors Proteins 0.000 description 1
- 102100029337 Thyrotropin receptor Human genes 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- 102000005747 Transcription Factor RelA Human genes 0.000 description 1
- 108010031154 Transcription Factor RelA Proteins 0.000 description 1
- 108050005223 Transcription factor Jun Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 102100029519 Tripartite motif-containing protein 29 Human genes 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000004136 Vasopressin Receptors Human genes 0.000 description 1
- 108090000643 Vasopressin Receptors Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 description 1
- ODOISJJCWUVNDJ-WCTZXXKLSA-N [(2r,3r,4r,5r)-2,3,4,5-tetrahydroxy-6-methylsulfonyloxyhexyl] methanesulfonate Chemical compound CS(=O)(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)COS(C)(=O)=O ODOISJJCWUVNDJ-WCTZXXKLSA-N 0.000 description 1
- DACWQSNZECJJGG-UHFFFAOYSA-N [1,2,4]triazolo[1,5-a]pyridine Chemical compound C1=CC=CN2N=CN=C21 DACWQSNZECJJGG-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- CNSGMDIIDUDBOM-UHFFFAOYSA-N [2-[3-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamic acid Chemical compound COCCOC1=CC=CC(C=2NC3=NC=C(NC(O)=O)C=C3C=2)=C1 CNSGMDIIDUDBOM-UHFFFAOYSA-N 0.000 description 1
- LYFQKBYNAGDVHO-UHFFFAOYSA-N [3-[(7-iodothieno[3,2-d]pyrimidin-2-yl)amino]phenyl]methanol Chemical compound OCC1=CC=CC(NC=2N=C3C(I)=CSC3=CN=2)=C1 LYFQKBYNAGDVHO-UHFFFAOYSA-N 0.000 description 1
- YSRJTUUULANOPJ-UHFFFAOYSA-N [3-[2-(3,4,5-trimethoxyanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]methanol Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C3C(C=4C=C(CO)C=CC=4)=CSC3=CN=2)=C1 YSRJTUUULANOPJ-UHFFFAOYSA-N 0.000 description 1
- PODDVUDBHBVDKT-UHFFFAOYSA-N [3-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]methanol Chemical compound OCC1=CC=CC(C=2C3=NC(NC=4C=CC(=CC=4)N4CCOCC4)=NC=C3SC=2)=C1 PODDVUDBHBVDKT-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- ZXEWMEPUPSMVPS-UHFFFAOYSA-N [3-[[4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]amino]phenyl]methanol Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=C(CO)C=CC=2)=NC2=CC=CC=C12 ZXEWMEPUPSMVPS-UHFFFAOYSA-N 0.000 description 1
- NVMCVWOODOWOLT-UHFFFAOYSA-N [4-({4-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile Chemical compound C1=CC(CC#N)=CC=C1NC1=NC(NC2=NNC(=C2)C2CC2)=C(C=CC=C2)C2=N1 NVMCVWOODOWOLT-UHFFFAOYSA-N 0.000 description 1
- KHMSBVAXKCCTCU-UHFFFAOYSA-N [4-[2-(3,4,5-trimethoxyanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]methanol Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C3C(C=4C=CC(CO)=CC=4)=CSC3=CN=2)=C1 KHMSBVAXKCCTCU-UHFFFAOYSA-N 0.000 description 1
- VBAPMKXSHRDSCJ-UHFFFAOYSA-N [4-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]methanol Chemical compound C1=CC(CO)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 VBAPMKXSHRDSCJ-UHFFFAOYSA-N 0.000 description 1
- VECOHILWTFSUCK-UHFFFAOYSA-N [7-methyl-4-[2-(pyridin-3-ylmethylidene)hydrazinyl]thieno[3,2-d]pyrimidin-6-yl]methanol Chemical compound N1=CN=C2C(C)=C(CO)SC2=C1NN=CC1=CC=CN=C1 VECOHILWTFSUCK-UHFFFAOYSA-N 0.000 description 1
- MEJQKZABPDRJSO-UHFFFAOYSA-N [[6-(2-bromophenyl)-2-(4-fluoroanilino)pyrido[2,3-d]pyrimidine-7-carbonyl]amino]urea Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NNC(=O)N)=NC2=NC=1NC1=CC=C(F)C=C1 MEJQKZABPDRJSO-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002580 adenosine A3 receptor antagonist Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000005090 alkenylcarbonyl group Chemical group 0.000 description 1
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 description 1
- 125000005137 alkenylsulfonyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- 125000005087 alkynylcarbonyl group Chemical group 0.000 description 1
- 125000005225 alkynyloxycarbonyl group Chemical group 0.000 description 1
- 125000005139 alkynylsulfonyl group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000852 alprenolol hydrochloride Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 1
- 229950000971 baricitinib Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 102000055574 bcl-2 Homologous Antagonist-Killer Human genes 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- LZSSRMGPZUCRKN-UHFFFAOYSA-N benzyl n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC(C=C1C=2)=CN=C1NC=2C1=CC=CC=C1 LZSSRMGPZUCRKN-UHFFFAOYSA-N 0.000 description 1
- UKPVXQGVJOQGPU-UHFFFAOYSA-N benzyl n-[2-(3-acetamidophenyl)-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound CC(=O)NC1=CC=CC(C=2NC3=NC=C(NC(=O)OCC=4C=CC=CC=4)C=C3C=2)=C1 UKPVXQGVJOQGPU-UHFFFAOYSA-N 0.000 description 1
- WZBONLLHYOJWHX-UHFFFAOYSA-N benzyl n-[2-[3-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound COCCOC1=CC=CC(C=2NC3=NC=C(NC(=O)OCC=4C=CC=CC=4)C=C3C=2)=C1 WZBONLLHYOJWHX-UHFFFAOYSA-N 0.000 description 1
- WTINRTWZDHAFMM-UHFFFAOYSA-N benzyl n-[2-[4-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound C1=CC(OCCOC)=CC=C1C1=CC2=CC(NC(=O)OCC=3C=CC=CC=3)=CN=C2N1 WTINRTWZDHAFMM-UHFFFAOYSA-N 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 150000005347 biaryls Chemical group 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229920013641 bioerodible polymer Polymers 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000009613 breast lymphoma Diseases 0.000 description 1
- FULYZVMODXYXHD-UHFFFAOYSA-N but-3-yn-2-yl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C#C)=CN=C2NC=1C1=CC=CC=C1 FULYZVMODXYXHD-UHFFFAOYSA-N 0.000 description 1
- WXBZCGACLIBGPB-UHFFFAOYSA-N butan-2-yl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)CC)=CN=C2NC=1C1=CC=CC=C1 WXBZCGACLIBGPB-UHFFFAOYSA-N 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 201000010039 central nervous system leukemia Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- RPKLZQLYODPWTM-KBMWBBLPSA-N cholanoic acid Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)CC2 RPKLZQLYODPWTM-KBMWBBLPSA-N 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- AQIXAKUUQRKLND-UHFFFAOYSA-N cimetidine Chemical compound N#C/N=C(/NC)NCCSCC=1N=CNC=1C AQIXAKUUQRKLND-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- MLUCVPSAIODCQM-NSCUHMNNSA-N crotonaldehyde Chemical compound C\C=C\C=O MLUCVPSAIODCQM-NSCUHMNNSA-N 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 125000006292 cyclic linker group Chemical group 0.000 description 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
- BABVUJPDRJTNND-UHFFFAOYSA-N cyclobutyl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound C1CCC1OC(=O)NC(C=C1N=2)=CN=C1NC=2C1=CC=CC=C1 BABVUJPDRJTNND-UHFFFAOYSA-N 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- DCFDVJPDXYGCOK-UHFFFAOYSA-N cyclohex-3-ene-1-carbaldehyde Chemical compound O=CC1CCC=CC1 DCFDVJPDXYGCOK-UHFFFAOYSA-N 0.000 description 1
- VFXCFKKFUPEJJE-UHFFFAOYSA-N cyclohexyl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound C1CCCCC1OC(=O)NC(C=C1N=2)=CN=C1NC=2C1=CC=CC=C1 VFXCFKKFUPEJJE-UHFFFAOYSA-N 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- XFGCMPIZIRTKIG-UHFFFAOYSA-N cyclopentyl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound C1CCCC1OC(=O)NC(C=C1N=2)=CN=C1NC=2C1=CC=CC=C1 XFGCMPIZIRTKIG-UHFFFAOYSA-N 0.000 description 1
- 150000001944 cysteine derivatives Chemical class 0.000 description 1
- 239000002852 cysteine proteinase inhibitor Substances 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000037437 driver mutation Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 102000013035 dynein heavy chain Human genes 0.000 description 1
- 108060002430 dynein heavy chain Proteins 0.000 description 1
- 235000014134 echinacea Nutrition 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 108700020302 erbB-2 Genes Proteins 0.000 description 1
- 210000000267 erythroid cell Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- NDZWEWJSWYERNF-UHFFFAOYSA-N ethyl 3-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]benzoate Chemical compound CCOC(=O)C1=CC=CC(C=2C3=NC(NC=4C=CC(=CC=4)N4CCOCC4)=NC=C3SC=2)=C1 NDZWEWJSWYERNF-UHFFFAOYSA-N 0.000 description 1
- QLVTZTHGFRDIPO-UHFFFAOYSA-N ethyl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound N=1C2=CC(NC(=O)OCC)=CN=C2NC=1C1=CC=CC=C1 QLVTZTHGFRDIPO-UHFFFAOYSA-N 0.000 description 1
- MEPLNBBVXOTRBB-UHFFFAOYSA-N ethyl n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)carbamate Chemical compound C=1C2=CC(NC(=O)OCC)=CN=C2NC=1C1=CC=CC=C1 MEPLNBBVXOTRBB-UHFFFAOYSA-N 0.000 description 1
- GHPQLWNDGRKPKN-UHFFFAOYSA-N ethyl n-[2-(3-acetamidophenyl)-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound C=1C2=CC(NC(=O)OCC)=CN=C2NC=1C1=CC=CC(NC(C)=O)=C1 GHPQLWNDGRKPKN-UHFFFAOYSA-N 0.000 description 1
- UUTUIHFNHYKTBH-UHFFFAOYSA-N ethyl n-[2-[3-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound C=1C2=CC(NC(=O)OCC)=CN=C2NC=1C1=CC=CC(OCCOC)=C1 UUTUIHFNHYKTBH-UHFFFAOYSA-N 0.000 description 1
- XZZWOJIKAHIYGC-UHFFFAOYSA-N ethyl n-[2-[4-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound C=1C2=CC(NC(=O)OCC)=CN=C2NC=1C1=CC=C(OCCOC)C=C1 XZZWOJIKAHIYGC-UHFFFAOYSA-N 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000389 fluoxetine hydrochloride Drugs 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229950008908 gandotinib Drugs 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 210000001703 glandular epithelial cell Anatomy 0.000 description 1
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 description 1
- 235000008466 glycitein Nutrition 0.000 description 1
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 description 1
- DUBPGEJGGVZKDD-PFKOEMKTSA-N glycitein 7-(6-O-acetyl-beta-D-glucoside) Chemical compound COC1=CC(C(C(C=2C=CC(O)=CC=2)=CO2)=O)=C2C=C1O[C@@H]1O[C@H](COC(C)=O)[C@@H](O)[C@H](O)[C@H]1O DUBPGEJGGVZKDD-PFKOEMKTSA-N 0.000 description 1
- 150000004548 gossypol derivatives Chemical class 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229960003050 guanabenz acetate Drugs 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000000232 haloalkynyl group Chemical group 0.000 description 1
- 125000003106 haloaryl group Chemical group 0.000 description 1
- 125000005216 haloheteroaryl group Chemical group 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
- 150000004687 hexahydrates Chemical class 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 125000005020 hydroxyalkenyl group Chemical group 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000005016 hydroxyalkynyl group Chemical group 0.000 description 1
- 125000005027 hydroxyaryl group Chemical group 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- DCLWNTIANRACSB-UHFFFAOYSA-N imidazo[1,2-b]pyridazin-6-amine Chemical compound N1=C(N)C=CC2=NC=CN21 DCLWNTIANRACSB-UHFFFAOYSA-N 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 1
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 150000002496 iodine Chemical class 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 102000003835 leukotriene receptors Human genes 0.000 description 1
- 108090000146 leukotriene receptors Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- OWMHCYFEIJPHFB-UHFFFAOYSA-N malonyl glycitin Natural products COc1cc2c(cc1OC1OC(COC(=O)CC(O)=O)C(O)C(O)C1O)occ(-c1ccc(O)cc1)c2=O OWMHCYFEIJPHFB-UHFFFAOYSA-N 0.000 description 1
- OWMHCYFEIJPHFB-GOZZSVHWSA-N malonylglycitin Chemical compound COC1=CC(C(C(C=2C=CC(O)=CC=2)=CO2)=O)=C2C=C1O[C@@H]1O[C@H](COC(=O)CC(O)=O)[C@@H](O)[C@H](O)[C@H]1O OWMHCYFEIJPHFB-GOZZSVHWSA-N 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- HNQIVZYLYMDVSB-NJFSPNSNSA-N methanesulfonamide Chemical compound [14CH3]S(N)(=O)=O HNQIVZYLYMDVSB-NJFSPNSNSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- SWXOJCVNZZWISE-UHFFFAOYSA-N methyl 2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidine-7-carboxylate Chemical compound N1=C2C(C(=O)OC)=CSC2=CN=C1NC(C=C1)=CC=C1N1CCOCC1 SWXOJCVNZZWISE-UHFFFAOYSA-N 0.000 description 1
- SJWFIFWXOATTKN-UHFFFAOYSA-N methyl 2-[2-methyl-4-[[4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]amino]phenyl]acetate Chemical compound C1=C(C)C(CC(=O)OC)=CC=C1NC1=NC(NC=2NN=C(C)C=2)=C(C=CC=C2)C2=N1 SJWFIFWXOATTKN-UHFFFAOYSA-N 0.000 description 1
- CMUHZRATLMUDJI-UHFFFAOYSA-N methyl 2h-pyridine-1-carboxylate Chemical compound COC(=O)N1CC=CC=C1 CMUHZRATLMUDJI-UHFFFAOYSA-N 0.000 description 1
- NGBXVIQLRDMLSG-UHFFFAOYSA-N methyl 3-[4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]oxybenzoate Chemical compound COC(=O)C1=CC=CC(OC=2N=C3C=CC=CC3=C(NC=3NN=C(C)C=3)N=2)=C1 NGBXVIQLRDMLSG-UHFFFAOYSA-N 0.000 description 1
- HHGGCFJPBVTVEL-UHFFFAOYSA-N methyl 3-[[4-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]amino]benzoate Chemical compound COC(=O)C1=CC=CC(NC=2N=C3C=CC=CC3=C(NC=3NN=C(C=3)C3CC3)N=2)=C1 HHGGCFJPBVTVEL-UHFFFAOYSA-N 0.000 description 1
- QSSJZLPUHJDYKF-UHFFFAOYSA-N methyl 4-methylbenzoate Chemical group COC(=O)C1=CC=C(C)C=C1 QSSJZLPUHJDYKF-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229950008814 momelotinib Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- GAQAKFHSULJNAK-UHFFFAOYSA-N moricizine hydrochloride Chemical compound [Cl-].C12=CC(NC(=O)OCC)=CC=C2SC2=CC=CC=C2N1C(=O)CC[NH+]1CCOCC1 GAQAKFHSULJNAK-UHFFFAOYSA-N 0.000 description 1
- 229940050868 moricizine hydrochloride Drugs 0.000 description 1
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 108700021654 myb Genes Proteins 0.000 description 1
- CJTQUMPIWOQTKE-UHFFFAOYSA-N n,n-dimethyl-3-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]benzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=CC(C=2C3=NC(NC=4C=CC(=CC=4)N4CCOCC4)=NC=C3SC=2)=C1 CJTQUMPIWOQTKE-UHFFFAOYSA-N 0.000 description 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
- HBEJHQWEIQIHCJ-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-6-(2-bromophenyl)-2-(4-fluoroanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound C1=CC(F)=CC=C1NC1=NC=C(C=C(C=2C(=CC=CC=2)Br)C(=N2)C(=O)NC3C4CCN(CC4)C3)C2=N1 HBEJHQWEIQIHCJ-UHFFFAOYSA-N 0.000 description 1
- JMZAJTAVWNDEPO-UHFFFAOYSA-N n-(1h-indazol-3-yl)-2-(2-phenylcyclopropyl)quinazolin-4-amine Chemical compound N=1C(NC=2C3=CC=CC=C3NN=2)=C2C=CC=CC2=NC=1C1CC1C1=CC=CC=C1 JMZAJTAVWNDEPO-UHFFFAOYSA-N 0.000 description 1
- ZMLVIZFHWCBVQR-UHFFFAOYSA-N n-(1h-indol-5-ylmethylideneamino)-7-methylthieno[3,2-d]pyrimidin-4-amine Chemical compound C1=C2NC=CC2=CC(C=NNC2=C3SC=C(C3=NC=N2)C)=C1 ZMLVIZFHWCBVQR-UHFFFAOYSA-N 0.000 description 1
- XDPJRGCCJOHFKO-UHFFFAOYSA-N n-(2,4-dimethoxyphenyl)-7-phenylthieno[3,2-d]pyrimidin-2-amine Chemical compound COC1=CC(OC)=CC=C1NC1=NC=C(SC=C2C=3C=CC=CC=3)C2=N1 XDPJRGCCJOHFKO-UHFFFAOYSA-N 0.000 description 1
- AVXDDGKFXOMHRU-UHFFFAOYSA-N n-(2-acetamidoethyl)-6-(2-bromophenyl)-2-(4-fluoroanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCCNC(=O)C)=NC2=NC=1NC1=CC=C(F)C=C1 AVXDDGKFXOMHRU-UHFFFAOYSA-N 0.000 description 1
- GHAJVMLZWITHMN-UHFFFAOYSA-N n-(2-amino-2-oxoethyl)-6-(2-bromophenyl)-2-(4-fluoroanilino)pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)Br)C(C(=O)NCC(=O)N)=NC2=NC=1NC1=CC=C(F)C=C1 GHAJVMLZWITHMN-UHFFFAOYSA-N 0.000 description 1
- GOFYYTINKZUOLP-UHFFFAOYSA-N n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)benzamide Chemical compound C=1C=CC=CC=1C(=O)NC(C=C1N=2)=CN=C1NC=2C1=CC=CC=C1 GOFYYTINKZUOLP-UHFFFAOYSA-N 0.000 description 1
- GVLWPGOBDOZPQA-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-7-(2,4-dimethoxypyrimidin-5-yl)thieno[3,2-d]pyrimidin-2-amine Chemical compound COC1=NC(OC)=NC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(OC)C(OC)=C1 GVLWPGOBDOZPQA-UHFFFAOYSA-N 0.000 description 1
- UDALSLVSZQGREF-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-7-(2,6-dimethoxypyridin-3-yl)thieno[3,2-d]pyrimidin-2-amine Chemical compound COC1=NC(OC)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(OC)C(OC)=C1 UDALSLVSZQGREF-UHFFFAOYSA-N 0.000 description 1
- MIRNGLYFHWGFOE-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-7-(2-methoxypyridin-3-yl)thieno[3,2-d]pyrimidin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(SC=C2C=3C(=NC=CC=3)OC)C2=N1 MIRNGLYFHWGFOE-UHFFFAOYSA-N 0.000 description 1
- UBSFNQIHDRAXIN-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-7-phenylthieno[3,2-d]pyrimidin-2-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(SC=C2C=3C=CC=CC=3)C2=N1 UBSFNQIHDRAXIN-UHFFFAOYSA-N 0.000 description 1
- PKIWVUOKEVEOIZ-UHFFFAOYSA-N n-(3-nitrophenyl)-7-phenylthieno[3,2-d]pyrimidin-2-amine Chemical compound [O-][N+](=O)C1=CC=CC(NC=2N=C3C(C=4C=CC=CC=4)=CSC3=CN=2)=C1 PKIWVUOKEVEOIZ-UHFFFAOYSA-N 0.000 description 1
- JJTRDVNEHVBIPH-UHFFFAOYSA-N n-(4-morpholin-4-ylphenyl)-7-(2-propan-2-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound CC(C)C1=CC=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 JJTRDVNEHVBIPH-UHFFFAOYSA-N 0.000 description 1
- TYVYCQWLJJUBMI-UHFFFAOYSA-N n-(4-morpholin-4-ylphenyl)-7-(4-nitrophenyl)sulfanyl-5h-pyrrolo[3,2-d]pyrimidin-2-amine Chemical compound C1=CC([N+](=O)[O-])=CC=C1SC(C1=N2)=CNC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 TYVYCQWLJJUBMI-UHFFFAOYSA-N 0.000 description 1
- GNXDKUBDWJMZAC-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-(3-methylphenoxy)quinazolin-4-amine Chemical compound CC1=CC=CC(OC=2N=C3C=CC=CC3=C(NC=3NN=C(C=3)C3CC3)N=2)=C1 GNXDKUBDWJMZAC-UHFFFAOYSA-N 0.000 description 1
- WOIPIGRLWFUOLG-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-(5,6,7,8-tetrahydronaphthalen-2-yloxy)quinazolin-4-amine Chemical compound C1CC1C1=NNC(NC=2C3=CC=CC=C3N=C(OC=3C=C4CCCCC4=CC=3)N=2)=C1 WOIPIGRLWFUOLG-UHFFFAOYSA-N 0.000 description 1
- LZTYGOLQKMIEES-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-(phenoxymethyl)quinazolin-4-amine Chemical compound N=1C(NC=2NN=C(C=2)C2CC2)=C2C=CC=CC2=NC=1COC1=CC=CC=C1 LZTYGOLQKMIEES-UHFFFAOYSA-N 0.000 description 1
- IYFMJNXFNDEBIK-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-(phenylmethoxymethyl)quinazolin-4-amine Chemical compound C=1C=CC=CC=1COCC(N=C1C=CC=CC1=1)=NC=1NC(NN=1)=CC=1C1CC1 IYFMJNXFNDEBIK-UHFFFAOYSA-N 0.000 description 1
- FYTNVOKHBXWLIO-UHFFFAOYSA-N n-(5-cyclopropyl-1h-pyrazol-3-yl)-2-methylquinazolin-4-amine Chemical compound C=12C=CC=CC2=NC(C)=NC=1NC(NN=1)=CC=1C1CC1 FYTNVOKHBXWLIO-UHFFFAOYSA-N 0.000 description 1
- FAEFHOMDLGPZFR-UHFFFAOYSA-N n-(5-fluoro-1h-indazol-3-yl)-2-(2-phenylcyclopropyl)quinazolin-4-amine Chemical compound C12=CC(F)=CC=C2NN=C1NC(C1=CC=CC=C1N=1)=NC=1C1CC1C1=CC=CC=C1 FAEFHOMDLGPZFR-UHFFFAOYSA-N 0.000 description 1
- CYYCFBRQWGDKOO-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-2-(2-phenylcyclopropyl)quinazolin-4-amine Chemical compound N1C(C)=CC(NC=2C3=CC=CC=C3N=C(N=2)C2C(C2)C=2C=CC=CC=2)=N1 CYYCFBRQWGDKOO-UHFFFAOYSA-N 0.000 description 1
- VXJWFKKEBMKRHY-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-2-(2-phenylpropan-2-yl)-6,7,8,9-tetrahydro-5h-cyclohepta[d]pyrimidin-4-amine Chemical compound N1N=C(C)C=C1NC1=NC(C(C)(C)C=2C=CC=CC=2)=NC2=C1CCCCC2 VXJWFKKEBMKRHY-UHFFFAOYSA-N 0.000 description 1
- HRKMCJXBURZQSY-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-2-(phenylsulfanylmethyl)-5,6,7,8-tetrahydroquinazolin-4-amine Chemical compound N1N=C(C)C=C1NC1=NC(CSC=2C=CC=CC=2)=NC2=C1CCCC2 HRKMCJXBURZQSY-UHFFFAOYSA-N 0.000 description 1
- ZJOBKIMAWIYZHQ-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-2-naphthalen-2-yloxyquinazolin-4-amine Chemical compound N1N=C(C)C=C1NC1=NC(OC=2C=C3C=CC=CC3=CC=2)=NC2=CC=CC=C12 ZJOBKIMAWIYZHQ-UHFFFAOYSA-N 0.000 description 1
- HPMITVJMOXAXLV-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-2-phenoxyquinazolin-4-amine Chemical compound N1N=C(C)C=C1NC1=NC(OC=2C=CC=CC=2)=NC2=CC=CC=C12 HPMITVJMOXAXLV-UHFFFAOYSA-N 0.000 description 1
- BIQKHBCAKKBUAB-UHFFFAOYSA-N n-(7-fluoro-1h-indazol-3-yl)-2-(2-phenylcyclopropyl)quinazolin-4-amine Chemical compound N=1NC=2C(F)=CC=CC=2C=1NC(C1=CC=CC=C1N=1)=NC=1C1CC1C1=CC=CC=C1 BIQKHBCAKKBUAB-UHFFFAOYSA-N 0.000 description 1
- JMINZMMVUOMWOD-UHFFFAOYSA-N n-(cyanomethyl)-2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N1=C2C(C(NCC#N)=O)=CSC2=CN=C1NC(C=C1)=CC=C1N1CCOCC1 JMINZMMVUOMWOD-UHFFFAOYSA-N 0.000 description 1
- RESVYOGEFUDMLA-UHFFFAOYSA-N n-(cyanomethyl)-3-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]benzamide Chemical compound N#CCNC(=O)C1=CC=CC(C=2C3=NC(NC=4C=CC(=CC=4)N4CCOCC4)=NC=C3SC=2)=C1 RESVYOGEFUDMLA-UHFFFAOYSA-N 0.000 description 1
- WMZQKFHEUADYIZ-UHFFFAOYSA-N n-(cyanomethyl)-3-[2-[4-(morpholin-4-ylmethyl)anilino]thieno[3,2-d]pyrimidin-7-yl]benzamide Chemical compound N#CCNC(=O)C1=CC=CC(C=2C3=NC(NC=4C=CC(CN5CCOCC5)=CC=4)=NC=C3SC=2)=C1 WMZQKFHEUADYIZ-UHFFFAOYSA-N 0.000 description 1
- ODAXMGKPEIAQSX-UHFFFAOYSA-N n-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]benzamide Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 ODAXMGKPEIAQSX-UHFFFAOYSA-N 0.000 description 1
- OFTCFZMUPWWHQB-UHFFFAOYSA-N n-(cyanomethyl)-n-[3-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound N#CCN(S(=O)(=O)C)C1=CC=CC(C=2C3=NC(NC=4C=CC(=CC=4)N4CCOCC4)=NC=C3SC=2)=C1 OFTCFZMUPWWHQB-UHFFFAOYSA-N 0.000 description 1
- LYGWVDVUGFARKL-UHFFFAOYSA-N n-(cyanomethyl)-n-[4-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound C1=CC(N(CC#N)S(=O)(=O)C)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 LYGWVDVUGFARKL-UHFFFAOYSA-N 0.000 description 1
- RFVIMZZOMGKYLF-UHFFFAOYSA-N n-(furan-2-ylmethylideneamino)-7-methylthieno[3,2-d]pyrimidin-4-amine Chemical compound N1=CN=C2C(C)=CSC2=C1NN=CC1=CC=CO1 RFVIMZZOMGKYLF-UHFFFAOYSA-N 0.000 description 1
- BYYVBPIKZCTQLO-UHFFFAOYSA-N n-(pyridin-3-ylmethylideneamino)-6-thiophen-3-ylthieno[3,2-d]pyrimidin-4-amine Chemical compound N=1C=NC=2C=C(C3=CSC=C3)SC=2C=1NN=CC1=CC=CN=C1 BYYVBPIKZCTQLO-UHFFFAOYSA-N 0.000 description 1
- RPYHCCKGMOUWKE-UHFFFAOYSA-N n-(thiophen-2-ylmethylideneamino)pyrido[2,3]thieno[2,4-d]pyrimidin-4-amine Chemical compound N=1C=NC=2C3=CC=CN=C3SC=2C=1NN=CC1=CC=CS1 RPYHCCKGMOUWKE-UHFFFAOYSA-N 0.000 description 1
- ZEZUTGWFMKGPGA-UHFFFAOYSA-N n-[(2-chlorophenyl)methylideneamino]-7-methylthieno[3,2-d]pyrimidin-4-amine Chemical compound N1=CN=C2C(C)=CSC2=C1NN=CC1=CC=CC=C1Cl ZEZUTGWFMKGPGA-UHFFFAOYSA-N 0.000 description 1
- RDLKHGFOOIQELP-UHFFFAOYSA-N n-[(2-methylphenyl)methyl]-2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-amine Chemical compound CC1=CC=CC=C1CNC1=CN=C(NC(=C2)C=3C=CC=CC=3)C2=C1 RDLKHGFOOIQELP-UHFFFAOYSA-N 0.000 description 1
- VWEJHOAFYMZUKT-UHFFFAOYSA-N n-[(3,4-dimethoxyphenyl)methylideneamino]-7-methylthieno[3,2-d]pyrimidin-4-amine Chemical compound C1=C(OC)C(OC)=CC=C1C=NNC1=NC=NC2=C1SC=C2C VWEJHOAFYMZUKT-UHFFFAOYSA-N 0.000 description 1
- OMLUZPAGJRMVHC-UHFFFAOYSA-N n-[(3,5-dimethoxyphenyl)methylideneamino]-7-methylthieno[3,2-d]pyrimidin-4-amine Chemical compound COC1=CC(OC)=CC(C=NNC=2C=3SC=C(C)C=3N=CN=2)=C1 OMLUZPAGJRMVHC-UHFFFAOYSA-N 0.000 description 1
- INKDEWPCMLQGGZ-UHFFFAOYSA-N n-[(3-bromophenyl)methylideneamino]-7-methylthieno[3,2-d]pyrimidin-4-amine Chemical compound N1=CN=C2C(C)=CSC2=C1NN=CC1=CC=CC(Br)=C1 INKDEWPCMLQGGZ-UHFFFAOYSA-N 0.000 description 1
- UZHUXNKHWASHQS-UHFFFAOYSA-N n-[(3-chlorophenyl)methylideneamino]-7-methylthieno[3,2-d]pyrimidin-4-amine Chemical compound N1=CN=C2C(C)=CSC2=C1NN=CC1=CC=CC(Cl)=C1 UZHUXNKHWASHQS-UHFFFAOYSA-N 0.000 description 1
- YVSNFFRAGSHAMW-UHFFFAOYSA-N n-[(4-fluorophenyl)methylideneamino]-6,7-dimethylthieno[3,2-d]pyrimidin-4-amine Chemical compound N1=CN=C2C(C)=C(C)SC2=C1NN=CC1=CC=C(F)C=C1 YVSNFFRAGSHAMW-UHFFFAOYSA-N 0.000 description 1
- UVPUHUPWXQWIIB-UHFFFAOYSA-N n-[(4-methoxyphenyl)methylideneamino]-7-methylthieno[3,2-d]pyrimidin-4-amine Chemical compound C1=CC(OC)=CC=C1C=NNC1=NC=NC2=C1SC=C2C UVPUHUPWXQWIIB-UHFFFAOYSA-N 0.000 description 1
- DAVIKTBRCQWOGT-GIJQJNRQSA-N n-[(e)-(4-oxochromen-3-yl)methylideneamino]pyridine-3-carboxamide Chemical compound C=1OC2=CC=CC=C2C(=O)C=1/C=N/NC(=O)C1=CC=CN=C1 DAVIKTBRCQWOGT-GIJQJNRQSA-N 0.000 description 1
- JZTXTFCSDJISNU-UHFFFAOYSA-N n-[2-(3-acetamidophenyl)-1h-imidazo[4,5-b]pyridin-6-yl]-2-chlorobenzamide Chemical compound CC(=O)NC1=CC=CC(C=2NC3=NC=C(NC(=O)C=4C(=CC=CC=4)Cl)C=C3N=2)=C1 JZTXTFCSDJISNU-UHFFFAOYSA-N 0.000 description 1
- BRAFICHEAQGJLM-UHFFFAOYSA-N n-[2-(3-acetamidophenyl)-1h-pyrrolo[2,3-b]pyridin-5-yl]-2,4-dichlorobenzamide Chemical compound CC(=O)NC1=CC=CC(C=2NC3=NC=C(NC(=O)C=4C(=CC(Cl)=CC=4)Cl)C=C3C=2)=C1 BRAFICHEAQGJLM-UHFFFAOYSA-N 0.000 description 1
- QJUISYNXVSIQMU-UHFFFAOYSA-N n-[2-(3-acetamidophenyl)-1h-pyrrolo[2,3-b]pyridin-5-yl]-2-chloro-5-methoxybenzamide Chemical compound COC1=CC=C(Cl)C(C(=O)NC=2C=C3C=C(NC3=NC=2)C=2C=C(NC(C)=O)C=CC=2)=C1 QJUISYNXVSIQMU-UHFFFAOYSA-N 0.000 description 1
- OAMHICYZXWCPHK-UHFFFAOYSA-N n-[2-(3-acetamidophenyl)-1h-pyrrolo[2,3-b]pyridin-5-yl]-2-chloro-6-methylbenzamide Chemical compound CC(=O)NC1=CC=CC(C=2NC3=NC=C(NC(=O)C=4C(=CC=CC=4C)Cl)C=C3C=2)=C1 OAMHICYZXWCPHK-UHFFFAOYSA-N 0.000 description 1
- SIQPQBZIPNKADH-UHFFFAOYSA-N n-[2-(3-acetamidophenyl)-1h-pyrrolo[2,3-b]pyridin-5-yl]-2-chlorobenzamide Chemical compound CC(=O)NC1=CC=CC(C=2NC3=NC=C(NC(=O)C=4C(=CC=CC=4)Cl)C=C3C=2)=C1 SIQPQBZIPNKADH-UHFFFAOYSA-N 0.000 description 1
- CPOQLGAEUYOHIB-UHFFFAOYSA-N n-[2-(3-acetamidophenyl)-1h-pyrrolo[2,3-b]pyridin-5-yl]-2-methoxybenzamide Chemical compound COC1=CC=CC=C1C(=O)NC1=CN=C(NC(=C2)C=3C=C(NC(C)=O)C=CC=3)C2=C1 CPOQLGAEUYOHIB-UHFFFAOYSA-N 0.000 description 1
- DCOQUDUBUSLJKM-UHFFFAOYSA-N n-[2-(3-acetamidophenyl)-1h-pyrrolo[2,3-b]pyridin-5-yl]-4-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CN=C(NC(=C2)C=3C=C(NC(C)=O)C=CC=3)C2=C1 DCOQUDUBUSLJKM-UHFFFAOYSA-N 0.000 description 1
- PMJVLGGFBXLJQR-UHFFFAOYSA-N n-[2-(3-aminophenyl)-1h-imidazo[4,5-b]pyridin-6-yl]-2-chlorobenzamide Chemical compound NC1=CC=CC(C=2NC3=NC=C(NC(=O)C=4C(=CC=CC=4)Cl)C=C3N=2)=C1 PMJVLGGFBXLJQR-UHFFFAOYSA-N 0.000 description 1
- DICGHNQGBGQCAR-UHFFFAOYSA-N n-[2-(3h-benzimidazol-5-yl)-1h-imidazo[4,5-b]pyridin-6-yl]-2-chlorobenzamide Chemical compound ClC1=CC=CC=C1C(=O)NC1=CN=C(NC(=N2)C=3C=C4N=CNC4=CC=3)C2=C1 DICGHNQGBGQCAR-UHFFFAOYSA-N 0.000 description 1
- LDMNSBCHYUCJKN-UHFFFAOYSA-N n-[2-(methanesulfonamido)ethyl]-2-(4-morpholin-4-ylanilino)-6-[2-(trifluoromethyl)phenyl]pyrido[2,3-d]pyrimidine-7-carboxamide Chemical compound N=1C=C2C=C(C=3C(=CC=CC=3)C(F)(F)F)C(C(=O)NCCNS(=O)(=O)C)=NC2=NC=1NC(C=C1)=CC=C1N1CCOCC1 LDMNSBCHYUCJKN-UHFFFAOYSA-N 0.000 description 1
- OCYADZFBBOCPOC-UHFFFAOYSA-N n-[2-[3-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]-2-methylbenzamide Chemical compound COCCOC1=CC=CC(C=2NC3=NC=C(NC(=O)C=4C(=CC=CC=4)C)C=C3C=2)=C1 OCYADZFBBOCPOC-UHFFFAOYSA-N 0.000 description 1
- BYHWIHUTQCADTL-UHFFFAOYSA-N n-[2-[4-[bis(2-methoxyethyl)amino]-3-fluorophenyl]-1h-imidazo[4,5-b]pyridin-6-yl]-2-chlorobenzamide Chemical compound C1=C(F)C(N(CCOC)CCOC)=CC=C1C1=NC2=CC(NC(=O)C=3C(=CC=CC=3)Cl)=CN=C2N1 BYHWIHUTQCADTL-UHFFFAOYSA-N 0.000 description 1
- OCGRRWLYYYUSJR-UHFFFAOYSA-N n-[2-cyano-4-[[4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]amino]phenyl]acetamide Chemical compound C1=C(C#N)C(NC(=O)C)=CC=C1NC1=NC(NC=2NN=C(C)C=2)=C(C=CC=C2)C2=N1 OCGRRWLYYYUSJR-UHFFFAOYSA-N 0.000 description 1
- QAORNCIDWJJIAL-UHFFFAOYSA-N n-[2-methoxy-4-[2-[4-(morpholin-4-ylmethyl)anilino]thieno[3,2-d]pyrimidin-7-yl]phenyl]acetamide Chemical compound C1=C(NC(C)=O)C(OC)=CC(C=2C3=NC(NC=4C=CC(CN5CCOCC5)=CC=4)=NC=C3SC=2)=C1 QAORNCIDWJJIAL-UHFFFAOYSA-N 0.000 description 1
- XQFCKSHIEBKWDU-UHFFFAOYSA-N n-[3-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2C3=NC(NC=4C=CC(=CC=4)N4CCOCC4)=NC=C3SC=2)=C1 XQFCKSHIEBKWDU-UHFFFAOYSA-N 0.000 description 1
- QYHLZBUMTADYQI-UHFFFAOYSA-N n-[3-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(C=2C3=NC(NC=4C=CC(=CC=4)N4CCOCC4)=NC=C3SC=2)=C1 QYHLZBUMTADYQI-UHFFFAOYSA-N 0.000 description 1
- LGTMIYZVEVWGHI-UHFFFAOYSA-N n-[3-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]prop-2-enamide Chemical compound C=CC(=O)NC1=CC=CC(C=2C3=NC(NC=4C=CC(=CC=4)N4CCOCC4)=NC=C3SC=2)=C1 LGTMIYZVEVWGHI-UHFFFAOYSA-N 0.000 description 1
- QWJOIOCEITWYGW-UHFFFAOYSA-N n-[3-[2-[4-(2-pyrrolidin-1-ylethoxy)anilino]thieno[3,2-d]pyrimidin-7-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2C3=NC(NC=4C=CC(OCCN5CCCC5)=CC=4)=NC=C3SC=2)=C1 QWJOIOCEITWYGW-UHFFFAOYSA-N 0.000 description 1
- RPRATBSQXQZMEI-UHFFFAOYSA-N n-[3-[2-[4-(morpholin-4-ylmethyl)anilino]thieno[3,2-d]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(C=2C3=NC(NC=4C=CC(CN5CCOCC5)=CC=4)=NC=C3SC=2)=C1 RPRATBSQXQZMEI-UHFFFAOYSA-N 0.000 description 1
- QSUXFKBYWCDRRL-UHFFFAOYSA-N n-[3-[5-(benzylamino)-1h-pyrrolo[2,3-b]pyridin-2-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2NC3=NC=C(NCC=4C=CC=CC=4)C=C3C=2)=C1 QSUXFKBYWCDRRL-UHFFFAOYSA-N 0.000 description 1
- RUQWOHKPZSEAPL-UHFFFAOYSA-N n-[3-[5-[(2-methylphenyl)methylamino]-1h-pyrrolo[2,3-b]pyridin-2-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2NC3=NC=C(NCC=4C(=CC=CC=4)C)C=C3C=2)=C1 RUQWOHKPZSEAPL-UHFFFAOYSA-N 0.000 description 1
- JMYOXLDNKPWWEH-UHFFFAOYSA-N n-[3-[5-methyl-2-(4-morpholin-4-ylanilino)pyrrolo[3,2-d]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound C12=NC(NC=3C=CC(=CC=3)N3CCOCC3)=NC=C2N(C)C=C1C1=CC=CC(NS(C)(=O)=O)=C1 JMYOXLDNKPWWEH-UHFFFAOYSA-N 0.000 description 1
- HTYGQYUCPPBJJY-UHFFFAOYSA-N n-[4-(morpholin-4-ylmethyl)phenyl]-7-(3-piperazin-1-ylphenyl)thieno[3,2-d]pyrimidin-2-amine Chemical compound C=1C=C(NC=2N=C3C(C=4C=C(C=CC=4)N4CCNCC4)=CSC3=CN=2)C=CC=1CN1CCOCC1 HTYGQYUCPPBJJY-UHFFFAOYSA-N 0.000 description 1
- HMEPXVKGBGJCCM-UHFFFAOYSA-N n-[4-[(4-ethylpiperazin-1-yl)methyl]phenyl]-7-(1h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=C1)=CC=C1NC1=NC=C(SC=C2C3=CNN=C3)C2=N1 HMEPXVKGBGJCCM-UHFFFAOYSA-N 0.000 description 1
- JRHMIDVQGPCTRL-UHFFFAOYSA-N n-[4-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 JRHMIDVQGPCTRL-UHFFFAOYSA-N 0.000 description 1
- OFKYPJFPTVMPEQ-UHFFFAOYSA-N n-[4-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]phenyl]prop-2-enamide Chemical compound C1=CC(NC(=O)C=C)=CC=C1C(C1=N2)=CSC1=CN=C2NC1=CC=C(N2CCOCC2)C=C1 OFKYPJFPTVMPEQ-UHFFFAOYSA-N 0.000 description 1
- YTXFVCJXBXZSRH-UHFFFAOYSA-N n-[4-[2-[4-(morpholin-4-ylmethyl)anilino]thieno[3,2-d]pyrimidin-7-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C(C1=N2)=CSC1=CN=C2NC(C=C1)=CC=C1CN1CCOCC1 YTXFVCJXBXZSRH-UHFFFAOYSA-N 0.000 description 1
- CWGCAXSXZAOMRF-UHFFFAOYSA-N n-[4-[4-(2-methylphenyl)-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1SC1=NC(NC=2NN=C(C)C=2)=CC(C=2C(=CC=CC=2)C)=N1 CWGCAXSXZAOMRF-UHFFFAOYSA-N 0.000 description 1
- KCKBBZRCPOVAQO-UHFFFAOYSA-N n-[4-[5-(benzylamino)-1h-pyrrolo[2,3-b]pyridin-2-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=CC2=CC(NCC=3C=CC=CC=3)=CN=C2N1 KCKBBZRCPOVAQO-UHFFFAOYSA-N 0.000 description 1
- HCCLNCCFKZGJKD-UHFFFAOYSA-N n-[4-[5-[(2-methylphenyl)methylamino]-1h-pyrrolo[2,3-b]pyridin-2-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=CC2=CC(NCC=3C(=CC=CC=3)C)=CN=C2N1 HCCLNCCFKZGJKD-UHFFFAOYSA-N 0.000 description 1
- SBYSBHXXYDBCTR-UHFFFAOYSA-N n-[4-[5-methyl-2-(4-morpholin-4-ylanilino)pyrrolo[3,2-d]pyrimidin-7-yl]phenyl]methanesulfonamide Chemical compound C12=NC(NC=3C=CC(=CC=3)N3CCOCC3)=NC=C2N(C)C=C1C1=CC=C(NS(C)(=O)=O)C=C1 SBYSBHXXYDBCTR-UHFFFAOYSA-N 0.000 description 1
- NNHVOAZSYHBHCC-UHFFFAOYSA-N n-[4-[[4-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]amino]-2-methylphenyl]acetamide Chemical compound C1=C(C)C(NC(=O)C)=CC=C1NC1=NC(NC=2NN=C(C=2)C2CC2)=C(C=CC=C2)C2=N1 NNHVOAZSYHBHCC-UHFFFAOYSA-N 0.000 description 1
- RRJHDRHRONWNDO-UHFFFAOYSA-N n-[4-[[4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]amino]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1NC1=NC(NC=2NN=C(C)C=2)=C(C=CC=C2)C2=N1 RRJHDRHRONWNDO-UHFFFAOYSA-N 0.000 description 1
- ZKYBJOMNNCJQBV-UHFFFAOYSA-N n-[5-(furan-2-yl)-1h-pyrazol-3-yl]-6-methyl-2-(phenoxymethyl)pyrimidin-4-amine Chemical compound N=1C(COC=2C=CC=CC=2)=NC(C)=CC=1NC(NN=1)=CC=1C1=CC=CO1 ZKYBJOMNNCJQBV-UHFFFAOYSA-N 0.000 description 1
- NHDXBRGCFCVKIB-UHFFFAOYSA-N n-[5-(furan-2-yl)-1h-pyrazol-3-yl]-6-methyl-2-(phenylsulfanylmethyl)pyrimidin-4-amine Chemical compound N=1C(CSC=2C=CC=CC=2)=NC(C)=CC=1NC(NN=1)=CC=1C1=CC=CO1 NHDXBRGCFCVKIB-UHFFFAOYSA-N 0.000 description 1
- POCKCAZPWWBDIG-UHFFFAOYSA-N n-[5-(furan-2-yl)-1h-pyrazol-3-yl]-6-methyl-2-[(4-methylphenyl)sulfanylmethyl]pyrimidin-4-amine Chemical compound C1=CC(C)=CC=C1SCC1=NC(C)=CC(NC=2NN=C(C=2)C=2OC=CC=2)=N1 POCKCAZPWWBDIG-UHFFFAOYSA-N 0.000 description 1
- PIEOISUBEHIUKN-UHFFFAOYSA-N n-benzyl-2-[3-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-amine Chemical compound COCCOC1=CC=CC(C=2NC3=NC=C(NCC=4C=CC=CC=4)C=C3C=2)=C1 PIEOISUBEHIUKN-UHFFFAOYSA-N 0.000 description 1
- NSYNDNYSQFKOGL-UHFFFAOYSA-N n-benzyl-2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-amine Chemical compound C=1C=CC=CC=1CNC(C=C1C=2)=CN=C1NC=2C1=CC=CC=C1 NSYNDNYSQFKOGL-UHFFFAOYSA-N 0.000 description 1
- MOSFBNKJEWWMGB-UHFFFAOYSA-N n-tert-butyl-3-[2-(3,4,5-trimethoxyanilino)thieno[3,2-d]pyrimidin-7-yl]benzenesulfonamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C3C(C=4C=C(C=CC=4)S(=O)(=O)NC(C)(C)C)=CSC3=CN=2)=C1 MOSFBNKJEWWMGB-UHFFFAOYSA-N 0.000 description 1
- CCMAMPOODMLVHB-UHFFFAOYSA-N n-tert-butyl-3-[2-(3,4-dimethoxyanilino)thieno[3,2-d]pyrimidin-7-yl]benzenesulfonamide Chemical compound C1=C(OC)C(OC)=CC=C1NC1=NC=C(SC=C2C=3C=C(C=CC=3)S(=O)(=O)NC(C)(C)C)C2=N1 CCMAMPOODMLVHB-UHFFFAOYSA-N 0.000 description 1
- ODENUOFQMKNVDG-UHFFFAOYSA-N n-tert-butyl-3-[2-(3-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]benzenesulfonamide Chemical compound CC(C)(C)NS(=O)(=O)C1=CC=CC(C=2C3=NC(NC=4C=C(C=CC=4)N4CCOCC4)=NC=C3SC=2)=C1 ODENUOFQMKNVDG-UHFFFAOYSA-N 0.000 description 1
- PFEINHKJSNZOFK-UHFFFAOYSA-N n-tert-butyl-3-[2-(4-morpholin-4-ylanilino)thieno[3,2-d]pyrimidin-7-yl]benzamide Chemical compound CC(C)(C)NC(=O)C1=CC=CC(C=2C3=NC(NC=4C=CC(=CC=4)N4CCOCC4)=NC=C3SC=2)=C1 PFEINHKJSNZOFK-UHFFFAOYSA-N 0.000 description 1
- PUJWNIZTMKAKMR-UHFFFAOYSA-N n-tert-butyl-3-[2-[3-(hydroxymethyl)anilino]thieno[3,2-d]pyrimidin-7-yl]benzenesulfonamide Chemical compound CC(C)(C)NS(=O)(=O)C1=CC=CC(C=2C3=NC(NC=4C=C(CO)C=CC=4)=NC=C3SC=2)=C1 PUJWNIZTMKAKMR-UHFFFAOYSA-N 0.000 description 1
- HQIOPIGWEJNWAB-UHFFFAOYSA-N n-tert-butyl-3-[2-[4-(1-ethylpiperidin-4-yl)oxyanilino]thieno[3,2-d]pyrimidin-7-yl]benzenesulfonamide Chemical compound C1CN(CC)CCC1OC(C=C1)=CC=C1NC1=NC=C(SC=C2C=3C=C(C=CC=3)S(=O)(=O)NC(C)(C)C)C2=N1 HQIOPIGWEJNWAB-UHFFFAOYSA-N 0.000 description 1
- LTMCPSLZUHVTOB-UHFFFAOYSA-N n-tert-butyl-3-[2-[4-(2-pyrrolidin-1-ylethoxy)anilino]thieno[3,2-d]pyrimidin-7-yl]benzenesulfonamide Chemical class CC(C)(C)NS(=O)(=O)C1=CC=CC(C=2C3=NC(NC=4C=CC(OCCN5CCCC5)=CC=4)=NC=C3SC=2)=C1 LTMCPSLZUHVTOB-UHFFFAOYSA-N 0.000 description 1
- SKCNLDGWGZAVLS-UHFFFAOYSA-N n-tert-butyl-3-[2-[4-(morpholin-4-ylmethyl)anilino]thieno[3,2-d]pyrimidin-7-yl]benzenesulfonamide Chemical compound CC(C)(C)NS(=O)(=O)C1=CC=CC(C=2C3=NC(NC=4C=CC(CN5CCOCC5)=CC=4)=NC=C3SC=2)=C1 SKCNLDGWGZAVLS-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical compound C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
- 229960003888 nifuroxazide Drugs 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 1
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000002669 organ and tissue protective effect Effects 0.000 description 1
- 229940045681 other alkylating agent in atc Drugs 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- HWXVIOGONBBTBY-ONEGZZNKSA-N pacritinib Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(C=3)=CC=CC=3COC\C=C\COCC=2C=1OCCN1CCCC1 HWXVIOGONBBTBY-ONEGZZNKSA-N 0.000 description 1
- 229950011410 pacritinib Drugs 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- KKJMVRNMMPYWLH-UHFFFAOYSA-N pentan-3-yl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound N=1C2=CC(NC(=O)OC(CC)CC)=CN=C2NC=1C1=CC=CC=C1 KKJMVRNMMPYWLH-UHFFFAOYSA-N 0.000 description 1
- 235000005693 perillyl alcohol Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 229960003243 phenformin Drugs 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 150000008299 phosphorodiamidates Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
- 229960003634 pimozide Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000010469 pro-virus integration Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- QJAIBMGYZUJKFG-UHFFFAOYSA-N propan-2-yl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound N1C2=CC(NC(=O)OC(C)C)=CN=C2N=C1C1=CC=CC=C1 QJAIBMGYZUJKFG-UHFFFAOYSA-N 0.000 description 1
- DPYIZFHYQCCLBU-UHFFFAOYSA-N propan-2-yl n-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-5-yl)carbamate Chemical compound C=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=CC=C1 DPYIZFHYQCCLBU-UHFFFAOYSA-N 0.000 description 1
- ZWSLWXHQASYSJQ-UHFFFAOYSA-N propan-2-yl n-(2-thiophen-2-yl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=CS1 ZWSLWXHQASYSJQ-UHFFFAOYSA-N 0.000 description 1
- YBWGDZPMCBLJLW-UHFFFAOYSA-N propan-2-yl n-(2-thiophen-3-yl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C=1C=CSC=1 YBWGDZPMCBLJLW-UHFFFAOYSA-N 0.000 description 1
- GQUPCGVQZHMRDX-UHFFFAOYSA-N propan-2-yl n-[2-(2-chloropyridin-4-yl)-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=NC(Cl)=C1 GQUPCGVQZHMRDX-UHFFFAOYSA-N 0.000 description 1
- IGMGBSKFRSHZSV-UHFFFAOYSA-N propan-2-yl n-[2-(2-methylpyridin-4-yl)-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=NC(C)=C1 IGMGBSKFRSHZSV-UHFFFAOYSA-N 0.000 description 1
- NDDHZDNWAMRGTQ-UHFFFAOYSA-N propan-2-yl n-[2-(3,4-difluorophenyl)-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=C(F)C(F)=C1 NDDHZDNWAMRGTQ-UHFFFAOYSA-N 0.000 description 1
- YPDXIMXBASSFHS-UHFFFAOYSA-N propan-2-yl n-[2-(3-acetamidophenyl)-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=CC(NC(C)=O)=C1 YPDXIMXBASSFHS-UHFFFAOYSA-N 0.000 description 1
- JFTGOZBNFKYGNK-UHFFFAOYSA-N propan-2-yl n-[2-(3-acetamidophenyl)-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound C=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=CC(NC(C)=O)=C1 JFTGOZBNFKYGNK-UHFFFAOYSA-N 0.000 description 1
- XLQARXUCBQXQSS-UHFFFAOYSA-N propan-2-yl n-[2-(3-aminophenyl)-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=CC(N)=C1 XLQARXUCBQXQSS-UHFFFAOYSA-N 0.000 description 1
- YUDDHGWBTNIPKI-UHFFFAOYSA-N propan-2-yl n-[2-(3-methylsulfinylphenyl)-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=CC(S(C)=O)=C1 YUDDHGWBTNIPKI-UHFFFAOYSA-N 0.000 description 1
- GEUYFTINDSXRPV-UHFFFAOYSA-N propan-2-yl n-[2-(3-methylsulfonylphenyl)-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=CC(S(C)(=O)=O)=C1 GEUYFTINDSXRPV-UHFFFAOYSA-N 0.000 description 1
- HFAGPDUYAYGKEE-UHFFFAOYSA-N propan-2-yl n-[2-(3-nitrophenyl)-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=CC([N+]([O-])=O)=C1 HFAGPDUYAYGKEE-UHFFFAOYSA-N 0.000 description 1
- LTPDVIAWBDWEAS-UHFFFAOYSA-N propan-2-yl n-[2-(3h-benzimidazol-5-yl)-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound C1=C2NC=NC2=CC(C=2NC3=NC=C(C=C3N=2)NC(=O)OC(C)C)=C1 LTPDVIAWBDWEAS-UHFFFAOYSA-N 0.000 description 1
- UJEZMWPSFYQDQH-UHFFFAOYSA-N propan-2-yl n-[2-(4-aminophenyl)-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=C(N)C=C1 UJEZMWPSFYQDQH-UHFFFAOYSA-N 0.000 description 1
- NUXDUFNFLCZNKQ-UHFFFAOYSA-N propan-2-yl n-[2-(4-methylsulfanylphenyl)-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound C1=CC(SC)=CC=C1C1=NC2=CC(NC(=O)OC(C)C)=CN=C2N1 NUXDUFNFLCZNKQ-UHFFFAOYSA-N 0.000 description 1
- HSNRLRXLOLTEIB-UHFFFAOYSA-N propan-2-yl n-[2-(4-methylsulfinylphenyl)-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=C(S(C)=O)C=C1 HSNRLRXLOLTEIB-UHFFFAOYSA-N 0.000 description 1
- IRLGHEOSBVBYFM-UHFFFAOYSA-N propan-2-yl n-[2-(4-methylsulfonylphenyl)-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=C(S(C)(=O)=O)C=C1 IRLGHEOSBVBYFM-UHFFFAOYSA-N 0.000 description 1
- CHNMEFIFNFRNRR-UHFFFAOYSA-N propan-2-yl n-[2-(4-nitrophenyl)-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=C([N+]([O-])=O)C=C1 CHNMEFIFNFRNRR-UHFFFAOYSA-N 0.000 description 1
- QYJAOSOKIMOHNL-UHFFFAOYSA-N propan-2-yl n-[2-(4-sulfamoylphenyl)-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=C(S(N)(=O)=O)C=C1 QYJAOSOKIMOHNL-UHFFFAOYSA-N 0.000 description 1
- OVDLZPHYTAOBLF-UHFFFAOYSA-N propan-2-yl n-[2-(6-methylpyridin-3-yl)-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=C(C)N=C1 OVDLZPHYTAOBLF-UHFFFAOYSA-N 0.000 description 1
- POQCYQMKNJRHCQ-UHFFFAOYSA-N propan-2-yl n-[2-[2-(3-methoxypropylamino)pyridin-4-yl]-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound C1=NC(NCCCOC)=CC(C=2NC3=NC=C(NC(=O)OC(C)C)C=C3N=2)=C1 POQCYQMKNJRHCQ-UHFFFAOYSA-N 0.000 description 1
- ZCAJHZWDJTYJJV-UHFFFAOYSA-N propan-2-yl n-[2-[3-(2-hydroxyethyl)phenyl]-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=CC(CCO)=C1 ZCAJHZWDJTYJJV-UHFFFAOYSA-N 0.000 description 1
- RIXPNCHZCXAFDN-UHFFFAOYSA-N propan-2-yl n-[2-[3-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound COCCOC1=CC=CC(C=2NC3=NC=C(NC(=O)OC(C)C)C=C3C=2)=C1 RIXPNCHZCXAFDN-UHFFFAOYSA-N 0.000 description 1
- IPVCEVOAHAKGNG-UHFFFAOYSA-N propan-2-yl n-[2-[3-(3-methoxypropanoylamino)phenyl]-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound COCCC(=O)NC1=CC=CC(C=2NC3=NC=C(NC(=O)OC(C)C)C=C3N=2)=C1 IPVCEVOAHAKGNG-UHFFFAOYSA-N 0.000 description 1
- QUBRRMQOMGHQNT-UHFFFAOYSA-N propan-2-yl n-[2-[3-(3-methoxypropylcarbamoyl)phenyl]-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound COCCCNC(=O)C1=CC=CC(C=2NC3=NC=C(NC(=O)OC(C)C)C=C3N=2)=C1 QUBRRMQOMGHQNT-UHFFFAOYSA-N 0.000 description 1
- WEKOEPKYZIMIJP-UHFFFAOYSA-N propan-2-yl n-[2-[3-(methanesulfonamido)phenyl]-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C1=CC=CC(NS(C)(=O)=O)=C1 WEKOEPKYZIMIJP-UHFFFAOYSA-N 0.000 description 1
- ASLQWRYCHAULHA-UHFFFAOYSA-N propan-2-yl n-[2-[4-(2-methoxyethoxy)phenyl]-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound C1=CC(OCCOC)=CC=C1C1=NC2=CC(NC(=O)OC(C)C)=CN=C2N1 ASLQWRYCHAULHA-UHFFFAOYSA-N 0.000 description 1
- JCPUGDMRRJXEBU-UHFFFAOYSA-N propan-2-yl n-[2-[4-(2-methoxyethoxy)phenyl]-1h-pyrrolo[2,3-b]pyridin-5-yl]carbamate Chemical compound C1=CC(OCCOC)=CC=C1C1=CC2=CC(NC(=O)OC(C)C)=CN=C2N1 JCPUGDMRRJXEBU-UHFFFAOYSA-N 0.000 description 1
- XMXFBMYALLFRBV-UHFFFAOYSA-N propan-2-yl n-[2-[4-(4-methylpiperazin-1-yl)phenyl]-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)C)=CN=C2NC=1C(C=C1)=CC=C1N1CCN(C)CC1 XMXFBMYALLFRBV-UHFFFAOYSA-N 0.000 description 1
- PEGIMAXTRFSLLB-UHFFFAOYSA-N propan-2-yl n-[2-[4-[2-(diethylamino)ethoxy]phenyl]-1h-imidazo[4,5-b]pyridin-6-yl]carbamate Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C1=NC2=CC(NC(=O)OC(C)C)=CN=C2N1 PEGIMAXTRFSLLB-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- SBGILJXZHNBPTD-UHFFFAOYSA-N propyl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound N1C2=CC(NC(=O)OCCC)=CN=C2N=C1C1=CC=CC=C1 SBGILJXZHNBPTD-UHFFFAOYSA-N 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- QKQGPTWJARHPJQ-UHFFFAOYSA-N pyrazolo[3,4-h]quinolin-2-one Chemical class C1=C2N=NC=C2C2=NC(=O)C=CC2=C1 QKQGPTWJARHPJQ-UHFFFAOYSA-N 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- ASFASEBLIZZGMH-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine-7-carboxylic acid Chemical compound C1=NC=NC2=NC(C(=O)O)=CC=C21 ASFASEBLIZZGMH-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 229960000611 pyrimethamine Drugs 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229960001077 pyrvinium pamoate Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 108010077182 raf Kinases Proteins 0.000 description 1
- 102000009929 raf Kinases Human genes 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000003590 rho kinase inhibitor Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 description 1
- 229950009919 saracatinib Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000009834 selective interaction Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
- BWUMVFCXSYXUOV-AFIPUWLUSA-N solanine alpha Chemical compound O([C@@H]1C[C@@](OC(CO)[C@@H]1O)(O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@@H]5N6C[C@@H](C)CC[C@@H]6[C@H]([C@@H]5[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1)C)O[C@@H]1C([C@@H](O)[C@@H](O)C(C)O1)O)[C@@H]1OC(CO)[C@@H](O)[C@@H](O)C1O BWUMVFCXSYXUOV-AFIPUWLUSA-N 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000002732 sphingomyelin phosphodiesterase inhibitor Substances 0.000 description 1
- 229950006315 spirogermanium Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 description 1
- 229940061353 temodar Drugs 0.000 description 1
- IGRFODZQTWGJMN-UHFFFAOYSA-N tert-butyl 4-[2-[4-(1-ethylpiperidin-4-yl)oxyanilino]thieno[3,2-d]pyrimidin-7-yl]pyrazole-1-carboxylate Chemical compound C1CN(CC)CCC1OC(C=C1)=CC=C1NC1=NC=C(SC=C2C3=CN(N=C3)C(=O)OC(C)(C)C)C2=N1 IGRFODZQTWGJMN-UHFFFAOYSA-N 0.000 description 1
- ATIFLMKJSCCIOR-UHFFFAOYSA-N tert-butyl 4-[2-[4-(morpholin-4-ylmethyl)anilino]thieno[3,2-d]pyrimidin-7-yl]-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(C=2C3=NC(NC=4C=CC(CN5CCOCC5)=CC=4)=NC=C3SC=2)=C1 ATIFLMKJSCCIOR-UHFFFAOYSA-N 0.000 description 1
- LSWNTXDGHBGOBU-UHFFFAOYSA-N tert-butyl 4-[2-[4-(morpholin-4-ylmethyl)anilino]thieno[3,2-d]pyrimidin-7-yl]pyrazole-1-carboxylate Chemical compound C1=NN(C(=O)OC(C)(C)C)C=C1C(C1=N2)=CSC1=CN=C2NC(C=C1)=CC=C1CN1CCOCC1 LSWNTXDGHBGOBU-UHFFFAOYSA-N 0.000 description 1
- HRKHOZXREJMADX-UHFFFAOYSA-N tert-butyl 5-[2-[4-(morpholin-4-ylmethyl)anilino]thieno[3,2-d]pyrimidin-7-yl]indole-1-carboxylate Chemical compound C=1C=C2N(C(=O)OC(C)(C)C)C=CC2=CC=1C(C1=N2)=CSC1=CN=C2NC(C=C1)=CC=C1CN1CCOCC1 HRKHOZXREJMADX-UHFFFAOYSA-N 0.000 description 1
- JRQXEMLSEVXCRI-UHFFFAOYSA-N tert-butyl n-(2-phenyl-1h-imidazo[4,5-b]pyridin-6-yl)carbamate Chemical compound N=1C2=CC(NC(=O)OC(C)(C)C)=CN=C2NC=1C1=CC=CC=C1 JRQXEMLSEVXCRI-UHFFFAOYSA-N 0.000 description 1
- PFRWHGRGFHCMKU-UHFFFAOYSA-N tert-butyl n-[4-[[4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]amino]phenyl]carbamate Chemical compound N1N=C(C)C=C1NC1=NC(NC=2C=CC(NC(=O)OC(C)(C)C)=CC=2)=NC2=CC=CC=C12 PFRWHGRGFHCMKU-UHFFFAOYSA-N 0.000 description 1
- ODQDMZNDBCLMMZ-UHFFFAOYSA-N tert-butyl n-[[3-[2-[4-(morpholin-4-ylmethyl)anilino]thieno[3,2-d]pyrimidin-7-yl]phenyl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=CC(C=2C3=NC(NC=4C=CC(CN5CCOCC5)=CC=4)=NC=C3SC=2)=C1 ODQDMZNDBCLMMZ-UHFFFAOYSA-N 0.000 description 1
- NUAGYORXQGYNLP-UHFFFAOYSA-N tert-butyl n-[[4-[2-[4-(morpholin-4-ylmethyl)anilino]thieno[3,2-d]pyrimidin-7-yl]phenyl]methyl]carbamate Chemical compound C1=CC(CNC(=O)OC(C)(C)C)=CC=C1C(C1=N2)=CSC1=CN=C2NC(C=C1)=CC=C1CN1CCOCC1 NUAGYORXQGYNLP-UHFFFAOYSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical class C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 description 1
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical class C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 1
- HUNGUWOZPQBXGX-UHFFFAOYSA-N tirbanibulin Chemical compound C=1C=CC=CC=1CNC(=O)CC(N=C1)=CC=C1C(C=C1)=CC=C1OCCN1CCOCC1 HUNGUWOZPQBXGX-UHFFFAOYSA-N 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- SYIKUFDOYJFGBQ-YLAFAASESA-N tofacitinib citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 SYIKUFDOYJFGBQ-YLAFAASESA-N 0.000 description 1
- 229960004247 tofacitinib citrate Drugs 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 108091005990 tyrosine-phosphorylated proteins Proteins 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 239000004066 vascular targeting agent Substances 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664279P | 2012-06-26 | 2012-06-26 | |
| US61/664,279 | 2012-06-26 | ||
| US201361824672P | 2013-05-17 | 2013-05-17 | |
| US61/824,672 | 2013-05-17 | ||
| KR20157002161A KR20150034209A (ko) | 2012-06-26 | 2013-06-24 | 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법 |
| PCT/US2013/047320 WO2014004376A2 (en) | 2012-06-26 | 2013-06-24 | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR20157002161A Division KR20150034209A (ko) | 2012-06-26 | 2013-06-24 | 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210138132A KR20210138132A (ko) | 2021-11-18 |
| KR102427777B1 true KR102427777B1 (ko) | 2022-08-01 |
Family
ID=49783991
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR20157002161A Ceased KR20150034209A (ko) | 2012-06-26 | 2013-06-24 | 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법 |
| KR1020217036438A Active KR102427777B1 (ko) | 2012-06-26 | 2013-06-24 | 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR20157002161A Ceased KR20150034209A (ko) | 2012-06-26 | 2013-06-24 | 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20150182490A1 (enExample) |
| EP (1) | EP2872161B1 (enExample) |
| JP (2) | JP6280546B2 (enExample) |
| KR (2) | KR20150034209A (enExample) |
| CN (2) | CN112755193A (enExample) |
| AU (2) | AU2013280644B2 (enExample) |
| BR (1) | BR112014032346A2 (enExample) |
| CA (1) | CA2880896C (enExample) |
| CL (1) | CL2014003526A1 (enExample) |
| IL (1) | IL236470B (enExample) |
| MX (1) | MX367055B (enExample) |
| SG (3) | SG11201408679XA (enExample) |
| WO (1) | WO2014004376A2 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101580714B1 (ko) | 2010-06-03 | 2016-01-04 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도 |
| BR112015001690A2 (pt) | 2012-07-24 | 2017-11-07 | Pharmacyclics Inc | mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk) |
| MY174813A (en) | 2013-03-15 | 2020-05-16 | Zymeworks Inc | Cytotoxic and anti-mitotic compounds, and methods of using the same |
| WO2014179528A2 (en) * | 2013-05-01 | 2014-11-06 | Brown Dennis M | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions |
| CA2935077C (en) * | 2013-12-27 | 2022-03-15 | Geoffrey C. Winters | Sulfonamide-containing linkage systems for drug conjugates |
| AU2014373640B2 (en) | 2013-12-27 | 2018-08-30 | Var2 Pharmaceuticals Aps | VAR2CSA-drug conjugates |
| JP2017509336A (ja) | 2014-03-20 | 2017-04-06 | ファーマサイクリックス エルエルシー | ホスホリパーゼｃガンマ２及び耐性に関連した変異 |
| SG11201608303QA (en) * | 2014-04-04 | 2016-11-29 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| EP3177366A4 (en) * | 2014-08-08 | 2018-04-04 | Pharmacyclics LLC | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
| CA2960899C (en) | 2014-09-17 | 2021-08-17 | Zymeworks Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
| CN108024987A (zh) * | 2014-10-10 | 2018-05-11 | 德玛医药 | 用于治疗癌症的二去水卫矛醇的类似物或衍生物与含铂抗肿瘤药物的组合 |
| WO2016059590A1 (en) * | 2014-10-16 | 2016-04-21 | Piramal Enterprises Limited | Stable injectable composition of small molecule drugs and process for its preparation |
| EP3328839A1 (en) * | 2015-07-30 | 2018-06-06 | Bristol-Myers Squibb Company | Aryl substituted bicyclic heteroaryl compounds |
| CA3000746A1 (en) * | 2015-10-02 | 2017-04-06 | Gilead Sciences, Inc. | Combinations of the btk inhibitor gs-4059 with inhibitors selected from a jak, ask1, brd and/or mmp9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases |
| US11446274B2 (en) | 2015-10-28 | 2022-09-20 | Del Mar Pharmaceuticals (Bc) Ltd. | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies |
| CN105476996B (zh) * | 2015-12-21 | 2017-12-26 | 神威药业集团有限公司 | 姜黄素与阿法替尼联合治疗非小细胞肺癌的用途 |
| CN105663028B (zh) * | 2016-02-23 | 2018-10-30 | 广西梧州制药（集团）股份有限公司 | 一种含去水卫矛醇的经直肠给药双层缓释栓剂 |
| CN105663075B (zh) * | 2016-02-23 | 2018-09-14 | 广西梧州制药（集团）股份有限公司 | 一种二溴卫矛醇肠溶片及其制备方法 |
| US10517958B2 (en) | 2016-10-04 | 2019-12-31 | Zymeworks Inc. | Compositions and methods for the treatment of platinum-drug resistant cancer |
| EP4357463A3 (en) * | 2016-12-01 | 2024-07-17 | Oxford BioDynamics PLC | Application of epigenetic chromsomal interactions in cancer diagnostics |
| EP3549608A4 (en) | 2016-12-01 | 2020-08-12 | Jiangsu Hengrui Medicine Co., Ltd. | USE OF A COMBINATION OF A VEGFR INHIBITOR AND PARP INHIBITOR IN THE MANUFACTURING OF A MEDICINAL PRODUCT FOR TREATMENT OF STOMACH CANCER |
| BR112019018687A2 (pt) | 2017-03-10 | 2020-04-07 | Athenex, Inc. | métodos de tratamento e/ou prevenção da ceratose actínica |
| US20200031920A1 (en) * | 2017-04-04 | 2020-01-30 | The George Washington University | Combination Therapy for Treating Cancer |
| JP2021505548A (ja) | 2017-12-06 | 2021-02-18 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 化学療法抵抗性の卵巣がんまたは乳がんの治療におけるｐａｒｐ阻害剤の使用 |
| KR20190106315A (ko) * | 2018-03-08 | 2019-09-18 | 고려대학교 산학협력단 | 비소세포폐암의 표피성장인자 수용체 표적 항암제에 대한 민감성 증진용 조성물 |
| KR20200143376A (ko) | 2018-03-13 | 2020-12-23 | 샤이어 휴먼 지네틱 테라피즈 인크. | 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도 |
| CN108653293B (zh) * | 2018-05-29 | 2020-08-11 | 复旦大学 | Jak2抑制剂在预防和治疗印戒细胞癌中的应用 |
| US20230093099A1 (en) * | 2019-04-02 | 2023-03-23 | Cullgen (Shanghai), Inc. | Compounds and methods of treating cancers |
| US12371421B2 (en) | 2019-04-29 | 2025-07-29 | Ribon Therapeutics, Inc. | Solid forms of a PARP7 inhibitor |
| CN114667289B (zh) | 2019-09-18 | 2025-08-26 | 武田药品工业有限公司 | 杂芳基血浆激肽释放酶抑制剂 |
| US11787796B2 (en) | 2019-09-18 | 2023-10-17 | Takeda Pharmaceutical Company Limited | Plasma Kallikrein inhibitors and uses thereof |
| CA3160091A1 (en) | 2019-11-05 | 2021-05-14 | Abbvie Inc. | Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax |
| CN111863159B (zh) * | 2020-06-01 | 2022-02-25 | 中山大学孙逸仙纪念医院 | 一种肿瘤免疫治疗疗效预测的列线图模型的建立方法 |
| GB202013466D0 (en) * | 2020-08-27 | 2020-10-14 | Inst De Medicina Molecular Joaeo Lobo Antunes | Genetic construct |
| AU2022205940A1 (en) * | 2021-01-06 | 2023-07-20 | Inaya Therapeutics, Inc. | Inhalable imatinib formulation |
| JP2024510504A (ja) * | 2021-03-17 | 2024-03-07 | 武田薬品工業株式会社 | 血漿カリクレインの多環式インヒビター |
| CN115745975B (zh) * | 2022-09-15 | 2023-11-24 | 中国药科大学 | 一种jak激酶结构域和假激酶结构域共抑制前药、制备方法及医药用途 |
| AU2024238830A1 (en) * | 2023-03-17 | 2025-10-23 | Cenovari Therapeutics, Inc. | Methods of use and compositions of bisbenzylisoquinolines for the treatment of malignancies |
| CN116987362B (zh) * | 2023-09-27 | 2023-12-05 | 常州宏巨电子科技有限公司 | 一种苯并噁嗪树脂基石墨烯薄膜材料及其制备方法和应用 |
| CN117405894B (zh) * | 2023-11-03 | 2025-02-18 | 华中科技大学同济医学院附属协和医院 | 蛋白激酶ck2在预测kras突变肺癌免疫治疗疗效中的新应用 |
Family Cites Families (222)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59186924A (ja) | 1983-04-08 | 1984-10-23 | Kureha Chem Ind Co Ltd | ヒト免疫グロブリン結合抗腫瘍剤 |
| US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
| US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
| US5484612A (en) | 1993-09-22 | 1996-01-16 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin |
| US6011069A (en) | 1995-12-26 | 2000-01-04 | Nisshin Flour Milling Co., Ltd. | Multidrug resistance inhibitors |
| US20020077461A1 (en) | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
| EP0923941B1 (en) | 1996-06-27 | 2006-05-17 | Chugai Seiyaku Kabushiki Kaisha | Remedies for myeloma to be used together with nitrogen mustard antitumor agents |
| US6121245A (en) | 1997-01-29 | 2000-09-19 | Firshein; Richard N. | Method of treating cancer using alkylglycerols in conjunction with chemotherapy |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| US20040072889A1 (en) | 1997-04-21 | 2004-04-15 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia |
| CA2294247C (en) | 1997-07-01 | 2004-10-26 | Atherogenics, Inc. | Antioxidant enhancement of therapy for hyperproliferative conditions |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| US6100254A (en) | 1997-10-10 | 2000-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of protein tyrosine kinases |
| AU4543899A (en) | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
| PT1104297E (pt) | 1998-07-09 | 2006-05-31 | Cephalon Inc | Composicoes para o tratamento da leucemia linfocitica cronica |
| BR9912938B1 (pt) | 1998-08-11 | 2011-06-28 | derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos. | |
| US6326390B1 (en) | 1998-08-25 | 2001-12-04 | King Pharmaceuticals Reseach And Development, Inc. | Use of adenosine A3 receptor antagonists to inhibit tumor growth |
| EP1165085B1 (en) | 1999-03-30 | 2006-06-14 | Novartis AG | Phthalazine derivatives for treating inflammatory diseases |
| WO2008109417A1 (en) | 2007-03-02 | 2008-09-12 | Case Western Reserve University | Mgmt inhibitor combinations for the treatment of neoplastic disorders |
| US7811981B2 (en) | 1999-08-30 | 2010-10-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of and compositions for inhibiting the proliferation of mammalian cells |
| AR030557A1 (es) | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
| US6921722B2 (en) | 2000-05-30 | 2005-07-26 | Ebara Corporation | Coating, modification and etching of substrate surface with particle beam irradiation of the same |
| US20030072794A1 (en) | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
| US6613736B2 (en) | 2000-06-16 | 2003-09-02 | Thomas T. Aoki | System and method for treating eye and nerve diseases in diabetic and non-diabetic patients |
| DE60141963D1 (de) | 2000-06-23 | 2010-06-10 | Mitsubishi Tanabe Pharma Corp | Antitumoreffekt-verstärker |
| US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2002022605A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| CN1116875C (zh) | 2000-10-19 | 2003-08-06 | 南京振中生物工程有限公司 | 紫杉醇脂质组合物及其制备方法 |
| US6503914B1 (en) | 2000-10-23 | 2003-01-07 | Board Of Regents, The University Of Texas System | Thienopyrimidine-based inhibitors of the Src family |
| US6733783B2 (en) | 2000-10-30 | 2004-05-11 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| US7619005B2 (en) | 2000-11-01 | 2009-11-17 | Cognition Pharmaceuticals Llc | Methods for treating cognitive impairment in humans with Multiple Sclerosis |
| US20020155565A1 (en) | 2000-11-10 | 2002-10-24 | Pilar Garin-Chesa | FAP-activated anti-tumor compounds |
| AP2003002825A0 (en) | 2000-12-21 | 2003-09-30 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
| US20100098691A1 (en) | 2001-01-24 | 2010-04-22 | S'bio Pte Ltd | Combination of benzimidazole anti-cancer agent and a second anti-cancer agent |
| US7318931B2 (en) | 2001-06-21 | 2008-01-15 | Genentech, Inc. | Sustained release formulation |
| US7005445B2 (en) | 2001-10-22 | 2006-02-28 | The Research Foundation Of State University Of New York | Protein kinase and phosphatase inhibitors and methods for designing them |
| US20030158118A1 (en) | 2001-11-26 | 2003-08-21 | Weidner Morten Sloth | Combination of cimetidine and cysteine derivatives for treating cancer |
| UA76810C2 (uk) | 2001-12-10 | 2006-09-15 | Мерк Енд Ко., Інк. | Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок |
| US7045534B2 (en) | 2002-02-12 | 2006-05-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of reducing angiogenesis |
| WO2003070823A2 (en) | 2002-02-20 | 2003-08-28 | The General Hospital Corporation | Conjugates comprising a biodegradable polymer and uses therefor |
| US7101576B2 (en) | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
| WO2004037814A1 (en) | 2002-10-25 | 2004-05-06 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| US7112676B2 (en) | 2002-11-04 | 2006-09-26 | Hoffmann-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
| TW200413381A (en) | 2002-11-04 | 2004-08-01 | Hoffmann La Roche | Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents |
| EP1560931B1 (en) | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| CL2003002287A1 (es) | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
| US7276519B2 (en) | 2002-11-25 | 2007-10-02 | Wyeth | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors |
| WO2004060313A2 (en) | 2002-12-30 | 2004-07-22 | Celgene Corporation | Fluoroalkoxy-substituted 1, 3-dihydro-isoindolyl compounds and their pharmaceutical uses |
| ES2502490T3 (es) | 2003-02-26 | 2014-10-03 | Sugen, Inc. | Compuestos aminoheteroarílicos como inhibidores de proteín quinasas |
| US20070207952A1 (en) | 2003-03-24 | 2007-09-06 | Sequoia Pharmaceuticals | Long Acting Biologically Active Conjugates |
| TW200502236A (en) | 2003-03-28 | 2005-01-16 | Hoffmann La Roche | Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents |
| US7220706B1 (en) | 2003-05-14 | 2007-05-22 | Praxair S.T. Technology, Inc. | Enhanced melt-textured growth |
| WO2004103958A2 (en) | 2003-05-19 | 2004-12-02 | Michigan State University | Preparation of hymenialdisine derivatives and use thereof |
| US7842835B2 (en) | 2003-07-07 | 2010-11-30 | Georgetown University | Histone deacetylase inhibitors and methods of use thereof |
| US20050009891A1 (en) | 2003-07-09 | 2005-01-13 | Lee Francis Y. | Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases |
| TW200514776A (en) | 2003-08-06 | 2005-05-01 | Vertex Pharma | Aminotriazole compounds useful as inhibitors of protein kinases |
| MXPA06001483A (es) | 2003-08-07 | 2006-05-15 | Schering Corp | Inhibidores novedosos de la proteina farnesil transferasa como agentes antitumorales. |
| MXPA06003758A (es) | 2003-10-02 | 2006-08-11 | Cephalon Inc | Derivados de indol substituido. |
| HUP0303313A2 (hu) | 2003-10-09 | 2005-07-28 | Richter Gedeon Vegyészeti Gyár Rt. | Transzdermális gyógyszerkészítmények |
| US7169781B2 (en) | 2003-10-17 | 2007-01-30 | Hoffmann-La Roche Inc. | Imidazole derivatives and their use as pharmaceutical agents |
| SG146681A1 (en) | 2003-11-06 | 2008-10-30 | Wyeth Corp | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml) |
| US7491725B2 (en) | 2004-02-06 | 2009-02-17 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
| EP1719771A1 (en) | 2004-02-19 | 2006-11-08 | Takeda Pharmaceutical Company Limited | Pyrazoloquinolone derivative and use thereof |
| RU2006136082A (ru) | 2004-03-15 | 2008-04-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | Новые производныедихлорфенилпиридо[2,3]пиримидина, их получение и применение в качестве фармацевтических агентов |
| WO2005092326A1 (en) | 2004-03-22 | 2005-10-06 | The Regents Of The University Of Michigan | Small molecule antagonists of xiap family proteins |
| US7754897B2 (en) | 2005-06-15 | 2010-07-13 | Cardiome Pharma Corp. | Synthetic processes for the preparation of aminocyclohexyl ether compounds |
| AU2005230682B2 (en) | 2004-04-05 | 2010-10-21 | Merck Hdac Research, Llc | Histone deacetylase inhibitor prodrugs |
| TW200538149A (en) | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
| TW200600091A (en) | 2004-05-21 | 2006-01-01 | Telik Inc | Sulfonylethyl phosphorodiamidates |
| ATE456579T1 (de) | 2004-07-20 | 2010-02-15 | Genentech Inc | Angiopoietin-like 4 protein hemmer kombinationen und deren verwendung |
| SE0402025D0 (sv) | 2004-08-13 | 2004-08-13 | Active Biotech Ab | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
| US7479561B2 (en) | 2004-08-16 | 2009-01-20 | Wyeth | 4-(2,4-dichloro-5-methoxyphenyl)amino-6-methoxy-7-{[5-substituted-amino)methyl]-3-furyl}-3-quinolinecarbonitriles as kinase inhibitors |
| CA2576924A1 (en) | 2004-08-31 | 2006-03-09 | F. Hoffmann-La Roche Ag | Amide derivatives of 7-amino-3-phenyl-dihydropyrimido [4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents |
| US20060100226A1 (en) | 2004-09-10 | 2006-05-11 | Sikorski James A | 2-Thiopyrimidinones as therapeutic agents |
| JP2008518883A (ja) | 2004-09-21 | 2008-06-05 | エフ．ホフマン−ラ ロシュ アーゲー | タンパク質キナーゼ阻害剤として有用な６−（２−アルキル−フェニル）−ピリド［２，３−ｄ］ピリミジン |
| US7355677B2 (en) | 2004-12-09 | 2008-04-08 | Asml Netherlands B.V. | System and method for an improved illumination system in a lithographic apparatus |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| WO2006066914A2 (en) | 2004-12-23 | 2006-06-29 | F. Hoffmann-La Roche Ag | Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors |
| EP1833829A2 (en) | 2004-12-23 | 2007-09-19 | F. Hoffmann-Roche AG | Benzamide substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors |
| US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
| US7884094B2 (en) | 2005-02-17 | 2011-02-08 | Synta Pharmaceuticals Corp. | Compounds for the treatment of proliferative disorders |
| US20060229277A1 (en) | 2005-04-08 | 2006-10-12 | Orbus Pharma, Inc. | Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor |
| WO2006123185A2 (en) | 2005-05-19 | 2006-11-23 | Merck Sharp & Dohme Limited | Sulphamides for treatment of cancer |
| CA2609343C (en) | 2005-06-07 | 2015-03-31 | Yale University | Methods of treating cancer and other conditions or disease states using lfmau and ldt |
| DK1896421T3 (da) | 2005-06-23 | 2012-01-09 | Merck Sharp & Dohme | Benzocyclohetapyridiner som hæmmere af receptoren tyrosinkinase MET |
| LT1912671T (lt) | 2005-07-18 | 2017-12-11 | Seattle Genetics, Inc. | Vaisto konjugatai, turintys gliukoronido linkerį |
| WO2007014707A1 (en) | 2005-08-01 | 2007-02-08 | F. Hoffmann-La Roche Ag | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents |
| CN101300233A (zh) | 2005-09-09 | 2008-11-05 | 先灵公司 | 氮杂稠合的细胞周期蛋白依赖性激酶抑制剂 |
| CA2626016A1 (en) | 2005-10-21 | 2007-06-21 | Panacea Biotec Limited | Pharmaceutical composition comprising at least one anticancer drug and at least one polymer |
| MY167260A (en) | 2005-11-01 | 2018-08-14 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US7528142B2 (en) | 2005-11-03 | 2009-05-05 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| AU2006322314A1 (en) | 2005-11-18 | 2007-06-14 | Synthon B.V. | Zolpidem tablets |
| PT1966202E (pt) | 2005-12-13 | 2012-01-03 | Incyte Corp | Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase |
| US8014957B2 (en) * | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
| WO2007081751A2 (en) | 2006-01-05 | 2007-07-19 | The Johns Hopkins University | Compositions and methods for the treatment of cancer |
| EP1981886B1 (en) | 2006-01-31 | 2009-08-12 | F.Hoffmann-La Roche Ag | 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors |
| WO2007106555A2 (en) | 2006-03-14 | 2007-09-20 | Neuren Pharmaceuticals Limited | Oral formulations of glycyl-2-methylprolyl-glutamate |
| US20100261758A1 (en) | 2006-03-28 | 2010-10-14 | Novartis Ag | Heterocyclic amides for use as pharmaceuticals |
| CN102671196B (zh) | 2006-04-05 | 2014-12-03 | 诺华股份有限公司 | 用于治疗癌症的治疗剂的组合 |
| AU2007243519A1 (en) | 2006-04-26 | 2007-11-08 | Merck Sharp & Dohme Corp. | Disubstituted aniline compounds |
| US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
| GB0609378D0 (en) | 2006-05-11 | 2006-06-21 | Novartis Ag | Organic compounds |
| US7964728B2 (en) | 2006-07-06 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition |
| TW200813021A (en) | 2006-07-10 | 2008-03-16 | Merck & Co Inc | Tyrosine kinase inhibitors |
| WO2008009407A2 (en) | 2006-07-17 | 2008-01-24 | Novartis Ag | Sulphonylaminocarbonyl derivatives of bile acid amides for use as immunomodulators |
| US8080252B2 (en) | 2006-07-19 | 2011-12-20 | The Cleveland Clinic Foundation | Compounds and methods of modulating angiogenesis |
| AU2007276760B2 (en) | 2006-07-24 | 2012-01-19 | Tetralogic Pharmaceuticals Corporation | Dimeric IAP antagonists |
| TW200817410A (en) | 2006-08-07 | 2008-04-16 | Incyte Corp | Triazolotriazines as kinase inhibitors |
| PT2068930E (pt) | 2006-08-07 | 2012-10-23 | Abbott Biotherapeutics Corp | Composições e métodos utilizando anticorpos anti-cs1 para tratar mieloma múltiplo |
| WO2008021364A2 (en) | 2006-08-17 | 2008-02-21 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| WO2008022771A1 (en) | 2006-08-23 | 2008-02-28 | Novartis Ag | Amides as sphingomyeline inhibitors |
| US8222288B2 (en) | 2006-08-30 | 2012-07-17 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
| ES2528316T3 (es) | 2006-09-01 | 2015-02-06 | Senhwa Biosciences, Inc. | Moduladores de la serina-treonina proteína quinasa y de PARP |
| WO2008030883A2 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
| WO2008030408A2 (en) | 2006-09-05 | 2008-03-13 | Yale University | Proteomimetic compounds as inhibitors of the interaction of a nuclear receptor with coactivator peptides |
| US8242080B2 (en) | 2006-10-13 | 2012-08-14 | The Regents Of The University Of California | Inhibitors of the EGFR kinase targeting the asymmetric activating dimer interface |
| CN103463621B (zh) | 2006-10-31 | 2016-01-06 | 托莱多大学 | Src和Src家族激酶的Na+/K+-ATP酶特异性肽抑制剂/激活剂 |
| JP5103604B2 (ja) | 2006-10-31 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | プロテインキナーゼ阻害剤としての２−アミノチアゾール−４−カルボン酸アミド |
| MY146474A (en) | 2006-11-06 | 2012-08-15 | Supergen Inc | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| US20120164075A1 (en) | 2006-11-21 | 2012-06-28 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of mammalian diseases |
| US20080125397A1 (en) | 2006-11-28 | 2008-05-29 | Telik, Inc. | 2 (SULFONYL)ETHYL N,N,N',N' tetrakis(2 chloroethyl)phosphorodia |
| US7655799B2 (en) | 2006-11-29 | 2010-02-02 | Telik, Inc. | 2{[2-(substituted amino)ethyl]sulfonyl}ethyl N,N,N',N'-tetrakis(2-chloroethyl)phosphorodiamidates |
| AU2007333105A1 (en) | 2006-12-11 | 2008-06-19 | Kempharm, Inc. | Non-standard amino acid conjugates of amphetamine and processes for making and using the same |
| EP1932820A1 (en) | 2006-12-14 | 2008-06-18 | Bp Oil International Limited | Process for manufacturing neohexene |
| US7956216B2 (en) | 2006-12-21 | 2011-06-07 | The Walter And Eliza Hall Institute Of Medical Research | Alpha-helical mimetics |
| US8536113B2 (en) | 2006-12-21 | 2013-09-17 | Janssen Biotech, Inc. | EGFR binding peptides and uses thereof |
| US8834920B2 (en) | 2006-12-21 | 2014-09-16 | Alza Corporation | Liposome composition for targeting egfr receptor |
| US20080293648A1 (en) | 2007-01-05 | 2008-11-27 | Saha Pharmaceuticals, Inc. | Compositions and Methods for Cancer Treatment |
| ATE483685T1 (de) | 2007-02-06 | 2010-10-15 | Novartis Ag | 1-benzensulfonyl-1h-indol-derivate als hemmer der ccr9-aktivität |
| EP2120900A2 (en) | 2007-02-15 | 2009-11-25 | Novartis AG | Combination of lbh589 with other therapeutic agents for treating cancer |
| AU2008226532B2 (en) | 2007-03-09 | 2011-09-22 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
| WO2008112277A2 (en) | 2007-03-13 | 2008-09-18 | Wake Forest University | Compositions and methods for treating cancer |
| DK2139484T3 (da) | 2007-04-10 | 2013-10-21 | Exelixis Inc | Fremgangsmåder til behandling af cancer ved brug af pyridopyrimidinon-inhibitorer af PI3K-alfa |
| CA2681311A1 (en) | 2007-04-13 | 2008-10-23 | Novartis Ag | Pyridazine-, pyridine- and pyrane-derivatives as gpbar1 agonisis |
| TWI448284B (zh) | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
| US7838495B2 (en) | 2007-04-27 | 2010-11-23 | University Of Maryland, Baltimore | Compositions and methods of use of EPB1, and ErbB3 binding protein |
| WO2008137619A2 (en) | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
| US20110021440A1 (en) | 2007-05-16 | 2011-01-27 | University Of Maryland, Baltimore | Apoptotic pathway targeting for the diagnosis and treatment of cancer |
| WO2008153900A1 (en) | 2007-06-06 | 2008-12-18 | University Of Florida Research Foundation | Kinase inhibitor compounds |
| US20110288023A1 (en) | 2007-06-08 | 2011-11-24 | The Regents Of The University Of California Office Of Technology Transfer | Cancer drug delivery using modified transferrin |
| WO2009003911A1 (en) | 2007-06-29 | 2009-01-08 | 4Sc Ag | Thiophene-imidazopyridines |
| JP2010532756A (ja) | 2007-07-06 | 2010-10-14 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法 |
| ES2411907T3 (es) | 2007-08-03 | 2013-07-09 | Facet Biotech Corporation | Uso terapéutico de anticuerpos antirreceptor TWEAK |
| HRP20160949T1 (hr) | 2007-09-10 | 2016-10-07 | Boston Biomedical, Inc. | Novi sastavi i metode za liječenje karcinoma |
| WO2009045504A1 (en) | 2007-10-04 | 2009-04-09 | President And Fellows Of Harvard College | Methods and compositions for treating cancer and modulating signal transduction and metabolism pathways |
| SI2211904T1 (sl) | 2007-10-19 | 2016-12-30 | Seattle Genetics, Inc. | CD19 vezavna sredstva in njihove uporabe |
| AU2008317406B2 (en) | 2007-10-25 | 2013-07-18 | Merck Sharp & Dohme Corp. | Therapeutic compounds |
| ES2524787T3 (es) | 2007-11-15 | 2014-12-12 | Msd Italia S.R.L. | Derivados de piridazinona como inhibidores de PARP |
| CA2703600C (en) | 2007-11-15 | 2017-04-25 | Ym Biosciences Australia Pty Ltd | Fused thieno or pyrrolo pyrimidine heterocyclic compounds and use thereof as jak1, jak2, and/or jak3 inhibitors |
| WO2009064835A1 (en) | 2007-11-16 | 2009-05-22 | Incyte Corporation | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
| CN101444490A (zh) * | 2007-11-26 | 2009-06-03 | 天津市金圭谷木糖醇有限公司 | 一种含脱水卫矛醇经注射给药的制剂及其制备方法 |
| CN101450100A (zh) * | 2007-11-28 | 2009-06-10 | 天津金世制药有限公司 | 一种治疗急慢性粒细胞白血病的药物组合物 |
| WO2009076629A2 (en) | 2007-12-12 | 2009-06-18 | The Regents Of The University Of Michigan | Compositions and methods for treating cancer |
| EP2240172B1 (en) | 2007-12-21 | 2014-03-19 | Novartis AG | Combination of nilotinib and chlorambucil for the treatment of chronic lymphocytic leukemia |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| JP2011511076A (ja) * | 2008-02-08 | 2011-04-07 | エイルロン セラピューティクス，インコーポレイテッド | 治療用ペプチド模倣大環状分子 |
| WO2009102707A2 (en) | 2008-02-11 | 2009-08-20 | Auspex Pharmaceuticals, Inc. | Substituted oxazaphosphorines |
| US20090209340A1 (en) | 2008-02-14 | 2009-08-20 | Aruze Gaming America, Inc. | Gaming Apparatus Capable of Conversation with Player and Control Method Thereof |
| US20110046071A1 (en) | 2008-03-05 | 2011-02-24 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | GLP-1 Receptor Agonists And Related Active Pharmaceutical Ingredients For Treatment Of Cancer |
| BRPI0909040B8 (pt) | 2008-03-11 | 2021-05-25 | Incyte Holdings Corp | derivados de azetidina e ciclobutano, seus usos, e composição |
| EP2110377A1 (en) | 2008-04-15 | 2009-10-21 | DAC S.r.l. | Spirocyclic derivatives as histone deacetylase inhibitors |
| KR101764927B1 (ko) | 2008-04-30 | 2017-08-03 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
| WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| EP2303269B1 (en) | 2008-06-03 | 2014-07-30 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| GB2475183B (en) | 2008-06-04 | 2011-11-23 | Gw Pharma Ltd | Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators |
| EP2133334A1 (en) | 2008-06-09 | 2009-12-16 | DAC S.r.l. | Heterocyclic derivatives as HDAC inhibitors |
| DK2310011T3 (da) * | 2008-06-17 | 2013-10-14 | Wyeth Llc | Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin |
| US8207195B2 (en) | 2008-06-26 | 2012-06-26 | Inspire Pharmaceuticals, Inc. | Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds |
| MX2011000235A (es) | 2008-07-08 | 2011-02-23 | Incyte Corp | 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa. |
| WO2010009334A1 (en) | 2008-07-17 | 2010-01-21 | Colorado State University Research Foundation | Method for preparing largazole analogs and uses thereof |
| JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| US20120230991A1 (en) | 2008-07-29 | 2012-09-13 | Douglas Kim Graham | Methods and compounds for enhancing anti-cancer therapy |
| WO2010021822A2 (en) | 2008-07-30 | 2010-02-25 | The Regents Of The University Of California | Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites |
| ES2438496T3 (es) | 2008-08-01 | 2014-01-17 | Ventirx Pharmaceuticals, Inc. | Formulaciones de agonistas de receptores de tipo toll y su uso |
| CN102186857A (zh) | 2008-08-26 | 2011-09-14 | 贝林格尔·英格海姆国际有限公司 | 用于药物组合物的噻吩并嘧啶 |
| US20100068302A1 (en) | 2008-09-17 | 2010-03-18 | Traslational Cancer Drugs Pharma, S.L. | Methods and compositions for the treatment of cancer |
| US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
| US20100111901A1 (en) | 2008-11-03 | 2010-05-06 | Auspex Pharmaceuticals, Inc. | Triazole inhibitors of aromatase |
| KR101805754B1 (ko) | 2008-12-08 | 2017-12-07 | 먼디파머 인터내셔널 코포레이션 리미티드 | 단백질 수용체 티로신 키나아제 억제제의 조성물 |
| US20100150896A1 (en) | 2008-12-12 | 2010-06-17 | Auspex Pharmaceuticals, Inc. | Diaminoquinazoline inhibitors of dihydrofolate reductase |
| PA8851101A1 (es) | 2008-12-16 | 2010-07-27 | Lilly Co Eli | Compuesto amino pirazol |
| US20110318430A1 (en) | 2008-12-18 | 2011-12-29 | New York University | Tumor therapy with antitumor agents in combination with sindbis virus-based vectors |
| US20100173013A1 (en) | 2009-01-08 | 2010-07-08 | Denis Drygin | Treatment of neoplastic disorders using combination therapies |
| RU2011136641A (ru) * | 2009-02-04 | 2013-03-10 | Байпар Сайенсиз, Инк. | Лечение рака легких с применением соединения нитробензамида в комбинации с ингибитором фактора роста |
| CN102405044A (zh) | 2009-02-06 | 2012-04-04 | 南加利福尼亚大学 | 含有单萜的治疗组合物 |
| KR101663339B1 (ko) | 2009-03-11 | 2016-10-06 | 플렉시콘 인코퍼레이티드 | Ｒａｆ 키나제의 억제를 위한 피롤로［２,３-ｂ］피리딘 유도체 |
| AU2010234916A1 (en) | 2009-03-30 | 2011-10-13 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
| WO2010114805A1 (en) | 2009-03-31 | 2010-10-07 | The Trustees Of The University Of Pennsylvania | Methods of treating cancer with phenformin |
| WO2010114881A1 (en) | 2009-04-01 | 2010-10-07 | Progenra Inc. | Anti-neoplastic compounds, compositions and methods |
| CN102448951B (zh) | 2009-04-06 | 2017-05-10 | 安吉奥斯医药品有限公司 | 丙酮酸激酶m2调节剂、治疗组合物和相关使用方法 |
| US20100291025A1 (en) | 2009-04-13 | 2010-11-18 | Auspex Pharmaceuticals, Inc. | Indazole inhibitors of tyrosine kinase |
| US20110053968A1 (en) | 2009-06-09 | 2011-03-03 | Auspex Pharmaceuticals, Inc. | Aminopyrimidine inhibitors of tyrosine kinase |
| US9151762B2 (en) | 2009-06-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Identification of DSG-3 as a biomarker for the detection of metastasis in lymph nodes |
| US8232318B2 (en) | 2009-07-31 | 2012-07-31 | The General Hospital Corporation | Approaches to treat cancer using HB-EGF inhibitors |
| PL2470546T3 (pl) | 2009-08-28 | 2013-12-31 | Takeda Pharmaceuticals Co | Związki heksahydrooksazynopterydynowe do zastosowania jako inhibitory MTOR |
| BR112012005550A2 (pt) | 2009-09-11 | 2015-09-08 | Cylene Pharmaceuticals Inc | lactamas heterociclo-substituídas farmaceuticamente úteis |
| BR112012005970A2 (pt) | 2009-09-16 | 2015-09-08 | Cylene Pharmaceuticals Inc | moduladores tricíclicos de proteína quinase |
| RU2600927C2 (ru) | 2009-09-28 | 2016-10-27 | Ф.Хоффманн-Ля Рош Аг | Бензоксазепиновые ингибиторы pi3k и способы применения |
| US8304577B2 (en) | 2009-10-09 | 2012-11-06 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
| PH12012500713A1 (en) * | 2009-10-14 | 2012-11-26 | Merck Sharp & Dohme | Substituted piperidines that increase p53 activity and the uses thereof |
| CN110054692A (zh) | 2009-10-23 | 2019-07-26 | 米伦纽姆医药公司 | 抗gcc抗体分子及其相关组合物和方法 |
| AU2010326268B2 (en) | 2009-12-04 | 2016-11-03 | Senhwa Biosciences, Inc. | Pyrazolopyrimidines and related heterocycles as CK2 inhibitors |
| US8445517B2 (en) | 2009-12-11 | 2013-05-21 | Dana-Farber Cancer Institute | Stat modulators |
| US20110195066A1 (en) | 2010-02-05 | 2011-08-11 | Auspex Pharmaceuticals, Inc. | Quinoline inhibitors of tyrosine kinase |
| CA2790199A1 (en) | 2010-02-24 | 2011-09-01 | Auspex Pharmaceuticals, Inc. | Trimethoxyphenyl inhibitors of tyrosine kinase |
| UY33241A (es) | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
| TW201141483A (en) | 2010-02-26 | 2011-12-01 | Boehringer Ingelheim Int | Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions |
| WO2011109799A1 (en) | 2010-03-05 | 2011-09-09 | Karyopharm Therapeutics, Inc. | Nuclear transport modulatiors and uses thereof |
| US8389525B2 (en) | 2010-05-05 | 2013-03-05 | Renee Desai | Small molecules for inhibition of protein kinases |
| MX2012013082A (es) | 2010-05-12 | 2013-05-09 | Vertex Pharma | Derivados de 2-aminopiridina utiles como iinhibidores de cinasa atr. |
| WO2011143665A1 (en) * | 2010-05-14 | 2011-11-17 | Genentech, Inc. | Treatment methods |
| EP2600860B1 (en) * | 2010-08-02 | 2020-07-01 | University of Central Florida Research Foundation, Inc. | Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of stat proteins |
| SG10201802116RA (en) * | 2010-08-18 | 2018-04-27 | Del Mar Pharmaceuticals | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol |
| US9029103B2 (en) * | 2010-08-27 | 2015-05-12 | Illumina Cambridge Limited | Methods for sequencing polynucleotides |
| US20120213854A1 (en) | 2010-09-30 | 2012-08-23 | Fetzer Oliver S | Methods of treating a subject and related particles, polymers and compositions |
| EP2637669A4 (en) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and their use |
| SG182016A1 (en) * | 2010-12-14 | 2012-07-30 | Univ Singapore | Method of detecting resistance to cancer therapy |
| CA2868302A1 (en) * | 2012-03-23 | 2013-09-26 | Dennis M. Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| WO2013169600A1 (en) * | 2012-05-09 | 2013-11-14 | Delmar Pharmaceuticals | Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies |
| US8729286B2 (en) * | 2012-05-10 | 2014-05-20 | Massachusetts Institute Of Technology | Platinum compounds as treatment for cancers, and related methods, kits, and compositions |
-
2013
- 2013-06-24 EP EP13809749.8A patent/EP2872161B1/en active Active
- 2013-06-24 KR KR20157002161A patent/KR20150034209A/ko not_active Ceased
- 2013-06-24 MX MX2014015795A patent/MX367055B/es active IP Right Grant
- 2013-06-24 CN CN202110071253.8A patent/CN112755193A/zh active Pending
- 2013-06-24 SG SG11201408679XA patent/SG11201408679XA/en unknown
- 2013-06-24 JP JP2015520365A patent/JP6280546B2/ja not_active Expired - Fee Related
- 2013-06-24 AU AU2013280644A patent/AU2013280644B2/en not_active Ceased
- 2013-06-24 SG SG10201805807PA patent/SG10201805807PA/en unknown
- 2013-06-24 CA CA2880896A patent/CA2880896C/en active Active
- 2013-06-24 KR KR1020217036438A patent/KR102427777B1/ko active Active
- 2013-06-24 CN CN201380042796.0A patent/CN104797267A/zh active Pending
- 2013-06-24 SG SG10201610869TA patent/SG10201610869TA/en unknown
- 2013-06-24 WO PCT/US2013/047320 patent/WO2014004376A2/en not_active Ceased
- 2013-06-24 US US14/409,909 patent/US20150182490A1/en not_active Abandoned
- 2013-06-24 BR BR112014032346A patent/BR112014032346A2/pt not_active Application Discontinuation
-
2014
- 2014-12-24 CL CL2014003526A patent/CL2014003526A1/es unknown
- 2014-12-25 IL IL236470A patent/IL236470B/en active IP Right Grant
-
2018
- 2018-01-19 JP JP2018007222A patent/JP2018087205A/ja active Pending
- 2018-10-29 AU AU2018256477A patent/AU2018256477A1/en not_active Abandoned
-
2021
- 2021-02-17 US US17/177,665 patent/US20210251944A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| Cancer, 1981, Vol. 47, pp. 442-451* |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104797267A (zh) | 2015-07-22 |
| EP2872161A4 (en) | 2016-07-20 |
| JP2015526410A (ja) | 2015-09-10 |
| IL236470B (en) | 2019-06-30 |
| JP6280546B2 (ja) | 2018-02-14 |
| WO2014004376A3 (en) | 2014-03-27 |
| AU2018256477A1 (en) | 2018-11-22 |
| CN112755193A (zh) | 2021-05-07 |
| MX367055B (es) | 2019-08-02 |
| IL236470A0 (en) | 2015-02-26 |
| BR112014032346A2 (pt) | 2017-06-27 |
| KR20210138132A (ko) | 2021-11-18 |
| CA2880896C (en) | 2021-11-16 |
| AU2013280644B2 (en) | 2018-08-02 |
| CA2880896A1 (en) | 2014-01-03 |
| SG10201610869TA (en) | 2017-02-27 |
| EP2872161B1 (en) | 2020-12-16 |
| US20210251944A1 (en) | 2021-08-19 |
| CL2014003526A1 (es) | 2015-08-28 |
| WO2014004376A2 (en) | 2014-01-03 |
| SG11201408679XA (en) | 2015-01-29 |
| MX2014015795A (es) | 2015-10-14 |
| US20150182490A1 (en) | 2015-07-02 |
| EP2872161A2 (en) | 2015-05-20 |
| AU2013280644A1 (en) | 2015-01-22 |
| JP2018087205A (ja) | 2018-06-07 |
| SG10201805807PA (en) | 2018-08-30 |
| KR20150034209A (ko) | 2015-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102427777B1 (ko) | 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법 | |
| AU2019283893B2 (en) | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor | |
| US20200206188A1 (en) | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | |
| AU2024200650A1 (en) | Therapeutic benefit of suboptimally administered chemical compounds | |
| US20190091195A1 (en) | Use of dianhydrogalactitol and derivatives thereof in the treatment of glioblastoma, lung cancer, and ovarian cancer | |
| TW201444551A (zh) | 使用衛康醇、二乙醯二脫水衛矛醇、二溴衛矛醇或類似物或其衍生物治療具有基因多型性或ａｈｉ１失調或突變患者的抗酪氨酸激酶抑制劑之惡性腫瘤的方法 | |
| HK1224581A1 (en) | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brian tumor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20211108 Application number text: 1020157002161 Filing date: 20150126 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20211208 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20220328 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20220628 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20220727 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20220728 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |